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ABSTRACT OF THE DISSERTATION 
MICROSPHERES FOR LIVER RADIOMICROSPHERE THERAPY AND  
PLANNING 
by 
Alejandro Amor Coarasa 
Florida International University, 2013 
Miami, Florida 
Professor Anthony J. McGoron, Major Professor 
Liver cancer accounts for nearly 10% of all cancers in the US. Intrahepatic Arterial 
Radiomicrosphere Therapy (RMT), also known as Selective Internal Radiation Treatment (SIRT), 
is one of the evolving treatment modalities. Successful patient clinical outcomes require suitable 
treatment planning followed by delivery of the microspheres for therapy. The production and in 
vitro evaluation of various polymers (PGCD, CHS and CHSg) microspheres for a RMT and RMT 
planning are described. Microparticles with a 30±10 µm size distribution were prepared by 
emulsion method. The in vitro half-life of the particles was determined in PBS buffer and porcine 
plasma and their potential application (treatment or treatment planning) established. Further, the 
fast degrading microspheres (≤ 48 hours in vitro half-life) were labeled with 68Ga and/or 99mTc as 
they are suitable for the imaging component of treatment planning, which is the primary emphasis 
of this dissertation. Labeling kinetics demonstrated that 68Ga-PGCD, 68Ga-CHSg and 68Ga-
NOTA-CHSg can be labeled with more than 95% yield in 15 minutes; 99mTc-PGCD and 99mTc-
CHSg can also be labeled with high yield within 15-30 minutes. In vitro stability after four hours 
was more than 90% in saline and PBS buffer for all of them. Experiments in reconstituted 
hemoglobin lysate were also performed. Two successful imaging (RMT planning) agents were 
found: 99mTc-CHSg and 68Ga-NOTA-CHSg. For the 99mTc-PGCD a successful perfusion image 
was obtained after 10 minutes, however the in vivo degradation was very fast (<30 min half-life), 
vi 
 
releasing the 99mTc from the lungs. Slow degrading CHS microparticles (> 21 days half-life) were 
modified with p-SCN-b-DOTA and labeled with 90Y for production of 90Y-DOTA-CHS. 
Radiochemical purity was evaluated in vitro and in vivo showing more than 90% stability after 72 
and 24 hours respectively.  All agents were compared to their respective gold standards (99mTc-
MAA for 68Ga-NOTA-CHSg and 99mTc-CHSg; 90Y-SirTEX for 90Y-DOTA-CHS) showing 
superior in vivo stability. RMT and RMT planning agents (Therapy, PET and SPECT imaging) 
were designed and successfully evaluated in vitro and in vivo. 
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CHAPTER 1 INTRODUCTION 
Radiomicrosphere Therapy (RMT), via hepatic arterial administration is a treatment for patients 
with primary and metastatic liver cancer (figure 1). Because the primary blood supply to liver 
tumors is from the hepatic artery while the majority of the blood supply to the normal liver is 
from the portal vein, this procedure offers selectivity to tumor.  
 
Fig 1. Liver and Tumor Vasculature (1) 
The micro-vascular density of liver tumors is 3-200 times greater than the surrounding liver 
parenchyma, further improving the selectivity of the therapy to the tumor (2). In this treatment, 30 
µm diameter spheres labeled with the radioactive isotope 90Y (yttrium-90, a high-energy beta 
particle–emitting radioisotope) become lodged in the arterioles within the tumor and destroy the 
tumor while leaving the normal liver tissue mostly unharmed. A randomized trial in 2001 with 74 
patients showed that combining SirSpheres (one of the available products in the market) with 
chemotherapy had a 44 % response versus a 17.6 % with chemotherapy alone (3).  
The 90Y disintegration within glass microspheres occurs without any chemical release because the 
radioisotope is completely trapped inside the microsphere and is part of the crystalline structure. 
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In other words, there is no surface degradation of the particles. Resin microspheres are basically 
ionic exchange matrices that bind the yttrium by means of strong non-specific ionic interactions. 
The earliest device of this kind (resin microspheres) was shown to release the isotope once in 
contact with blood (4) and also showed some other complications (5; 6). Although there is no 
report of leaching of 90Y for the commercial SirSpheres product, such behavior is a possibility, 
even if not significant, because of the ionic nature of the radioisotope attachment to the particles. 
SirSpheres are prescribed to be injected using pure water instead of saline solution to avoid any 
ionic exchange before injection. The main advantage of the resin spheres is that the radiation dose 
and concentration of spheres can be manipulated in situ to provide a patient specific treatment. In 
contrast the glass spheres need to be allowed to decay in order to achieve the proper dose. 
The possibility of injury to gastrointestinal tract and lungs are complications that can be evaluated 
(predicted), to a certain extent, using a hepatic arterial flow imaging study with 99mTc labeled 
macroaggregated albumin (99mTc-MAA) prior to treatment (6). For treatment planning 99mTc-
MAA is infused into the proper hepatic artery and a perfusion scintigraphy is performed. 
However, the significant differences in size, shape, and other properties between the MAA and 
90Y microspheres (Fig 2) complicates the treatment planning because the MAA particles cannot 
be expected to distribute exactly like the 90Y microspheres. 
 
Fig 2. Comparison of A: MAA microparticles and B: Resin microspheres 
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The present dissertation addresses the development and use of a new biodegradable sphere for 
accurate RMT planning/treatment. Several polymers: Chitosan, Chitosan Glycol and a new 
synthetic biodegradable elastomer Poly(glycerol-citric-dodecanedioate)) are evaluated employing 
different emulsion techniques to produce approximately 30 µm size biodegradable microspheres 
that match the size and shape of the 90Y microspheres commercial products. The obtained 
particles were submitted to in vitro degradation studies and characterized with respect to size, 
shape, and size distribution.  
Different radiolabeling techniques were evaluated for labeling yields, radiochemical purity and 
stability of the final product. The in vivo evaluation of the particles was performed in Sprague 
Dawley rats. The animals were imaged using full body autoradiography/X-Ray techniques and 
later euthanized at different times. Several organ samples were collected for measuring of 
radioactive content in a Cobra 5000 NaI(Tl) well detector [Perkin Elmer, USA]. Numerical 
dosimetry calculations were done using MCNPx to evaluate the radiation field and dose 
distributions and to assure radioprotection standards were met. 
1.1 Objective and Specific Aims and hypotheses 
The overall objective is to design and evaluate a complete RMT package with fast (12 to 48 
hours, planning) and slow (>21 days, therapy) degradation half-life 30 ± 10 µm 
biodegradable microspheres to be labeled with 68Ga or 99mTc for RMT planning and with 
90Y for RMT (respectively) with high yield and >90% radiochemical purity.  
This objective was accomplished by addressing the following specific aims: 
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1.1.1 Specific Aim #1 
Develop and implement appropriate emulsion and purification methods for the creation of 30±10 
µm polymer particles.  
The outcome of this aim provided the necessary raw materials for the subsequent experiments. 
1.1.2 Specific Aim #2 
Perform radiolabeling of the particles with more than 90% 68Ga, 99mTc or 90Y labeling yield and in 
vitro radiochemical purity for the studied periods. 
The outcome of this aim was to demonstrate that the created particles were capable of trapping 
and retaining the radioisotopes. This aim includes the surface modification of the particle with 
specific chelating agents to improve in vitro and ultimately in vivo stability. 
1.1.3 Specific Aim #3  
Perform in vitro stability studies of the particles in saline, PBS buffer and animal plasma to 
determine their degradation half-lives. 
The outcome of this aim was to assess the possibility of using different particles as a RMT 
planning (as a prospective replacement for MAA) with a degradation half-life of 12 to 48 hours 
and treatment agent as a potential replacement for resin or glass microspheres with a degradation 
half-life of more than 21 days. 
1.1.4 Specific Aim #4 
Conduct in vivo lung perfusion studies in Sprague Dawley rats to evaluate the stability and bio-
distribution of the particles and the radioactive labels. 
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The outcome of this aim was to assess the feasibility of translating our microsphere design to a 
clinical setting for RMT. 
The following hypotheses will be tested in the specific aims of research. 
 #1  Particles measuring 30±10 µm diameter can be created from biocompatible 
polymers using emulsion and purification methods. 
 #2 The particles can be radiolabeled with 68Ga or 99mTc for RMT planning and 90Y 
for RMT with ≥ 90% in vitro radiochemical purity. 
 #3 The radiolabeled particles can have 12-48 hours in vitro half-life for RMT 
planning and >21 days in vitro half-life for RMT. 
 #4 The radiolabeled particles can have > 90% in vivo stability for proper lung 
perfusion imaging studies. 
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CHAPTER 2 BACKGROUND 
2.1 Nuclear Medical Imaging 
There are five basic modalities of nuclear medical imaging: Planar Scintigraphy, SPECT, PET, 
nMR and X-Ray (CT). X-Ray emission in medical imaging is almost entirely due to electronic 
excitation, however it is considered “nuclear imaging” because of the high energy of the emitted 
quantum. These five basic modalities can be separated into two subcategories: Functional 
Medical Imaging (Planar Scintigraphy, SPECT and PET) and Anatomical Medical Imaging (CT 
and nMR). Though these subcategories are not set in stone since contrast CT and functional nMR 
are also performed. The current review will concentrate on the functional imaging subcategory 
and their combination with the nMR and CT considered for their importance attenuation 
correction and anatomical registration purposes. 
2.1.1 Planar Scintigraphy. The Anger Camera. 
Since George de Hevesy (considered the father of nuclear medicine) devised the term radiotracer 
in the 1920s a new age started. The main advantage of radiotracers was that since they could be 
injected in very small amounts, the system could easily be studied without being disturbed. The 
first nuclear imaging camera, called Scintigraphy Camera, was designed in 1957 by Hal Anger 
(also called Anger Camera), still widely used today (7). It consist of a single NaI(Tl) (sodium 
iodide, thallium activated) crystal, coupled to several photomultipliers for detection and 
amplification. The thickness of the crystal is between 6-25 mm and it is optimized at 10 mm for 
detection of 120-200 keV gamma energy. Thinner crystals provide better spatial resolution but 
decreased sensitivity (8). A collimator is also used in front of the scintillation crystal to allow 
only perpendicular (or near perpendicular) photons to interact with the crystal (Fig 3). 
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Fig 3 Basic components of the Anger Camera (7). 
The interaction of the gamma quantum with the crystal produces excitation with subsequent 
emission of light. The light interacts with a photocathode emitting electrons, later amplified in the 
photomultipliers. Since only perpendicular gamma was allowed to enter the crystal, the location 
of the amplification is aligned with the location of emission in the patient. With all the 
independent intensities and coordinates, a planar image is formed. 
2.1.2 Single Photon Emission Tomography 
Single photon emission tomography is just an application of the anger camera to obtain tri-
dimensional (3D) images of the radioisotope distribution. Most Clinical SPECT systems are 
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based on a dual planar camera system that rotates on the patient axis to obtain different 
projections for image reconstruction.  
 
Fig 4 Some commercially available SPECT/CT systems: A: Philips Medical Systems BrightView 
XCT, B: GE Healthcare Infinia-Hawkeye and C: Siemens Healthcare Systems Symbia (9). 
Attenuation effects are more severe in body imaging than in brain imaging since the photon 
carries a shorter path in the latter. Additionally, attenuation is not uniform throughout the patient, 
so attenuation correction becomes a major limitation of SPECT, hence quantification of the tracer 
is very difficult. Several approaches have been taken to correct attenuation with some level of 
success. A 153Gd source is sometimes used to generate transmission scans while obtaining the 
image projections (10), combined CT scans (Fig 4) are also used for correction (11). All these 
methods remain under evaluation. Nevertheless SPECT and SPECT/CT images have excellent 
medical diagnostic value (e.g. Fig 5). 
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Fig 5 131I scan of thyroid cancer (red arrow) A: Planar Scintigraphy and B: SPECT/CT (12) 
2.1.3 Positron Emission Tomography 
Positron emission tomography is a medical imaging technique that is not based on positron 
emission detection (as its name indicated) but rather on the detection of the result of the positron 
annihilation (Fig 6). 
 
Fig 6 Radioactive disintegration for A: single photon emission and B: positron emission. 
As can be seen in Fig 6, the positron travels some distance before annihilation, and this is directly 
proportional to the maximum energy of the beta disintegration. The linear distance traveled is 
referred to as the positron range (Fig 6 B). The annihilation produces two perpendicular photons 
10 
 
(180±0.25º) that are identified by opposing detectors (arranged circularly) in coincidence mode 
(only two detection events happening within 1 nanosecond are registered). The line of detection 
of the photons is registered and intercepted with other detected paths to conform the image (Fig 
7). 
Compared to those used in SPECT, PET detectors need to be thicker. Annihilation emission has 
an energy of 511 keV (compare to the regular 100-200 keV in SPECT) hence the detector needs 
greater stopping power. Crystals normally used in PET are made of Bismuth Germanium Oxide 
(BGO, also Bismuth Germanate, Bi4Ge3O12) and Cerium-doped lutetium oxyorthosilicate (LSO). 
These have a relatively good light output and a short time constant (80% more efficient than 
NaI(Tl) for the 511 keV energy). The electronics of PET cameras are rather complicated and 
further detail can be found in several publications (13; 14). 
 
Fig 7 Positron Emission Tomography image and registration (15) 
Resolution of PET cameras has increased significantly over time. Starting at 10 mm spatial 
resolution in the 1980’s to the current 4 mm (1.2 mm in micro-PET) (16). The theoretical spatial 
resolution of PET is limited by the positron range while spatial resolution is limited primarily by 
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the collimator design. Thus, the election of proper radionuclides (based on its physical 
characteristics) to be used in the development of future drugs becomes important (Table 1). 
Table 1 Physical Properties of Positron Emitting Radionuclides Most Commonly Used. Isotopes 
with particular importance in PET are bolded. (16) 
Radionuclide T ½ % β+ 
Emission 
Max β E 
(MeV) 
Max 
Range 
Water 
(mm) 
 
Ave Range 
Water 
(mm) 
Produced 
11C 20.4 min 99 0.96 3.9 0.4 Cyclotron 
13N 9.96 min 100 1.2 5.1 0.6 Cyclotron 
15O 2.05 min 100 1.7 8.0 0.9 Cyclotron 
18F 1.83 h 97 0.64 2.3 0.2 Cyclotron 
62Cu 9.74 min 98 2.9 15 1.6 62Zn/62Cu 
64Cu 12.7 h 19 0.58 2.0 0.2 Cyclotron 
66Ga 9.49 h 56 3.8 20 3.3 Cyclotron 
68Ga 1.14 h 88 1.9 9.0 1.2 68Ge/68Ga 
76Br 16.1 h 54 3.7 19 3.2 Cyclotron 
82Rb 1.3 min 95 3.4 18 2.6 82Sr/82Rb 
86Y 14.7 h 32 1.4 6.0 0.7 Cyclotron 
124I 4.18 d 22 1.5 7.0 0.8 Cyclotron 
 2.2 Radioisotope Production.  
There are two basic nuclear installations to produce radioisotopes: nuclear reactors (to include 
neutron sources) and particle accelerators. With different designs and working principles, both 
nuclear installations are capable of producing radioisotopes for nuclear medicine applications. 
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2.2.1 Nuclear Reactor Produced Radioisotopes. 
Nuclear reactors were most commonly used in the past 50 years of nuclear medicine history. 
Whether the radionuclides are produced by fission of heavier nuclides or by neutron irradiation 
they both yield radioisotopes with excess neutrons, which indistinctively decay by electron 
emission (β-, excluding some rare exceptions). This production was aligned with the needs of 
nuclear medicine since β- emitting nuclides are still used for therapy and the gamma emitting 
daughters for SPECT imaging (e. g. 99Mo/99mTc) (Fig 8). 
 
Fig 8 Fission of 235U (17) with neutron generation and yield of fragments (18). 
Fission is not a desired production method, since a full distribution of both long and short lived 
isotopes is obtained. Radiochemical separation of the products is a lengthy process not yielding 
enough purity for medical applications. Neutron irradiation of defined, pure targets is a better 
approach to production, however high neutron flux is needed to yield sufficient radioisotope 
amounts. Neutron activation of cold targets is explained by the following equation: 
ܣ = ܰߪ∅൫1 − ݁ିఒ௧೔ೝೝೌ೏೔ೌ೟೔೚೙൯ (2.2.1.1) 
Where N is the number of target atoms present in the initial material; Φ is the neutron flux; λ is 
the decay constant of the product and σ is the cross section. The cross section is given in barns (1 
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barn=10-24 cm2), which intuitively represents the cross sectional area of the nuclei in question. 
However it is much more complex, including the efficiency of neutron capture, reaction yield, 
and incident neutron energy among others. Regardless of the complexity of the cross section 
concept, a bigger value of Φ aids the radionuclide production. Some isotopic productions benefit 
from thermal (low energy) neutrons and others from higher energy (Table 2). 
Table 2 Neutron Energy Ranges needed to produce several medical isotopes (19). 
Neutron Energy Isotope Production 
Thermal Epithermal (0.01 eV – 10 keV) 75Se, 89Sr, 90Y, 103Pd, 125I, 131I, 127Xe, 131Cs, 
153Gd, 153Sm, 165Dy, 166Ho, 177Lu, 186Re, 188W, 
192Ir, 198Au, 223Ra, 225Ac 
Fast (10 keV - 1.0 MeV) 99Mo, 117mSn 
High Energy (1.0 MeV – 10 MeV) 32P, 33P, 57Co, 62Cu, 64Cu, 67Cu, 89Sr 
14 MeV 99Mo, 225Ac 
The recent shortages in the production of radioisotopes have evidenced a crude reality: Reactors 
are getting old, production yields are decreasing and no new facilities are being built (20). 
Alternatives are being used, research reactors are included in production, new low enriched 
uranium neutron sources are being used and finally new production reactions (especially of 99Mo) 
are being studies in particle accelerators (21). 
2.2.2 Cyclotron Produced Radioisotopes 
With the advent of the PET camera, positron emitters to be used in medical imaging were needed 
(18F, 11C, 13N, 15O, etc.). These radioisotopes are, in contrast to β- emitters, neutron deficient 
isotopes. Thus they cannot be produced in nuclear reactors or with neutron sources. The last 
statement does not preclude the production of radioisotopes with excess neutrons in cyclotrons, 
since it only depends on the initial target material used and the energy of the incident proton 
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beam. In contrast with nuclear reactors that cannot be shut down once built and keep producing 
high level nuclear waste until the fuel is spent, cyclotron are started and stopped at will (Fig 9). 
 
Fig 9 Cyclotron working principle; A and B: Dees; yellow dots: perpendicular magnetic field 
(22). 
With a constant perpendicular magnetic field (yellow dots in Fig 9), a charged particle is 
generated in the center (normally a proton, an ionized H+ atom). Dees charge is change 
sequentially to accelerate the proton and increase its energy. The particle is finally release 
through a port to irradiate the targets. The maximum kinetic energy obtained is: 
ܧ௠௔௫ = ௤
మ∙஻మ∙௥మ
ଶ∙௠   (2.2.2.1) 
Where q is the charge of the particle, B is the incident magnetic field and r is the maximum radius 
before release (radius of the cyclotron). For every day clinical use (especially for production of 
18F) high energy cyclotrons are not needed. Since the energy is proportional to the square of the 
cyclotron radius, smaller cyclotrons can be built. For these reasons and to reduce initial 
investment and running costs, small cyclotrons are currently produced and commercialized.  
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Fig 10 Siemens Eclipse™ series cyclotron produces high quantities of 18F, 11C, 13N, 64Cu and 15O 
(Width: 95 in. (240 cm), Depth: 73 in. (184 cm), Height: 90 in. (230 cm)) (23) 
Higher energies (translated into bigger machines and costs) are needed for the production of other 
positron emitters and positron emitter parent for the production of radioisotopic generators (Table 
3). 
Table 3 Positronic radionuclides production vs. incident proton energy 
Proton Energy (MeV) Radionuclides Produced (usable quantities) 
0-10 18F, 15O 
11-16 11C, 18F, 13N, 15O, 22Na, 48V 
17-30 124I, 123I, 67Ga, 111In, 11C, 18F, 13N, 15O, 
22Na, 48V, 201Tl 
30 + 124I, 123I, 67Ga, 111In, 11C, 18F, 13N, 15O, 82Sr, 
68Ge, 22Na, 48V 
 
2.2.3 Radioisotopic Generators 
A radioisotopic generator is a radiochemical separation system in which quasi stable decay 
equilibrium is reached between a parent and a daughter nuclide (half-life (t1/2) of parent has to be 
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at least a 10 fold greater that the half-life of the daughter). The system should allow the effective 
separation of the daughter nuclide from its parent nuclide with high radiochemical and 
radionuclidical purity. It is goverened by the exponential disintegration and accumulation laws 
formulated by Rutherford and Soddy in 1902 (24).  
2.2.3.1 Nuclear Physics of Radioisotopic Generators 
Given the disintegration scheme: 
ଵܺ
ఒభ→ ܺଶ
ఒమ→ ܺଷ(௦௧௔௕௟௘)  
The number of daughter nuclides (N2) formed by disintegration of the parent nuclide (N1) is given 
by the following equation:  
ଶܰ = ఒభఒమିఒభ ଵܰ൫݁
ିఒభ௧ − ݁ିఒమ௧൯ + ଶܰ݁ିఒమ௧ (1.1) 
Substituting ܣ௜ = ௜ܰߣ௜ the Activity is expressed as: 
ܣଶ = ఒమఒమିఒభ ܣଵ൫݁
ିఒభ௧ − ݁ିఒమ௧൯ + ܣଶ݁ିఒమ௧ (1.2) 
where ߣ௜ = ୪୬ଶ௧భ/మ(೔) is the disintegration constant of the particular radioisotope (i). 
The first part of the equation represents the activity of the daughter nuclide while being formed 
by decay of the parent. The second part corresponds to the decay of the daughter nuclides existing 
at initial time (t=0). After complete extraction (elution) of the daughter nuclide, the second part 
nullifies, thus the first part describes the daughter nuclide accumulation in the system. To obtain 
the maximum accumulation time equation (1.2) is derived and equated to cero: 
ݐ୫ୟ୶୧୫୳୫௔௖௖௨௠௨௟௔௧௜௢௡ =
୪୬ഊమഊభ
ఒమିఒభ (1.3) 
The equation (1.3) is used to calculate the optimum elution time for the system. 
As stated before the condition ܴ௧ =
௧భ
మ೛ೌೝ೐೙೟
௧భ
మ೏ೌೠ೒೓೟೐ೝ
≥ 10 is needed for an effective generator. Taking 
Rt into consideration three different conditions can be defined: ܴ௧ < 10	݊݋	݁ݍݑ݈ܾ݅݅ݎ݅ݑ݉, 
17 
 
10 < ܴ௧ < 100	ݐݎܽ݊ݏ݅݁݊ݐ	݁ݍݑ݈ܾ݅݅ݎ݅ݑ݉ and ܴ௧ > 100	ܵ݁ܿݑ݈ܽݎ	ܧݍݑ݈ܾ݅݅ݎ݅ݑ݉. In transient 
equilibrium the process is governed by equation (1.2) and no approximation is possible. Daughter 
nuclide is initially accumulated and then decays with the half-life of the parent nuclide (Fig 11 
A). However in secular equilibrium the parent nuclide can be considered almost stable compared 
to the decay of the daughter so only apparent accumulation is observed (Fig 11 B). 
 
Fig 11 Decay and accumulation representation of A: the 99Mo/99mTc generator and B: the 
68Ge/68Ga generator. 
The useful life of a radioisotopic generator is given mainly by the half-life of the parent nuclide. 
However, other factors like the chemical, radiochemical and radionuclidical purity of the elution, 
the elution yield and radiolytic damage to the supporting material also affect the effective life of a 
system. Based only on nuclear properties, some examples of parent/daughter couples for 
generator production are shown on Table 4. 
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Table 4 Some Parent/Daughter couples with transient and secular equilibrium 
Pair Parent t½ Daughter t½ 
28Mg/28Al 20.9 h 2.24 min 
42Ar/42K 32.9 y 12.36 h 
47Ca/47Sc 4.54 d 3.35 d 
90Sr/90Y 28.8 y 64 h 
99Mo/99mTc 66.02 h 6.02 h 
113Sn/113mIn 115.1 d 99.5 min 
115Cd/115mIn 53.5 h 4.5 h 
125Sb/125mTe 2.77 y 58 d 
132Te/132I 78.2 h 2.3 h 
137Cs/137mBa 30.1 y 2.55 min 
188W/188Re 69.4 d 17.0 h 
44Ti/44Sc 60.0 y 3.93 h 
68Ge/68Ga 278 d 67.7 min 
2.2.3.2 Radiochemistry of Radioisotopic Generators 
Once a parent/daughter system is identified as idoneous according to its nuclear properties for 
generator construction, a new set of challenges is faced.  There is a need for an effective 
radionuclidical separation that allows both: potential use of the daughter nuclide in the desired 
application and conservation of the parent nuclide for further daughter production. Further, the 
designed system has to be simple, reliable, and easy to use.  
Liquid-liquid extraction was one of the first approaches and it is still used to date (e. g. 72Se/72As, 
(25)). However, simplicity is not one of the virtues of these generators. Long manipulation times 
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of open radiation sources (resulting in high radiation exposure) are never desired for general use. 
Chromatographic columns are the best chemical separation systems to produce radioisotopic 
generators. The parent nuclide has to be trapped with high specificity in the column material 
while no (or very low) attachment must be shown for the daughter nuclide. Thus, eluting the 
column with a given solution will yield pure daughter ready for applications. The column 
material is also preferred to be inorganic, to minimize a radiolytical effect (Fig 12). 
 
Fig 12 Schematics of the 99Mo/99mTc generator’s chromatographic column (26). 
However, sometimes it is virtually impossible to achieve ideal conditions. So it’s the case of the 
90Sr/90Y generator, in which 90Sr is absorbed in an organic cation exchanger and the daughter 
(90Y) is eluted or “milked” from the column using a diluted (0.005 M) EDTA solution. The 
EDTA chelation of 90Y severely limits the applications of the radioisotope; therefore extended 
post-elution treatment has to be made in order to obtain pure, ionic 90Y for medical applications 
(27). Some of the available radioisotopic generators for medical applications are shown on Table 
5. 
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Table 5 Some commercially available radioisotopic generators for medical use 
Pair Separation 
Technology 
Use Drugs Available Nuclear 
Imaging 
90Sr/90Y Cation 
Exchanger 
Therapy TheraSpheres, 
RMTSpheres. 
PET-double 
scape, pure beta 
emitter 
188W/188Re Alumina Therapy HDD/lipiodol, 
phase II 
Planar Scan, 
SPECT 
99Mo/99mTc Alumina Diagnostic Sestamibi, Sulfur 
Colloids, MAA, 
others 
Planar Scan, 
SPECT 
44Ti/44Sc AG-1x8 Diagnostic None Approved PET 
68Ge/68Ga TiO2, SnO2 Diagnostic DOTATOC,  
phase III 
PET 
2.2.3.3 The 68Ge/68Ga generator. 
Several inorganic matrices have been used to construct the 68Ge/68Ga generator: Al2O3 (28), TiO2 
(29), α-Fe2O3 (30) and SnO2 (31). Lately, attempts to use organic resins have been made (32). 
These generators benefit from the fact that there should be no metallic impurities in the eluate, 
thus producing better labeling. However concerns about radiolysis and the insertion of other 
organic contaminants are still present. These organic generators are still under evaluation. Table 6 
resumes the technology currently available for production of 68Ge/68Ga generators.  
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Table 6 Available 68Ge/68Ga Generator Systems 
Generator 
matrix 
68Ga elution 
yield (%) 
Eluent 68Ge content in 
the eluate 
Other 
Contaminants 
Al2O3 - 
Not 
Commercialized 
60-70% initially, 
decreasing to 
under 40%. 
0.005 % EDTA More than 
0.001% of the 
generator 
activity 
Contains Al3+ in 
huge amounts 
Al2O3 - 
Not 
Commercialized 
50% for more 
than a year 
NaOH solution 
(pH=12) 
0.0001% of the 
total activity 
when combined 
with a second 
Al2O3 column. 
Around 20 ppm 
of Al3+ 
TiO2 (Second 
Generation, 
IGG-100) -  
Eckert & Ziegler 
60-80% for two 
years 
0.1 N HCl < 0.00001% Low amounts of 
Ti and others 
SnO2 - iThemba 
Labs 
75-80% for two 
years. 
1N HCl 0.0002% Low amounts of 
Sn and others 
Liq-Liq  Not 
Commercialized 
60%, huge 
losses in 68Ge in 
reextraction. 
8-
hydroxyquinoline 
0.003% No metal 
impurities 
SiO2 ITG GmbH 80 % for 6 
month 
0.05 M HCl 0.005% No metal 
impurities 
Organic Matrix -  
Not 
Commercialized 
70-80% stable 
for 2 years (with 
very low 68Ge 
initial activity). 
0.1 N HCl 0.0001% No metal 
impurities 
 
From the two commercially available generators, iThemba Labs’s SnO2 and Eckert and Ziegler’s 
TiO2, the one with the best results (already with FDA’s manufacturing authorization (33)) is the 
later (Fig 13). SnO2 generators have the additional complication of high HCl content in the eluate, 
making it harder to buffer for labeling. However, the iThemba Labs generator is nearly 7 
thousand dollars cheaper than the TiO2 (Eckert and Ziegler). The iThemba Labs generator could 
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benefit from a 68Ga pre-labeling concentration/ purification method which would ease the use of 
the eluted 68Ga. 
 
Fig 13 Eckert & Ziegler IGG 100 Gallium-68 radioisotopic generator 
2.3 Lung Perfusion Agents 
Lung perfusion scintigraphy with 99mTc-MAA is the current medical gold standard for the 
diagnosis of pulmonary embolism (34). The principle is that intravenously injected labeled 
microparticles (99mTc-MAA, > 10 µm) will be trapped in the lung’s capillaries (or pre-capillaries 
with diameter of 7-10 µm (Fig 14) (35)) causing temporary micro-embolisms (36). The number 
of these embolisms is proportional to the local rate of blood flow (37). After elimination from the 
lungs (biological half-life of 1-24 h (38; 39)) 99mTc is excreted to the urine (40). The radioactivity 
allocation in the lungs is used to detect areas of poor or absent blood perfusion and to localize the 
embolism.  
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Fig 14 A: Lung corrosion cast showing vasculature (41), and B: Lung perfusion SPECT with 
99mTc-MAA (42) 
Although the use of MAA as a perfusion agent is extensive, it has been acknowledged to not be 
“ideal” (43). The presented size distribution (10-90 µm) did not comply with optimal 
specifications (20-40 µm) to allocate in precapillary arterioles. Orientation of macroaggregates 
(seldom spherical) in the blood flow becomes important to determine “effective size”, making it 
difficult to predict the in vivo behavior. Aggregate degeneration is another component making the 
size distribution variable and unreliable (43). The ideal (theoretical) perfusion particle should be 
spherical (size not to be dependent on particle orientation) with a size distribution of 13.5±1.5 
µm, to allow distribution only in capillaries (estimated 2.8•1011 available in lungs) and not 
precapillary arterioles (estimated 3•108 available in lungs) (43). However, for practical 
preparation purposes a size distribution of 30±10 µm is also considered safe since only about 105 
particles are injected (43). The highly anastomotic nature of pulmonary circulation assured no 
disruption in blood flow or pressure during lung perfusion imaging. Human Serum Albumin 
(HSA) microspheres (also called HAM) were identified early as potentially ideal perfusion 
agents. The first lyophilized kit was produced in 1970 (44) but needed a boiling water bath for 
high labeling yield. It also had thiosulfate (reducing agent) and detergent as part of the excipients, 
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due to the strong aggregation of the HAM. Aggregation and easiness of preparation are probably 
the main reasons why MAA prevailed over HAM as a lung perfusion agent. 
Human albumin (MAA and HSA) has other known side effects ranging from nausea to cardiac 
arrest (45). Although these adverse reactions are extremely rare since the blood has a high human 
albumin concentration, there is always a risk for disease transmission (e.g. hepatitis C). Despite 
differences in MAA from the “ideal perfusion particle” (with respect to size distribution and 
morphology), there are no reports in the literature of failed studies or inconsistent distribution. 
Therefore 99mTc-MAA must be considered a satisfactory lung perfusion agent. 
However, more to the point of this dissertation, another important application of 99mTc-MAA is in 
the Radiomicrosphere Therapy (RMT) planning (46). Non-spherical macroaggregates (MAA, 10-
90 µm) are used to predict the distribution behavior of perfectly spherical spheres (SirTEX and 
TheraSpheres ≈ 30±5 µm) (Fig 2) used for RMT. Despite the differences in size and morphology, 
MAA prediction of particle allocation is a valuable tool in RMT planning; however, whether a 
better planning agent can ultimately produce a better outcome is still an open question. 
2.4 Radiomicrosphere Therapy (RMT) 
In 2010 new cases of primary liver and intrahepatic bile duct cancer in the US reached 24120, 
with 18910 deaths, and colorectal cancer new cases reached 142570 with 51370 deaths, which 
nearly half of the latter becoming metastatic liver cancer (47). Liver cancer (primary or 
metastatic) accounts for nearly 10% of all cancers in the US alone with incidence being even 
greater in eastern countries. Treatment modalities involve surgery (48), chemotherapy (49), 
chemoembolization (50), thermal ablation using radiofrequency or microwave probes (51; 52) 
and Radiomicrosphere Therapy (RMT) (53; 54). The current RMT, also called Selective Internal 
Radiomicrosphere Treatment (SIRT) is indicated for patients with unresectable liver cancer, 
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especially hepatic cell carcinoma and metastatic liver cancer (54). RMT in combination with 
chemotherapy, also known as chemo-RMT, has been proposed to improve patient outcome (3; 2). 
The sphere size (≈30 µm) is slightly larger than the smallest blood vessels (≈10 µm), which 
assures the deposition of these particles as the arterial branches decrease in size. The narrow size 
distribution is necessary so that no particles escape and pass into the venous circuit. Further, the 
micro-vascular density of liver tumors is 3-200 times greater than the surrounding liver 
parenchyma (Fig 15), making the tumor allocation preferential with respect to normal tissue. The 
treatment undergoes several stages, as will be described next. 
  
Fig 15. Anatomy of the Liver (55) and corrosion cast of the venous and arterial system (56) 
When the patient is admitted several studies are performed including a 18F-fluorodexoxy glucose 
or (18F)FDG. A PET-CT scan is performed to assess tumor viability and to evaluate lesion 
(cancer) extent. A biopsy is also recommended to determine the nature of the cancer. If RMT or 
chemo-RMT is indicated as the proper treatment option, the patient is then prepared for treatment 
planning. The patient is put under local anesthesia and a catheter is inserted through the patient’s 
groin and guided towards the hepatic artery under fluoroscopic imaging (Fig 16). Dyes are 
injected (hepatic angiogram) to identify the branches that go to the stomach and other organs. 
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These branches are properly coil embolized to prevent the particles from moving to these areas 
(Fig 16). The angiogram also provides valuable information about the main branches feeding the 
tumor, this information is used for the treatment planning as well (57). 
 
Fig 16. Hepatic Artery Angiography with preferential flow to tumors and coil embolization 
example (58). 
Once all the steps are completed, macroaggregated albumin particles labeled with 99mTc are 
injected into the site. A planar scintigraphy to visualized lung, gastrointestinal (GI) and liver 
allocations is performed after injection (Fig 17). The tumor to liver ratio is also calculated to 
evaluate the potential effectiveness of the future treatment. The greater the tumor/liver ratio, the 
greater the potential effect of RMT while reducing the damage to healthy liver. The liver to lung 
ratio is used to evaluate if some of the therapeutic particles will allocate in the lungs after 
injection and produce radiation pneumonitis. If 20% or more of the particles go to the lung then 
the patient is no longer a candidate for RMT or a different approach must be followed (2). If any 
GI allocation is observed, the conducing vessels need to be coil-embolized before the treatment is 
administered. 
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Once the planning is complete, radiomicrospheres are injected into the different branches as 
planned and follow up PET and CT scans are performed to assess the effectiveness. Response to 
this treatment varies and over a third of all patients do not respond at all (59). The advantage of 
RMT plus chemo vs. chemo alone has been observed. In a double arm controlled phase II clinical 
trial RMT was selectively administered to half of the liver along with chemotherapy to the entire 
organ.  This highly selective injection protocol allowed for half of the liver to be treated with 
Chemo-RMT while the other half with chemo alone (figure 7) (59) so that each patient could 
serve as their own control. The results clearly demonstrated the advantage of adding RMT to 
chemotherapy. 
 
Fig 19. (18F)FDG PET-CT before and after treatment in three patients, lower half of the liver (left 
of green line) treated with Chemo-RMT, other half (right of line) treated with Chemo only (59) 
demonstrating improved response of RMT combined with chemotherapy and the potential for 
“highly” RMT. 
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2.4.1 Limitations of RMT 
The greatest limitation of RMT is the difficulty of dosimetric quantifications during the treatment 
planning. This is due to the fact that the 99mTc-MAA scintigraphy (Fig 20) is a single photon 
emission tomography technique (SPECT) and the difficulty in obtaining proper attenuation 
correction as compared to positron emission tomography (PET).  
 
Fig 20. Anterior and Posterior 99mTc-MAA Planar Scintigraphy (58) 
From the 99mTc-MAA planar image above (Fig 20) it is clearly impossible to determine what is 
lung and liver and how much overlapping exists. However better visualization is achieved when 
SPECT/CT is used (Fig 21) but as discussed previously quantification is very difficult. 
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Fig 21 Duodenal accumulation (arrow) in a patient with colorectal cancer, not definable on planar 
images. A: planar scan, B:SPECT/CT coronal view (60) 
The RMT planning will be greatly benefited by the inclusion of a PET isotope, since the 
technique is generally considered better than SPECT because of the ability for absolute 
attenuation correction and potentially superior resolution. Important advances were made in early 
years by labeling MAA with the PET isotope 68Ga (61), obtaining an 80 % labeling yield and 
purity > 95% for the Pulmolite MAA kit. However the potential of 68Ga-MAA was forgotten until 
recently, when new lung perfusion studies were made using this drug, partially due to availability 
of a reliable 68Ge/68Ga generator with minimal breakthrough impurities and high 68Ga yield (62) 
(Fig 22).  
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Fig 22 Results for 68Ga-MAA lung perfusion studies showing areas of low perfusion not seen 
with 99mTc-MAA SPECT (62). 
Similarly to 99mTc-MAA, 68Ga-MAA use was quickly extrapolated to RMT planning (63). 
Preliminary results show some advantages of a PET tracer over the common 99mTc-MAA for 
SPECT in tumor/liver ratio calculations and lung shunting localization (Fig 23).  
 
Fig 23 PET/CT image of 68Ga-MAA used for RMT planning (63) 
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The 68Ga-MAA used for both: the lung perfusion and RMT in planning studies; was prepared 
using the original MAA kit for 99mTc. This kit needs to be modified (washed) to obtain high 68Ga 
labeling yields which increase manipulation and therefore the risk of product contamination (61). 
A 68Ga specific lyophilized kit for labeling is not available in the market. Further, the MAA 
particles are supposed to act as surrogates for the 90Y labeled spheres and thus serve to predict the 
volume distribution of the 90Y. Imaging is mainly utilized for determination of lung-shunt 
fraction, and detection of extra-hepatic gastrointestinal uptake, both of which could be restrictive 
for safe administration of the treatment. Thus an accurate measurement is dependent on the 
distribution of the MAA particles and the assumption that its distribution will be identical to that 
of the 90Y microspheres. However, the size (10 to 90 µm with no particle over 150 µm) and the 
very irregular shape of the MAA do not at all resemble spheres. Hence the MAA used for 
imaging and treatment planning is actually a poor surrogate for the 90Y microspheres used for the 
actual therapy (Fig 2). Therefore, new biodegradable particles are needed for treatment planning.
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CHAPTER 3 68Ga PURIFICATION SYSTEM 
3.1 Abstract 
Purification of 68Ga obtained from the existing 68Ge/68Ga generators is a must.  With great 
potential for radiopharmaceutical use, the long half-life of the parent nuclide (68Ge, 278 days) 
demands absolute 68Ga radionuclidical purity. Metal impurities (Ti, Sn, Fe and Zn mainly) also 
interfere in the radiopharmaceutical labeling process. A combination of chromatographic 
exchange resins was used and a full system was designed to be used in four simple steps: elution - 
cleaning - purification - extraction. The solutions concentrations and volumes were optimized. 
With low cost and less than 10 minutes processing, the final 68Ga solution is easily buffered with 
Sodium Acetate for labeling. The disposable system can easily be recycled and re-sterilized to 
reduce cost even more. It is also an alternative for 68Ga research laboratories since it can be used 
for over 100 elutions for more than 3 months without reconditioning for non-human applications 
and still provide reliable purification and labeling. 
3.2 Introduction 
Positron Emission Tomography (PET) is a medical imaging technique with high resolution and 
sensitivity. It can use the so called “biogenic” radioisotopes (11C, 13N and 15O) produced in a 
cyclotron; however their short half-life (20.3 min, 9.97 min and 2.03 min, respectively) (64). The 
most used cyclotron produced radioisotope is 18F (half-life 109.7 min) in its 18FDG form. Another 
cyclotron produced radioisotope is 68Ga, which can also be obtained from the 68Ge/68Ga 
generator. 68Ga (half-life 68 min) presents great potential for radiolabeling of several imaging 
agents, especially peptides for theranostic applications. Whether it is cyclotron or generator 
produced, the product needs purification before labeling (65; 66). Existing systems employ either 
34 
 
acetone as elution media (65) which poses a patient risk or high HCl volumes that complicate 
handling (29) (Fig 24).  
 
Fig 24 Schematic representation of available systems for 68Ga post-elution processing (29). 1: 
Direct Elution; 2: Purification with HCl/Acetone mix after Cation absorption; 3: Elution to Conc. 
HCl; 4: Absorption into anion exchanger; 5: Desorption with water; 6: Fractionated elution. 
Fractioning is a safer method than using acetone or high HCl volumes, however only around 60% 
of the eluted activity (already around 60 % of the activity of the generator) can be used (29). A 
new, cGMP capable, single use and low cost 68Ga purification system is needed for 
radiopharmaceutical applications. 
3.3 Materials and Methods 
A combination of chromatographic exchange resins was used to build the purification system 
(67). Two luer-fitting column beds were prepared. First, 40±10 mg of AG-50Wx8 cation 
exchange (Eichrom, USA) column is connected to a three-way stopcock. Next, 15±5 mg of 
UTEVA® anion exchange (Eichrom, USA) resin in a column is positioned. Finally, another 
three-way stopcock is located at the end (Fig 25 Purification System setup). The purification of 
the 68Ge/68Ga eluent takes place in four simple steps: elution (from the generator, 5 ml of 0.1 M 
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HCl) - cleaning (1 ml of 0.1 M HCl) - purification (1 ml of 5 M HCl) – extraction (1 ml of 
Millipore Water). 
3.4 Results and Discussion 
The assembly of the purification system is simple and easy to use (figure 2).   
 
Fig 25 Purification System setup 
The optimized and simple four-step purification process is as follows: 1. Elution of the generator 
using a 0.1 M HCl solution. During this step the gallium is trapped with most of the metal 
impurities in the cation exchanger. Most of the 68Ge contamination is removed in this step. 2. 
Cleaning is performed with one extra mL of 0.1 M HCl through the syringe dock to remove the 
excess solution coming from the generator. One mL of air is then vented to the system. 3. 
Purification is performed with slow elution using 1 mL of 5 M HCl. The Ga3+ forms a GaCl4- 
complex so it is released from the cation exchanger and absorbed onto the anion exchanger. One 
mL of air is also used to vent the system. All the metal impurities are eliminated in this step 
(especially Fe, Ti, and Zn). 4. Extraction is done using 1 mL of Millipore water in which the 
gallium complex is destroyed and released from the anion exchanger into the labeling vial. One 
mL of air is pushed through the system to remove most of the 68Ga (figure 3). The purification 
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system retrieves approximately 85% of the eluted gallium activity after 10 minutes of processing. 
It provides pure, pre-concentrated 68Ga in slightly acidic solution that is easily buffered by adding 
0.3 mL of 3 N ultrapure sodium acetate (67). All the 68Ge is eliminated in the process, 
consequently radio-nuclide impurities are eliminated from the labeling process. 
 
Fig 26 68Ga recovery and 68Ge elimination during the purification process 
The purification system can be reused for 100+ times without altering its performance. However 
to maintain sterility it is recommended to be used once and disposed of or reconditioned. 
3.5 Conclusions 
An inexpensive, simple to use and cGMP capable purification and preconcentration method for 
the 68Ga generator elution was created and optimized. Labeling yields obtained for different 
products are high (90 - 99.9 % depending on the application) and consistent. Great repeatability 
was shown in all purifications. The system is used but not limited to the Eckert and Ziegler IGG-
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100 68Ge/68Ga generator. It has also been used for purification of cyclotron produced 68Ge and it 
is a good candidate for use with the iThemba 68Ge/68Ga generator.  
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CHAPTER 4 68Ga-MAA 
4.1 Abstract 
Rapid developments in the field of medical imaging have opened new avenues for the use of 
positron emitting labeled microparticles. The radioisotope used in our research was 68Ga, which is 
easy to obtain from a generator and has good nuclear properties for PET imaging. METHODS: 
Commercially available macroaggregated albumin (MAA) microparticles were suspended in 
sterile saline, centrifuged to remove the free albumin and stannous chloride, re-lyophilized, and 
stored for later labeling with 68Ga. Labeling was performed at different temperatures and times. 
68Ga purification settings were also tested and optimized. Labeling yield and purity of re-
lyophilized MAA microparticles were compared with those that were not re-lyophilized. 
RESULTS: MAA particles kept their original size distribution after re-lyophilization. Labeling 
yield was 98% at 75 ºC when a 68Ga purification system was used, compared to 80% with 
unpurified 68Ga. Radiochemical purity was over 97% up to 4 hours after the labeling. The re-
lyophilized MAA and labeling method eliminates the need for purification and simplifies the 
labeling process. Animal experiments demonstrated the high in vivo stability of the obtained PET 
agent with more than 95% of the activity remaining in the lungs after 4 hours. 
4.2 Introduction 
Starting in 1964, several efforts have been made to find an agent for perfusion and embolization 
(68; 69). A lyophilized kit for the preparation of 99mTc-MAA was created in 1974 for Single 
Photon Emission Tomography (SPECT) imaging. With the arrival of Positron Emission 
Tomography (PET) the formulation of an analogue drug with a positron emitter was needed. 
Among the available PET isotopes 68Ga is easily obtained from its parent nuclide 68Ge by 
chromatographic column separation with different inorganic exchangers. The long lived parent 
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allows the construction of a generator that can last up to two years (70) compare to a 99mTc/99Mo 
generator which lasts only for 1-2 weeks. MAA was first successfully labeled with 68Ga in 1989 
(61), but never used, probably due to unreliability of the existing 68Ge/68Ga generators and low 
availability of PET imaging cameras. Revived interest has been shown recently (71), and the first 
PET lung perfusion studies in humans have been performed (Fig 27) (62).  
 
Fig 27 Comparison of A: Coronal and sagittal SPECT perfusion; B: Coronal and sagittal PET 
perfusion and C: axial PET/CT perfusion WITH 68Ga-MAA 
Radiomicrosphere Therapy (RMT), a technique used to treat metastatic liver cancer, could also 
benefit from a PET perfusion tracer. During the planning stage, a 99mTc-MAA perfusion scan is 
performed to assess the allocation in lung and gastrointestinal tract. It is also used to calculate 
tumor to normal liver allocation ratio (46). The distribution acts as a predictor of the treatment 
safety and effectiveness. A PET perfusion agent (e.g. 68Ga-MAA) could provide valuable, 
quantifiable information to calculate precise doses, which could potentially improve the treatment 
outcome. Initial work with 68Ga-MAA for RMT planning has already been performed (72). 
All reported 68Ga labeling of MAA has been done using a commercial MAA kit for 99mTc. The 
original kit contains 100 µg of stannous chloride and free albumin; hence the particles need to be 
washed with saline before 68Ga labeling. The maximum reported labeling yield using this kit is 
around 80% (71). Elimination of the free 68Ga via centrifugation is therefore necessary. The 
purification process is also required to eliminate traces of the long half-life 68Ge that are eluted 
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from the generator. A new 68Ga specific MAA lyophilized kit is needed for labeling. Further, it 
needs to be combined with a pre-purification system that assures prior elimination of 68Ge traces 
and provides pure, pre-concentrated 68Ga for labeling. 
4.3 Materials and Methods 
 4.3.1 MAA lyophilized kit preparation 
Macroaggregated Albumin (MAA) was obtained from Triad Isotopes® (DraxImage® Kit). The 
content was reconstituted with 0.9% saline solution, separated into two 15 ml centrifuge tubes, 
centrifuged (Eppendorf, Germany) and the supernatant discarded (“Washed MAA”) (61). The 
particles were then re-lyophilized overnight and stored for labeling (“Re-Lyophilized MAA”). 
Size and morphology analysis was performed on the reconstituted MAA using an optical 
microscope (Micromaster, Fisher-Sci, USA) and a hemacytometer (Reichert, USA) before and 
after re-lyophilization. The 68Ge/68Ga generator used was the 50 mCi IGG-100 (Eckert & Ziegler, 
Germany), based on the TiO2 resin technology, eluted with 5 ml of 0.1 M ultrapure HCl (Sigma-
Aldrich, USA) solution. 
 4.3.2 MAA Labeling  
Both, washed MAA and re-lyophilized MAA, were labeled (using the original Green’s method 
(61; 71)) with either purified or unpurified 68Ga solution. The unpurified 68Ga solution was 
obtained directly from the generator (5 ml, pH=1). The purified 68Ga elution (1 mL with pH=0.6) 
was obtained from the purification system. Both were buffered using 0.3 ml of 3N ultrapure 
sodium acetate (Sigma-Aldrich, USA). The solution was added to the 15 ml centrifuge tube 
containing the MAA. Labeling was performed using a thermomixer with a heating block for 15ml 
centrifuge tubes and stirring at 750 rpm (Eppendorf, Germany). Labeling temperature was 25 
(room temperature), 50, 75 and 95 degrees Celsius. Labeling time was set at 15 minutes based on 
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previous reports of 68Ga-MAA labeling kinetics (61; 71). Particles were separated from the 
supernatant by centrifugation. The particles and supernatant were measured separately using an 
Atomlab 100 dose calibrator (Biodex, USA). Final particles were re-suspended in 5mL saline 
solution with a vortex mixer (Fisher-Sci, USA). 
4.3.3 Lung Perfusion Experiments: 
Sprague Dawley rats (200-225 grams, 2 per time point) were obtained from Harlan Laboratories 
(Harlan, USA). Animals were weighed before the procedure and anesthetized using an Ohmeda 
Isotec 3 isolfurane vaporizer (GE Healthcare, USA). Isolfurane levels were kept ≤3 % at all 
times. Once completely anesthetized, animals were restrained in the supine position and a torso 
X-Ray was obtained (Belmont Acuray 071A, USA). Later, 100 µL of the labeled MAA (8,000-
10,000 particles) with an activity ranging from 50 to 100 µCi (1.85-3.7 MBq) was injected 
through the lateral tail vein. Animals were euthanized at 2 or 4 hours. For either time points their 
lungs, liver, spleen, heart, kidneys, ribs and 0.2 ml of blood and urine were collected, weighed 
and activity measured using a Cobra 5000 well counter (Packard, USA). Un-collimated 
autoradiography images (in the unaltered supine position the X-Ray was obtained) were also 
taken at 1, 2, 3 and 4 hours (Packard Phosphorimager, Perkin Elmer, USA). Free 68Ga was 
injected as a control. Additionally, imaging and organ collection were performed following 
99mTc-MAA and free 99mTc injection for comparison purposes. 99mTc-MAA and Na99mTcO4 were 
purchased from a local pharmacy (Triad Isotopes®, USA). Pertechnetate was reduced with 100 
µg of Stannous Chloride (Sigma-Aldrich, USA) before injection. The obtained X-Rays and the 
autoradiography images were superimposed to provide anatomical and functional data. 
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4.4 Results and Discussion 
 4.4.1 MAA re-lyophilization 
The elimination of the excess free albumin is a necessary step prior to successful labeling with 
68Ga (“washed MAA”) [4, 5]. Re-suspension of the particles was fast using a vortex mixer; 
manual shaking of the vial was also efficient. Re-lyophilization of the MAA did not change either 
the particle’s size distribution or morphology (figure 1). 
 
Fig 28 MAA microscope images; A: From original un-modified MAA kit and B: From re-
lyophilized MAA. 
4.4.2 MAA Labeling 
Labeling yield of MAA with unpurified 68Ga was 78.3±3.1 % after 15 minutes at 75 ºC, similar to 
that reported by other investigators [4]. A labeling yield of 72.1±6.2 % was obtained at 50 ºC 
(Figure 4). Better labeling yield (96.9±2.1 %) was obtained at 95 ºC, however the particle 
morphology was considerably changed. Smaller particles were detected and in higher 
concentration, apparently due to the rupture of bigger macroaggregates. The labeling yield at 
room temperature was 50±4 %. Radiochemical purity tests were conducted for all the products 
showing more than 97% in vitro stability in all cases after 4 hours. 
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Fig 29 68Ga-MAA labeling yield results. 
The introduction of the 68Ga purification system improved the labeling yield significantly 
(p<0.003). An 84.1±3.1 % labeling yield was obtained at room temperature (25ºC). This yield is 
higher than the maximum yield obtained at 75 ºC with unpurified 68Ga. However, if room 
temperature labeling is performed, post-labeling purification is still needed to assure a final 
radiochemical purity >90 %. In the particular case of MAA, labeling at up to 75ºC has been 
proven to not damage the particles. Nevertheless, synthesis near room temperature or elimination 
of the heating step all together is obviously desirable. Good labeling yield of 92.8±2.6 % was 
obtained at 50 ºC. However, when labeling at this temperature, purification is still recommended 
since nearly 10 % of free 68Ga will be present in the final product. 
The labeling of MAA with purified 68Ga yielded the best results at 75 ºC (figure 4). A labeling 
yield of 97.6±1.5 % was obtained after 15 minutes of reaction. Particle distribution and 
morphology remained well within specifications and a >95% radiochemical purity was obtained. 
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Labeling at this temperature eliminates the need for a final purification of the product, rendering 
the radiopharmaceutical ready for injection immediately. Experiments with purified 68Ga-MAA at 
95 ºC were not performed because of the previously observed particle change at that temperature. 
Re-lyophilized MAA labeling with purified 68Ga showed no significant difference from the 
results obtained with the Washed MAA (but not lyophilized, p>0.8). The elimination of the free 
albumin and the stannous chloride from the original formulation followed by re-lyophilization of 
the MAA does not compromise either re-suspension or morphology (and size distribution) of the 
particles. The re-lyophilized MAA (or MAA prepared without SnCl2 and free albumin), in 
combination with the 68Ga purification system, allows for the preparation of a single-use 
lyophilized kit for the preparation of 68Ga-MAA. This kit can be used for Positron Emission 
Tomography in lung perfusion studies, radiomicrosphere therapy (for liver cancer) planning and 
other applications requiring perfusion imaging. 
4.4.3 Lung Perfusion Experiments: 
More than 97% of the injected dose per gram of (ID/g) 68Ga-MAA activity was detected in the 
lungs after tail vein injection (seen in the image taken after 10 minutes, not shown) and until at 
least 4 hours after injection (Fig 30). Less than 2 % of ID/g activity was measured in any organ 
other than lungs after 2 and 4 hours. In contrast, most of the injected free 68Ga (> 60 %) remains 
in the blood after 4 hours (presumably as 68Ga-native transferrin complex). The remaining 
activity was extracted by the kidneys to the bladder (13 %) or absorbed by the liver (15 %).  
The behavior and “in vivo” radiochemical purity of 99mTc-MAA was different than that of 68Ga-
MAA. 99mTc was slowly released from the MAA and extracted by the kidneys into the urine 
(7.6±1.3 after 2 hours and 12.3±1.2 after 4 hours). Only 86.6±0.7 % of the decay corrected 
activity was found in the lungs after 2 hours, decreasing to 79.2±1.5 % at 4 hours. 
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Fig 30 Decay Corrected Organ Biodistribution of 68Ga-MAA, free 68Ga, 99mTc-MAA and free 
99mTc. 
Free 99mTc (reduced with SnCl2) allocates mainly in the lungs and liver. The % ID/g did not 
change over the study period. 68Ga-MAA exhibited better in vivo stability than 99mTc-MAA (Fig 
30). The autoradiography images clearly showed the preferential allocation of 68Ga-MAA in the 
lungs over the period studied (Fig 32). The drug-product in-vivo half-life was determined using 
regions of interest in the autoradiography images. A square cell of 40x40 mm was used to count 
the activity in the lung region for each time point. For 99mTc-MAA biological half-live was found 
to be T½=11.4±1.7 hours. This is consistent with the previously reported value of 11.5±4 hour 
biological half-life (73). The biological half-life of 99mTc-MAA is not to be confused with the 
MAA biological half-life. These are equal only if 100% in vivo radiochemical purity of 99mTc-
MAA is assumed. The assumption was reinforced by the fact that injected free 99mTc behaves 
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differently than that released from the MAA (Fig 30 and Fig 32). The only feasible explanation is 
that when free 99mTc is injected it forms nanocolloids with the SnCl2, being absorbed by the liver 
and lungs. While 99mTc released from the MAA is quickly absorbed by the kidneys. Furthermore, 
it is very unlikely that some form of degraded 99mTc-Albumin will be absorbed by the kidneys for 
excretion rather than be degraded in the liver. For over 40 years MAA half-life was considered to 
be in the 6-12 hour range (68; 73). However if MAA half-life happened to be so short, 
degradation would have been observed in the 68Ga-MAA experiments. The stronger 68Ga-MAA 
binding, with superior in vivo stability, proves that MAA half-life is much longer than previously 
assumed (46) and the shorter half-life can be attributed to the poorer stability of 99mTc-MAA. 
 
Fig 31 Normalized and radio-decay-corrected lung allocation for 68Ga-MAA and 99mTc-MAA at 
1, 2, 3 and 4 hours (n=2 per time point). 
The assumption of a shorter MAA half-life has little or no implication in lung perfusion studies or 
probe guided surgery. However a greater implication is present when using the radiolabeled 
MAA in planning for liver cancer RMT. The radio-microsphere technique is based on several 
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planning steps. One of them is a particle distribution assessment using 99mTc-MAA, mainly to 
determine lung and gastrointestinal (GI) allocation after hepatic artery injection. If only liver 
allocation is found (less than 20% lung allocation and no GI allocation), then the radio-
microsphere treatment is administered after 48 hours since the MAA is assumed to have been 
cleared from the vessels (assuming a MAA half-life of 6-12 hours). Despite the wrong MAA half-
life assumption, the treatment is successful. Therefore, it must be concluded that the effectiveness 
of the treatment does not require the complete decay of the treatment planning microparticles. 
Because they are injected in small numbers, enough arterioles seem to still be available for the 
allocation of the therapy particles. However, whether or not the treatment could benefit from the 
use of faster degrading planning particles (faster than MAA), remains an open question. 
Nevertheless, a precise determination of MAA half-life is needed, and can probably be measured 
by combining the strong gallium binding with an isotope with a longer radioactive half-life (e.g. 
67Ga-MAA, t½(67Ga)= 3.26 days). 
48 
 
 
Fig 32 Non decay-corrected, un-collimated full body autoradiography for free 68Ga (T½= 68 
min), 68Ga-MAA, 99mTc-MAA and free 99mTc (T½= 6.02 h) at 1, 2, 3 and 4 hours. Labeling of 
68Ga-MAA was performed with re-lyophilized MAA and purified 68Ga at 75 ºC for 15 minutes. 
The autoradiograph is superimposed on an X-ray image of the same animal in the unaltered 
supine position. 
The re-lyophilization of washed MAA was a first approach to show the feasibility of a 
lyophilized kit specifically for 68Ga-MAA. In a production facility the pharmaceutical 
development would need to be different from that of the 99mTc-MAA kit. Free albumin and SnCl2 
would not need to be added to the final product. The high labeling yield obtained during the 
preparation of 68Ga-MAA eliminates the need for final centrifugation for purification. What 
seems to be the apparent elimination of a single step has major implications. In these conditions 
the purification/labeling scheme can be easily automated using one of the available modular labs 
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for PET synthesis (e.g. Modular-Lab PharmTracer, Eckert and Ziegler, Germany), or it could 
easily be accomplished in a nuclear medicine hot-lab in a hospital. 
4.5 Conclusions. 
A Gallium specific lyophilized kit for 68Ga-MAA production was created. The kit is comprised of 
a vial containing MAA (re-lyophilized DraxImage® Kit), a 68Ga purification system and working 
solutions in the following syringes: 5 mL of 0.1 M HCl (elution), 1 mL 0.1 of M HCl (cleaning), 
1 mL of 5 M HCl (purification), 1 mL of Millipore Water (extraction) and 0.3 mL of 3 N NaAc 
solution (buffer). Labeling at 75 ºC for 15 minutes is recommended for labeling yields higher 
than 95% with no further purification necessary. Room temperature labeling is possible for 
producing 80% labeling yield, but post-labeling purification is needed. The in vivo stability of the 
obtained 68Ga-MAA drug product is superior to that of 99mTc-MAA. Use of 68Ga-MAA in RMT 
planning is potentially possible and likely to benefit from superior imaging/quantification and 
more accurate dosimetric calculations.  
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CHAPTER 5 99mTc Labeled Microspheres 
5.1 Abstract 
Chitosan Glycol (CHSg) and poly(glycerol-citric-dodecanediooate) (PGCD) microspheres are 
labeled with 99mTc as an alternative for MAA in perfusion SPECT studies. Microspheres are 
created and characterized. Labeling study and in vitro radiochemical stability were performed. 
Particle degradation in PBS buffer was also performed over 48 hours. A feasible particle size 
distribution of ≈30±10 µm was obtained for both compositions. High in vitro radiochemical 
purity was found for the labeled particles in the 4 hours study. Particle degradation was 24 hours 
for PGCD and 48 hours for CHSg in PBS buffer. Labeled microspheres were injected into 
Sprague Dawley Rats and biodistribution was determined after 2 and 4 hours. Both 99mTc-PGCD 
and 99mTc-CHSg were quickly allocated in the lungs after injection. PGCD microspheres 
degraded at a fast rate and most of the injected 99mTc activity was released from the lungs after 1 
hour. CHSg microspheres were proven useful for lung perfusion studies with 91 % and 83 % of 
the injected activity remaining in the lungs after 2 and 4 hours respectively. 
5.2 Introduction 
Since 1974 the use of 99mTc-MAA (macroaggregated albumin) has been established as the gold 
standard for lung perfusion studies (73). The availability of a MAA lyophilized kit (73) and the 
99Mo/99mTc radioisotopic generator (74) facilitated the use of 99mTc-MAA as a lung perfusion 
agent. As discussed previously, orientation of macroaggregates (seldom spherical) in the blood 
flow becomes important to determine “effective size”, making it difficult to predict the in vivo 
behavior. Aggregate degeneration is another component making the size distribution variable and 
unreliable (43). The ideal (theoretical) perfusion particle should be spherical (size not to be 
dependent on particle orientation) with a practical size distribution of 30±10 µm. Polymeric 
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spherical microparticles with narrow size distributions have been previously obtained (75). As 
stated before, RMT planning will most likely benefit from particles with shape and size 
distribution similar to that of the therapy microspheres. It will also decrease the risk of disease 
transmission due to human derived materials (MAA).  
Many of the available biocompatible polymers have been labeled with 99mTc. Some examples are 
99mTc-PLGA (poly(DL-lactide-co-glycolide)) nanoparticles (76), 99mTc-PLA (poly lactic acid) 
(77) and 99mTc-CHS (Chitosan) (78) among others. PLGA and PLA have known long (months) 
degradation times. CHS has been found to have an in vitro half-life greater than 21 days (79). 
This characteristic is relatively undesired when performing lung perfusion studies or for RMT 
planning, as the particles need to degrade fast (maximum 48 hour half-life) and restore blood 
flow. 
There are some alternatives of CHS in the market with both high and low solubility in water (80). 
Solubility of the polymer is directly related to particle degradation half-life. There is a 
compromise in the ideal particle degradation: it has to be slow enough to allow allocation in the 
lungs and imaging, but fast enough to clear the vessels and restore blood flow afterwards (half-
life 12-48 hours). One of the best candidates is found in Chitosan Glycol (CHSg), with only 2 
mg/ml solubility in water, well characterized and commercially available (Sigma-Aldrich, CHSg 
≥60%). Degradation can be manipulated using glutaraldehyde as crosslinking agent. Another 
potential polymer for microparticle preparation is our “in-house” poly(glycerol-citric-
dodecanediooate) (PGCD), since it degrades fast by hydrolysis and all the possible degradation 
products are biocompatible. Also, the speed of degradation can be manipulated by changing the 
C/D ratio, the greater the ratio, the faster it degrades. 
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5.3 Materials and Methods 
5.3.1 Particle Preparation and Characterization 
Chitosan glycol (Sigma-Aldrich, USA) particles were prepared using water in oil (w/o) emulsion 
technique. One ml of CHSg solution (2% w/v solution in 2% v/v Acetic Acid) was added drop 
wise to a round bottom flask containing an egg shaped magnetic stirrer, 20 ml of Toluene and 100 
µl of Tween® 80 (surfactant). Stirring rate was set at 1150 rpm (Corning-Cole Palmer, USA). The 
emulsion was stabilized for 15 minutes and 100 µl of glutaraldehyde (25 % in water, FisherSci, 
USA) was added. Stirring was continued for another 105 minutes. Later, toluene was decanted. 
Particles were washed three times with 200-proof ethanol (Sigma-Aldrich, USA) and lyophilized 
(Lyophilizer). PGCD was dissolved in 1 ml dichloromethane and added dropwise to a round 
bottom flask containing 20 ml of 0.5 Pluronic (F-127, BASF, Germany) solution stir at 850 rpm 
(Corning-Cole Palmer, USA). The emulsion was stirred for 2 hours until total evaporation of the 
CH2Cl2. Obtained particles were washed 3 times with water and lyophilized (Lab-Conco, USA). 
Size distribution, concentration and particle morphology were obtained with a hemacytometer 
(Reichert, USA) using an optical microscope (Micromaster, FisherSci, USA). 
5.3.2 99mTc-PGCD and 99mTc-CHSg labeling and stability  
Na99mTcO4 was obtained from a local pharmacy (Triad Isotopes, Miami, USA). One mCi was 
used to label approximately 100,000 particles in a 15 ml centrifuge vial containing the lyophilized 
particles after addition of 100 µl of 1 mg/ml SnCl2 stock solution (Sigma-Aldrich, USA). 
Labeling was performed during 30 minutes at 25 ºC and 750 rpm in a Thermomixer (Eppendorf, 
Germany). Particles were centrifuged, decanted from the supernatant and both measured for 
labeling yield.  
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Labeled particles (n=4) were resuspended in reconstituted (1% w/v) bovine hemoglobin lysate 
(FisherSci, USA). Particles were stirred for 4 hours at 37 ºC in a thermomixer (Eppendorf, 
Germany). Every hour the particles were centrifuged, decanted and measured together with the 
supernatant to assess radiochemical purity. 
Unlabeled particles were suspended in PBS buffer (pH≈7) and incubated at 37 °Celsius for a 
period of 48 hours. Samples were taken at 4, 12, 24 and 48 hours, gravity filtered through a 20 
µm nylon filter [Spectrumlabs, USA], recovered and counted in a hemacytometer to establish the 
remaining concentration. Decay profiles are shown in figure 22 demonstrating the potential for 
CHSg and PGCD for RMT planning (imaging). Therefore, these particles were further evaluated 
in vivo for lung perfusion studies. Thus, preliminary experiments were performed to evaluate in 
vivo degradation of CHSg in mouse (ND4 Swiss Webster, Harlan, USA) 
Lyophilized CHSg microparticles were re-suspended in carbonate buffer (pH=9.34). NHS-
Fluorescein (Thermo Scientific, USA) was dissolved in Dimethyl Sulfoxide (DMSO, Thermo 
Scientific, USA) with a concentration of 10 mg/ml. A total 1 mg of NHS-Fluorescein (100 µl of 
the stock solution) was added to the vial containing the particles and stirred for 2 hours (Fig 33). 
At the end of the reaction particles were centrifuged, washed three times with water and finally 
lyophilized (Lyophilized CHSg-Fluorescein).  
 
Fig 33 CHSg + NHS-Fluorescein reaction 
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For these preliminary experiments in mice, particles were re-suspended in saline solution for 
injection (FisherSci, USA) and ≈5000 particles were injected to each animal in the lateral tail 
vein. Animals were euthanized at 12 and 24 hours (n=2 per time point). Before extraction of the 
lungs, the trachea was isolated and a V cut was made. A syringe containing Optimal Cutting 
Temperature (OCT, Tissue-Tek, USA) liquid was inserted in the trachea and the lungs were filled 
with 0.5 ml. Lungs were finally extracted and frozen in a plastic mold filled with OCT and dipped 
in cyclopentane cooled to -80 ºC with dry ice. Specimens were obtained by cryosectioning the 
frozen samples in a Microtome (Leica, Japan). Sections were analyzed in a florescent microscope 
(Olympus IX81 with a Q Imaging Retiga 1300 Camera, USA). 
5.3.3 Lung Perfusion Experiments 
Animals (Sprague Dawley rats 200-225 grams, 2 per time point, Harlan, USA) were weighed 
before the procedure and anesthetized using an Ohmeda Isotec 3 isolfurane vaporizer (GE 
Healthcare, USA). Animals were restrained in the supine position (completely anesthetized) and a 
torso X-Ray was obtained (Belmont Acuray 071A, USA). Later, 100 µL of the labeled 99mTc-
PGCD or 99mTc-CHSg (8,000-10,000 particles) with an activity ranging from 1.85-3.7 MBq (50 
to 100 µCi) was injected through the lateral tail vein. Animals were euthanized at 2 or 4 hours. 
For both time points lungs, liver, spleen, heart, kidneys, ribs and 0.2 ml of blood and urine were 
collected, weighed and measured for activity using a Cobra 5000 well counter (Packard, USA). 
Non-collimated autoradiography images (in the unaltered supine position the X-Ray was 
obtained) were also taken at 1, 2, 3 and 4 hours (Packard Phosphorimager, Perkin Elmer, USA). 
In one group 68Ga was injected as a control. Additionally, imaging and organ collection were also 
performed with 99mTc-MAA and free 99mTc for comparison purposes. 99mTc-MAA was purchased 
from a local pharmacy (Triad Isotopes®, USA). Pertechnetate (obtained as Sodium Pertechnetate 
from Triad Isotopes, USA) was reduced with 100 µg of Stannous Chloride (Sigma-Aldrich, USA) 
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before injection. The obtained X-Rays and the autoradiography images were superimposed to 
provide anatomical and functional data. 
5.4 Results and Discussion 
5.4.1 Particle Preparation and Characterization 
The emulsion method used created spherical particles with a size distribution of approximately 
30±10 µm (figure 2). 
 
Fig 34 Obtained particles A: PGCD and B: CHSg. 
Lyophilization and labeling of the particles did not affect their size and morphology. Chitosan 
microparticles swelled 20-25% when placed in contact with water, a feature that was taken into 
consideration when producing these particles (Fig 35). The produced PGCD microparticles 
needed to be filtered through a 20 µm nylon filter (Spectra/Mesh, Cole Palmer, USA) to assure 
proper distribution (Fig 35). 
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Fig 35 Size distribution for: A: PGCD size distribution before and after filtration and B: CHSg 
size distribution in saline solution. 
5.4.2 99mTc-PGCD and 99mTc-CHSg Labeling and stability 
Particles were labeled obtaining 87.5±4.1 % and 94.7±0.2 % labeling for PGCD and CHSg 
respectively (Fig 36). PGCD microspheres showed better in vitro stability with over 97 % 
radiochemical purity at all times during the 4 hour study. CHSg microparticles quickly decreased 
the radiochemical purity to 82% remaining fairly constant afterwards (80% after 4 hours) (Fig 
36). 
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Fig 36 Labeling yield and in vitro radiochemical purity of 99mTc-CHSg and 99mTc-PGCD. 
Even though the in vitro radiochemical purity of 99mTc-CHSg decreased rapidly to 80% after 
labeling, the particles were tested in animal experiments. Lung perfusion studies are performed 
with particles allocating in the vessels and the vessel occlusion locally reduces the fluid in contact 
with the particles increasing the chances of a successful image. Because of the high labeling yield 
obtained for 99mTc-CHSg (96.1±0.3 %) the particles did not need post-labeling purification. The 
87.5% labeling yield obtained for the PGCD microspheres was high enough for imaging studies 
but post-labeling purification is required. This was performed by centrifuging the particles (1000 
rcf, 30 seconds) and removing the supernatant using a 5” spinal needle. Particles were later 
resuspended in saline for injection.  
Microsphere in vitro degradation showed an approximated half-life of 24 hours for PGCD and 48 
hours for CHSg (Fig 37). Chitosan (CHS) is shown as a control since its degradation is known to 
be longer. In vivo degradation (for both CHSg and PGCD microparticles) is expected to be faster. 
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number of images were necessary to quantify the particles half-life. Extended lung crysectioning 
experiments were performed and are described in Chapter 6. 
 
Fig 39 Cryosection Images. A and C: bright field and fluorescence images of a 12 hour sample; B 
and D: bright field and fluorescence images of a 24 hour sample. 
5.4.3 Lung Perfusion Experiments 
Following tail vein injection, most of the injected 99mTc-CHSg activity was allocated in the lungs 
within the first 30 seconds (checked with Geiger counter, Victoreen ASM-990, Fluke, USA). 
After 2 hours 91.6±6.5% of the injected activity (decay corrected) was allocated in the lungs 
(Cobra 5000 well counter, Packard, USA). After 4 hours 83.2±4.1% was still found in the lungs 
(Fig 40).  
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Fig 40 Decay Corrected Biodistribution of 99mTc-CHSg compared to 99mTc-MAA 
The activity released from the lungs was almost exclusively excreted to the urine accounting for 
4.9±2.5% and 10.0±2.1% decay corrected injected dose per gram (DC-ID/g) after 2 hours and 4 
hours respectively. Less than 3% DC-ID/g was detected in all the other organs at any given time 
point (Fig 40). Lung perfusion images were obtained at several time points confirming the 
preferential lung allocation (Fig 41). Lung perfusion performance of the 99mTc-CHSg particles is 
slightly better than that of 99mTc-MAA. 
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Fig 41 Un-collimated, non-decay-corrected full body X-Ray/Autoradiography of 99mTc-CHSg, 
99mTc-MAA and free 99mTc. 
Injected 99mTc-PGCD was also allocated in the lungs within the first 30 seconds (checked with 
Geiger counter, Victoreen ASM-990, Fluke, USA), and confirmed with a 10 minutes image (Fig 
43). However, the 2 and 4 hour biodistribution (Fig 42) shows strong degradation of these 
particles.  
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Fig 42 Decay Corrected Biodistribution of 99mTc-PGCD Biodistribution compared to 99mTc-MAA 
A significant 56.4±2.9% DC-ID/g was found in the lungs after 2 hours, decreasing to 29.9±1.1% 
DC-ID/g after 4 hours (Fig 42). The behavior of 99mTc when injected free and as 99mTc-PGCD is 
fairly different. The first 99mTc-PGCD degradation products are eliminated to the bladder 
(27.1±4.1% DC-ID/g after 2 hours, increasing to 31.4±5.3 % DC-ID/g at 4 hours). Contrary to 
free 99mTc (44.6±2.8 % DC-ID/g in liver after 2 hours), only 2.8±0.5 % DC-ID/g is found in the 
liver after 2 hours. However the liver allocation is increased to 19.8±1.9 DC-ID/g after 4 hours. 
The blood concentration did not vary during the study (7.3±0.1 and 7.6±1.2 % DC-ID/g after 2 
and 4 hours). The in vivo biodistribution of 99mTc-PGCD was similar to that of 99mTc-MAA but 
with a much faster degradation and larger liver allocation after 4 hours. 
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Fig 43 Un-collimated, non-decay-corrected full body X-Ray/Autoradiography of A: 99mTc-PGCD 
compared to B: free 99mTc after 10 minutes. 
Even when strong lung allocation is observed in the 10 minutes image, some free 99mTc is already 
observed in the blood stream at this time point (Fig 43). Nevertheless, 99mTc-PGCD remains a 
potential perfusion agent, however more experiments varying the D:C ratio in the polymer are 
needed. The greater the D:C ratio, the more hydrophobic the polymer. However, with a greater 
the D:C ratio the polymer becomes more positively charged decreasing the labeling yield for 
radiometals. Therefore, in order to have proper degradation half-life and maximize labeling yield, 
the D:C ratio needs to be optimized. 
5.5 Conclusions 
Microspheres within the desired 30±10 µm size range were successfully obtained for PGCD and 
CHSg.  Labeling was performed with >90% yield and in vitro radiochemical stability after 4 
hours. Particle in vitro degradation half-life in PBS showed a faster degradation speed for PGCD 
(half-life ≈ 24 h) compared to that of CHSg (half-life ≈ 48 h). In vivo studies with 99mTc-PGCD 
labeled microspheres show strong initial allocation in the lungs, however fast degradation of 
PGCD was observed releasing 99mTc into the blood stream.  Much better results were found for 
99mTc-CHSg labeled microparticles. Two hours post injection 91.6±6.5% of the injected activity 
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(decay corrected) was allocated to the lungs with 83.2±4.1% after 4 hours. It can be concluded 
that 99mTc-CHSg is a feasible microsphere lung perfusion agent that has the potential to be used 
as surrogate during RMT planning. 
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CHAPTER 6 68Ga Labeled Microspheres 
6.1 Abstract 
Fast biodegradable microspheres (12 h < half-life < 48 h) labeled with a positron emitter are 
needed for PET lung perfusion and RMT planning. An emulsion method was used to create 
30±10 µm size range microspheres with biodegradable polymers (PGCD and CHSg). The surface 
of CHSg microspheres was modified with NOTA for higher in vivo stability. 68Ga labeling of all 
the microspheres was performed with >90% yield and in vitro radiochemical stability after 4 
hours. Particle in vitro degradation half-life in porcine plasma showed a fast <30 minutes half-life 
for PGCD and approximately 24 hours for CHSg and CHSg-NOTA. In vivo studies with 68Ga-
PGCD labeled microspheres show fast release of 68Ga.  Similar results were found for the 68Ga-
CHSg labeled microparticles demonstrating the need for surface decoration of CHSg 
micropsheres with p-SCN-Bn-NOTA. For the obtained 68Ga-NOTA-CHSg microspheres, lung 
allocation was very high with 98.9±0.2 % and 95.6±0.9 % after 2 and 4 hours respectively. Even 
when remarkable lung allocation was obtained another important result is that the addition of p-
SCN-Bn-NOTA acts as a radioprotectant quickly eliminating the released activity from the lungs 
to the bladder. 
6.2 Introduction 
The greatest limitation of RMT is the impossibility of quantifying the dosimetry during the 
treatment planning. This is due to the fact that the 99mTc-MAA scintigraphy is a single photon 
emission tomography technique (SPECT) and the difficulty in obtaining proper attenuation 
correction as compared to positron emission tomography (PET). The RMT planning will be 
greatly benefited by the inclusion of a positron emitter radioisotope; since absolute attenuation 
correction and potentially superior resolution is present in PET. Important advances were made in 
early years by labeling the Pulmolite MAA kit with 68Ga (61), obtaining an 80 % labeling yield 
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and purity > 95% for. The advantages of spherical microspheres for perfusion studies, with a 
practical size distribution of 30±10 µm have been discussed extensively in previous chapters 
(Chapter 1, 2 and 5). There is a need for fast biodegradable (12 h < half-life < 48 h) microspheres 
that can be labeled with a PET isotope for proper RMT planning. 
6.3 Materials and Methods 
6.3.1 Particle Preparation and Surface Modification 
PGCD (75:25 and 50:50 D:C ratio) was prepared similarly to that used for 99mTc labeling. 
Approximately 150 µg were dissolved in 1 ml dichloromethane and added drop wise to a flask 
containing 20 ml of 0.5 Pluronic (F-127, BASF, Germany) solution while stirring at 850 rpm 
(Corning-Cole Palmer, USA). The emulsion was stirred for 2 hours until total evaporation of the 
CH2Cl2. Obtained particles were washed 3 times with water, filtered through a 20 µm filter 
(Spectra/Mesh, Cole Palmer, USA) and lyophilized (Lab-Conco, USA).  
Chitosan glycol (Sigma-Aldrich, USA) was dissolved in a 2% w/v, 2% v/v acetic acid solution. 
Microspheres were prepared in a w/o emulsion adding dropwise 1 ml of CHSg stock solution to a 
flask containing 20 ml of Toluene and 100 µl of Tween® 80 (surfactant) while stirring at 1150 
rpm. After 15 minutes 100 µl of glutaraldehyde (25 % in water, FisherSci, USA) was added. 
After 2 hours (total time since CHSg stock solution was added) toluene was decanted, and 
spheres were washed three times with 200-proof ethanol (Sigma-Aldrich, USA) and lyophilized 
(Lyophilizer). Size distribution, concentration and particle morphology were obtained with a 
hemacytometer (Reichert, USA) using an optical microscope (Micromaster, FisherSci, USA). 
A stock solution of p-SCN-Bn-NOTA (Macrocyclics, USA) with concentration 1 mg/ml in 
Na2HCO3/NaH2CO3 (pH 9.3-9.4, Sigma-Aldrich, USA), was prepared. Microspheres were 
resuspended in 1 ml of the p-SCN-Bn-NOTA Stock solution. The suspension was stirred at room 
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temperature for 4, 12, 24 and 48 hours (n=3 per time point) to form the NOTA-CHSg particles 
(81). The reaction yield was evaluated using a UV/Visible spectrophotometer (Varian/Agilent 
Technologies, Switzerland) at the 224 nm absorption peak of the p-SCN-Bn-NOTA (Fig 44). 
 
Fig 44 Surface decoration of CHSg microparticles with p-SCN-Bn-NOTA 
6.3.2 68Ga Labeling and CHSg Microspheres Degradation 
Labeling of 68Ga-NOTA-CHSg (pH=4), 68Ga-CHSg (pH=5.5) and 68Ga-PGCD (pH=5.5) was 
performed at room temperature in acetate buffer. A labeling kinetics study was done using four 
different reaction times: 5, 10, 15 and 60 minutes. In vitro radiochemical stability studies were 
performed in PBS buffer (pH=7) measuring the activity of centrifuged particles (Eppendorf, 
Germany) and the supernatant in a dose calibrator (Biodex, USA) at 1, 2, 3 and 4 hours after 
resuspension. 
For the in vitro degradation studies of the particles porcine blood was obtained from Mataderos 
Cabrera (Miami, USA), and centrifuged at 3000 rcf for 30 minutes. Plasma was later decanted 
and used for microsphere degradation experiments. Lyophilized CHSg, NOTA-CHSg and PGCD 
(both 50:50 and 75:25 D:C ratio) microspheres were resuspended in the plasma. CHSg and 
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NOTA-CHSg microspheres samples were extracted at 1, 2, 4, 12, 24, 48 and 72 hours. PGCD 
microspheres were also extracted but at 5, 10, 30 and 60 minutes. All samples (n=3 per time 
point) were analyzed for size distribution and particle concentration using a hemacytometer 
(Reichert, USA) and an optical microscope (Micromaster, FisherSci, USA). 
For in vivo particle degradation studies, lyophilized CHSg microparticles were re-suspended in 
carbonate buffer (pH=9.34). NHS-Fluorescein (Thermo Scientific, USA) was dissolved in 
Dimethyl Sulfoxide (DMSO, Thermo Scientific, USA) with a concentration of 10 mg/ml. A total 
1 mg of NHS-Fluorescein (100 µl of the stock solution) was added to the vial containing the 
particles and stirred for 2 hours (Fig 33). At the end of the reaction particles were centrifuged, 
washed three times with water and finally lyophilized (Lyophilized CHSg-Fluorescein).  
The mouse experiments described above were used to optimize the cryosectioning experiments in 
rats. Particles were re-suspended in saline solution for injection (FisherSci, USA) and ≈10000 
particles were injected to each Sprague Dawley Rat (200-225 grams, Harlan, USA) in the lateral 
tail vein. Animals were euthanized at 2, 6, 12 and 24 hours (n=2 per time point). Before 
extraction of the lungs, the trachea was isolated and a V cut was made. A syringe containing 
Optimal Cutting Temperature (OCT, Tissue-Tek, USA) cryoembedding media was inserted in the 
trachea and the lungs were filled with 2 ml. Lungs were finally extracted and frozen in a plastic 
mold filled with OCT and dipped in liquid nitrogen. Specimens were obtained by cryosectioning 
the frozen samples (14 µm slices) in a Microtome (Leica, Japan). Lung cryo-specimens (4 lung 
sections per animal) were analyzed with a florescence microscope (Olympus IX81 with a Q 
Imaging Retiga 1300 Camera, USA). The entire area of each specimen was imaged using a 4x 
objective. Obtained images were analyzed using in-house software and particles were measured 
and counted. 
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6.3.3 Lung Perfusion Experiments 
Sprague Dawley rats (2 per time point, Harlan, USA) were purchased and weighed (200-225 
grams). Animals were anesthetized using an Ohmeda Isotec 3 isolfurane vaporizer (GE 
Healthcare, USA). After surgical plane anesthesia was reached, animals were restrained in the 
supine position. A torso X-Ray was then obtained (Belmont Acuray 071A, USA). Immediately 
after, 100 µL of the labeled 68Ga-PGCD, 68Ga-CHSg or 68Ga-NOTA-CHSg (8,000-10,000 
particles) with a 68Ga activity range going from 1.85 to 3.7 MBq (50 to 100 µCi) were injected 
through the lateral tail vein. Animals were euthanized at 2 or 4 hours. Lungs, liver, spleen, heart, 
kidneys, ribs and 0.2 ml of blood and urine were collected for either time point. Organs were 
weighed and measured for activity using a Cobra 5000 well counter (Packard, USA). Non-
collimated autoradiography images (in the unaltered supine position the X-Ray was obtained) 
were also taken at 10 minutes for initial assessment and 1, 2, 3 and 4 hours (Packard 
Phosphorimager, Perkin Elmer, USA). In one group free 68Ga was injected as a control. The 
obtained X-Rays and the autoradiography images were superimposed to provide anatomical and 
functional data. 
6.4 Results and Discussion 
6.4.1 Particle Preparation and Surface Modification 
Over 95% of the obtained CHSg microspheres are in the 30±10 size range (Fig 35) and did not 
change after the 12 hour reaction with p-SCN-Bn-NOTA (Fig 45). 
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Fig 45 CHSg size distribution before and after p-SCN-Bn-NOTA surface decoration. 
However size distribution and size concentration was mildly and severely altered for the 24 and 
48 hours p-SCN-Bn-NOTA reactions respectively. Better p-SCN-Bn-NOTA attachment was 
obtained at these later time points compared to the 12 hours reaction, but it was due to rupture of 
the CHSg microspheres and exposure of new available free amine groups for the reaction (Fig 
44). 
Around 260±15 µg of p-SCN-Bn-NOTA (of the total 1 mg added) were covalently attached to the 
surface of the CHSg microspheres after 12 hours reaction. The net p-SCN-Bn-NOTA amount that 
bonded to the microspheres surface was increased to 297±25 and 347±40 µg after 24 and 48 
hours of reaction. However, as stated before, particle degradation altered the final size 
distribution. 
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Fig 46 Surface decoration of CHSg with p-SCN-Bn-NOTA with different reaction times 
Maximum reaction yield taking into consideration the totality of available NH2 groups was 
slightly over 1%. Nevertheless it is a biased calculation since only a fraction of these groups are 
exposed for the p-SCN-Bn-NOTA reaction. Regardless of the yield, the addition of 260 
micrograms of p-SCN-Bn-NOTA to the batch represents a theoretical loading capacity (assuming 
95% labeling yield) of 12.8 µCi/particle (1.28 Ci for 100,000 particles). In molecular imaging 
only 3-5 mCi total are used, 3 order of magnitude less than the total available capacity. 
6.4.2 68Ga Labeling and CHSg Microspheres Degradation 
CHSg, PGCD and CHSg-NOTA microparticles were labeled with 68Ga successfully with more 
than 90% yield at room temperature. Reaction kinetics placed the optimum reaction time at 15 
minutes (Fig 47). Specific labeling yields after 15 minutes were 93±3 % for 68Ga-PGCD, 
96±3.5 % for 68Ga-CHSg and 97±3 % for 68Ga-NOTA-CHSg. 
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Fig 47 Reaction Kinetics for CHSg, PGCD and CHSg-NOTA with 68Ga 
Radiochemical stability was shown to be over 90 % after 4 hours of study at 37 ºC in saline, PBS 
buffer and 1% reconstituted bovine hemoglobin lysate. The particles conserved their shape and 
distribution during the labeling process and in vitro radiochemical stability studies.  
Porcine plasma studies showed faster microsphere degradation than when they were in PBS 
buffer (see previous chapter) for all studied particles (Fig 48). PGCD degradation half-life was 
found to be around 24 hours in the PBS. However when placed in contact with plasma 
degradation is much faster. PGCD (50:50 D:C ratio) microparticles disappear from solution 
within 5 minutes of contact with plasma. The other PGCD composition (75:25 D:C ratio) showed 
increased stability in the plasma, though the half-life of these particles was found to be shorter 
than 30 minutes, disappearing completely after 1 hour. This degradation half-life might be 
considered too fast for both lung perfusion and RMT planning applications. However, because of 
the nature of the perfusion studies blood contact might be diminished when injected in vivo and 
half-life might be greater. For these reasons in vivo testing of these particles was not discarded. 
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Fig 48 Porcine Plasma microsphere degradation studies for A: PGCD (50:50); B: PGCD (75:25); 
C: CHSg and D: CHSg-NOTA (n=3) 
Equally to PGCD, CHSg (and CHSg-NOTA) in vitro degradation was faster than expected from 
the PBS buffer experiments. As can be seen in Fig 48, CHSg degradation undergoes a different 
process from that of PGCD. CHSg particles are first swollen in plasma (effect not observed in 
any PBS buffer degradation experiments) and then particle division into smaller pieces. The 
dramatic increase observed in particle concentration after 12 hours, together with the decrease in 
average particle size is due to the rupture of the original particles into smaller fractions. These 
fractions are later dissolved (degraded) disappearing gradually from the suspension. The observed 
half-life for both, CHSg and CHSg-NOTA, was found to be around 24 hours with no significant 
difference in their degradation profiles. 
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Particle degradation experiments performed in vivo show a similar degradation mechanism to that 
obtained in vitro (Fig 49).  
 
Fig 49 CHSg microspheres in vivo degradation studies (n=2 per time point) 
Particle concentration is initially increased because of microsphere rupture. Smaller pieces are 
later slowly dissolved. This dissolution results in a steady decrease of the particles average 
diameter and also in particle concentration in the tissue (Fig 50). The in vivo half-life of the 
particles was determined to be 18-20 hours, since this the time when the particle concentration is 
reduced to half (50% of initial particle concentration). 
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Fig 50 Representation of the in vivo CHSg microsphere degradation mechanism. Collage of 
representative microarticles found in the cryosections for different time points: A: 2 hours, B: 6 
hours, C: 12 hours and D: 24 hours. Relative particle amount in the images is related to the real 
particle concentration found in the tissue sections. 
Results obtained in the in vivo experiments are highly qualitative since many assumptions were 
made for the calculations of average size and concentration. Particles concentration was assumed 
to be homogeneous in the entire lung, and particles under 10 micrometers were not included in 
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the analysis since those should no longer occlude the vessels and therefore will not interfere with 
the later injection of the therapeutic particles in final the RMT phase.  
Furthermore, the average size calculation is only an estimate due to the artifacts inherent to the 
sectioning method; there is no way to know if a particle that is sized represents the whole cross-
section or only a part of the particle, the latter being more likely. Therefore, the particle size 
distribution is probably an underestimate of the true in vivo size distribution. Nevertheless, by 24 
hours, comparatively few particles were observed in the sections. Also, no particle clumping was 
observed as the particles were found to be evenly distributed and thus a good estimation of 
particles half-life was obtained. The particle degradation half-life was found to be between 18 and 
20 hours, which makes the CHSg microspheres a potential candidate for lung perfusion imaging 
and RMT planning. 
6.4.3 Lung Perfusion Experiments 
The first obtained image (10 minutes) after injection of 68Ga-PGCD showed severe release of the 
radioisotope from the particles (compared to the 10 minutes image for 99mTc-PGCD, Fig 43). The 
68Ga-PGCD chelation was apparently weaker than that of the competing native transferrin (Fig 
51). 
 
Fig 51 Comparison of images 10 minutes after injection for A: Free 68Ga and B: 68Ga-PGCD 
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However, despite the similarities organ collection at 2 hours showed a different picture (Fig 52). 
Only 49.0±3.3 % of the 68Ga injected as 68Ga-PGCD was found in the blood while 84.9±4.5 % 
was present in the blood for the free 68Ga experiments. Equally different was the amount of tracer 
in the urine: 35.1±4.0 % for 68Ga-PGCD versus 6.8±2.9 % for the free 68Ga. These differences 
evidence a combination of trans-chelation (PGCD to native transferrin) and PGCD in vivo 
degradation. Small dissolved polar fragments with 68Ga (probably some form of Gallium Citrate) 
are cleared quickly by the kidneys and moved to the bladder. Despite the evidence of some 68Ga 
chelation strength by PGCD, it is not enough to perform lung perfusion imaging studies as shown 
in Fig 51. The fast released of 68Ga to the blood significantly increases the body background and 
makes difficult to obtain lung perfusion images with diagnostic value. 
 
Fig 52 Decay corrected organ biodistribution after 2 hours for free 68Ga and 68Ga-PGCD. 
Similar to 68Ga-PGCD, and despite the excellent in vitro results obtained, 68Ga-CHSg did not 
perform well as a lung perfusion imaging agent. Strong evidence of 68Ga trans-chelation by native 
transferring was observed (Fig 53). 
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Fig 53 Comparison of images 10 minutes after injection for A: Free 68Ga and B: 68Ga-CHSg 
Nevertheless, 68Ga-CHSg in vivo behavior was notably different than that of free 68Ga 2 hours 
post-injection (Fig 54). 
 
Fig 54 Organs biodistribution after 2 hours for free 68Ga and 68Ga-CHSg. 
After 2 hours 31.9±1.3 % of the injected activity can be found in the lungs (compared to the 
3.1±2.9 % found for the free 68Ga) but 46.7±1.2 % was already released to the blood. The slow 
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degradation of CHSg (compared to PGCD) was expected. However the 68Ga release to the blood 
was not expected since in vitro experiments were remarkable. Obtained result made necessary the 
surface decoration of the CHSg microspheres with a 68Ga specific chelator (NOTA) to increase in 
vivo stability of the labeling. 
Animal experiments performed with 68Ga-NOTA-CHSg showed high lung allocation and stability 
during the 4 hour study (Fig 55). 
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Fig 55 Non decay-corrected, un-collimated full body X-Ray/Autoradiography for free 68Ga and 
68Ga-NOTA-CHSg at 1, 2, 3 and 4 hours. 
From the images can be concluded that I vivo stability of the prepared 68Ga-NOTA-CHSg is 
remarkable and the microspheres are a good candidate for lung perfusion imaging. However, 
organs were collected and measured for quantification at 2 and 4 hours (Fig 56). 
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Fig 56 Decay Corrected Biodistribution of 68Ga-NOTA-CHSg and Free 68Ga at 2 and 4 hours. 
After 2 hours 98.9±0.2 % of the injected activity of 68Ga-NOTA-CHSg was found in the lungs, 
decreasing to 95.6±0.9 % after 4 hours. The activity released from the lungs moved directly to the 
bladder (3.5±0.6 % after 4 hours). The absence of activity in the blood (0.1±0.1 % at 2 hours and 
0.5±0.1 % after 4 hours) evidenced the high radiochemical stability of the NOTA-68Ga complex.  
The activity found in the urine must be due to early particle degradation releasing small polar 
fragments as frag-NOTA-68Ga. The addition of the NOTA chelator to the surface of the particles 
also served as a radioprotectant to the rest of the organs, since less than one percent of the 
injected activity was found in the blood at any time. For the obtained perfusion agent imaging is 
recommended within the first hour post injection because of 68Ga decay. 
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6.5 Conclusion 
Microspheres within the desired 30±10 µm size range were successfully obtained for PGCD and 
CHSg. Surface modification of CHSg microspheres with NOTA for 12 hours did not affect the 
original size distribution or morphology. Addition of 260 micrograms of p-SCN-Bn-NOTA to the 
particles represents a theoretical loading capacity (assuming 95% labeling yield) of 12.8 
µCi/particle. Labeling was performed for all compositions with >90% yield and in vitro 
radiochemical stability after 4 hours. Particle in vitro degradation half-life in porcine plasma 
showed a fast <30 minutes half-life for PGCD and approximately 24 hours for CHSg and CHSg-
NOTA. In vivo studies with 68Ga-PGCD labeled microspheres show fast release of 68Ga.  Similar 
results were found for the 68Ga-CHSg labeled microparticles evidencing the need for surface 
decoration with p-SCN-Bn-NOTA. For the obtained 68Ga-NOTA-CHSg lung allocation was very 
high with 98.9±0.2 % and 95.6±0.9 % after 2 and 4 hours respectively. Even when remarkable 
lung allocation was obtained another important result is that the addition of p-SCN-Bn-NOTA 
acts as a radioprotectant quickly eliminating the released activity from the lungs to the bladder. 
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CHAPTER 7 90Y Labeled Microspheres 
7.1 Abstract 
Chitosan (CHS) is used to prepare 30±10 µm size microspheres. Surface modification with p-
SCN-Bn-DOTA was performed. A maximum 90Y capacity was found to be 12.1 ± 4.4 
µCi/particle. The best obtained labeling yield was 87.7±0.6 %.  More than 90% in vitro stability 
was found. Particle in vitro degradation half-life in PBS was found to be greater than 21 days. In 
vivo studies with 90Y-DOTA-CHS show more than 95 % of the injected activity (decay corrected) 
in the lungs after 24 hours.  90Y-DOTA-CHS performance was superior to the commercially 
available SirTex microspheres. The addition of p-SCN-Bn-DOTA served as a radioprotectant for 
bone marrow. The 5 % 90Y released from the lungs during the first 24 hours was quickly 
eliminated via urine. 
7.2 Introduction 
The available products in the market for Selective Internal Radiation Treatment (Fig 57) show 
several limitations. High specific gravity making injection challenging and null biodegradability 
are among them. 
 
Fig 57 A: Commercially available products for RMT; A1: TheraSpheres, A2: SirSpheres and B: 
Representation of tumors being treated with 90Y microspheres 
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For the TheraSpheres (also known as glass spheres), the relation between 90Y activity and number 
of spheres can only be controlled by decay, since there is only one universal composition 
prepared. On the other side SirSpheres can be prepared with the desired 90Y activity/number of 
spheres ratio, however the nature of 90Y attachment is not specific (rather it is by ionic exchange 
absorption), increasing the risk of 90Y release and bone marrow suppression. 
RMT is almost always accompanied by chemotheraphy that is administered independently of the 
radiotherapeutic particles. Since these particles are non-biodegradable, chemotherapy entrapment 
and in situ release is not possible. Polymeric microparticles with high in vivo 90Y radiochemical 
stability to protect bone marrow, and the capability to entrap chemotherapy drugs for 
simultaneous radio/chemotherapy are needed. The proper design of these particles will most 
likely improve the safety and effectiveness of the current RMT practice. Among the many 
materials available, a clear candidate for this application is Chitosan, a chitin derivate that has 
been extensively used for drug entrapment/release and has very low (if any) in vitro and in vivo 
toxicity (82). 
7.3 Materials and Methods 
7.3.1 Particle Preparation and Surface Modification 
Chitosan (CHS, Sigma-Aldrich, USA) particles were prepared similar to the CHSg microspheres 
using a water in oil (w/o) emulsion technique. One ml of CHS solution (2.5 % w/v solution in 2% 
v/v acetic acid) was added drop wise to a round bottom flask and stirred (Corning-Cole Palmer, 
USA) at 1150 rpm. The flask contained 20 ml of Toluene (Acros Organics, USA) and 100 µl of 
Tween® 80 (surfactant, Sigma-Aldrich, USA). After 15 minutes 200 µl of glutaraldehyde (25 % 
in water, FisherSci, USA) was added and the emulsion was stirred for another 105 min. Toluene 
was finally decanted and particles were washed three times with 200-proof ethanol (Sigma-
Aldrich, USA) and lyophilized (Lab-Conco, USA). 
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A 1 mg/ml solution of p-SCN-Bn-DOTA (Macrocyclics, USA, Fig 58) was prepared in 
Na2HCO3/NaH2CO3 buffer (Sigma-Aldrich, USA) with a pH 9.3-9.4. Particles were resuspended 
in 1 ml of the p-SCN-Bn-DOTA solution and stirred for 4, 12, 24 or 48 hours to form the DOTA-
CHS particles. The reaction yield was evaluated using the p-SCN-Bn-DOTA absorption peak at 
224 nm with a UV/Visible spectrophotometer (Varian/Agilent Technologies, Switzerland). All 
experiments were done in triplicate for all time points. 
7.3.2 90Y Labeling and in vitro stability 
A labeling study was performed at two different pH values: 5 and 7. The temperature influence 
on labeling was also studied using 25, 35 and 37 ºC. CHS microspheres and resin spheres (kindly 
provided by SirTEX, USA) were labeled for comparison in similar conditions.  A 72 hours in 
vitro stability study using PBS buffer at pH 7 was performed to evaluate radiochemical purity. 
With 90Y present to account for radiolytic effects CHS microspheres were studied for degradation 
over 21 days.  
Using stable YCl3 (Sigma-Aldrich, USA) as carrier for the radioactive 90YCl3 (Perkin-Elmer, 
USA), a radioactive indicator experiment was performed to calculate the maximum 90Y capacity 
of the prepared microspheres. Experiments were also performed with SirSpheres for comparison. 
For the in vitro work all activity measurements were made in an AtomLab 100 Dose Calibrator 
(Biodex, USA). 
7.3.3 Lung Perfusion Experiments 
Sprague Dawley rats (200-225 grams, 2 per time point, Harlan, USA) were anesthetized with an 
Ohmeda Isotec 3 isolfurane vaporizer (GE Healthcare, USA) after weighed. Once restrained in 
the supine position (completely anesthetized) and a torso X-Ray was obtained (Belmont Acuray 
071A, USA). Immediately after, 100 µL (8,000-10,000 particles) of the labeled microspheres 
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(90Y-DOTA-CHS and 90Y-SirSpheres) with an activity ranging from 555-925 kBq (15 to 25 µCi) 
were injected through the lateral tail vein. Animals were imaged with non-collimated 
autoradiography (in the unaltered supine position the X-Ray was obtained) at 10 min, 12 and 24 
hours post injection (Packard Phosphorimager, Perkin Elmer, USA). After the last image was 
obtained, animals were euthanized (24 hours post injection). For either time point their lungs, 
liver, spleen, heart, kidneys, ribs and 0.2 ml of blood and urine were collected, weighed and 
measured for activity using a Cobra 5000 well counter (Packard, USA). One group received free 
90Y as a control. The obtained X-Rays and the autoradiography images were superimposed to 
provide anatomical and functional data.  
For the collected organs measurements, an activity vs. radiation counts linearity test (with known 
activity samples) was performed to the Cobra 5000 well counter (Packard, USA). A test tube 
(similar to the ones used in the organs) was filled with absorbent paper and soak in water to 
simulate auto absorption of the organs. Later, a known amount of 90Y was deposited (ranging 
from 2 to 5 µCi, close to the activity range found in the organs) in the paper and measured (n=3 
per activity point) in the well counter. Results were linear fitted and correlation coefficient was 
found. Spectra obtained for the lowest and highest activity points were also compared. 
7.4 Results and Discussion 
7.4.1 Particle Preparation and Surface Modification 
The size distribution obtained for CHS particles was an average of 30.7±8.3 µm. After the 
preparation of the microspheres, the DOTA decoration reaction was performed (Fig 58). 
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Fig 58 CHS - p-SCN-Bn-DOTA reaction. 
The kinetic study for the reaction showed that saturation is reached at 12 hours (optimum reaction 
time), with no extra addition of p-SCN-Bn-DOTA in the subsequent time points. The total p-
SCN-Bn-DOTA-CHS reaction yield is around 1% (with a maximum 250 µg of p-SCN-Bn-DOTA 
addition, similar to the result obtained for p-SCN-Bn-NOTA). The approximated 6.3 mg of CHS 
(total mass of 100,000 particles, 63 ng/particle) present in each preparation accounts for 2.33·1019 
available NH2 groups in total. However, only a fraction of these groups are exposed to the 
microsphere surface and to further complicate the problem, the surface is not perfectly flat (Fig 
63 A). 
 
Fig 59 p-SCN-Bn-DOTA-CHS reaction kinetics 
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After the p-SCN-Bn-DOTA decoration a size distribution of 31.3±8.1 was obtained. As expected 
for CHS microspheres, there is no significant change in the distribution or particle morphology 
before and after the addition reaction (Fig 60). This is due to the high pH (9.4) in which the 
reaction is being held and the already low solubility and slow degradation rate of CHS. 
 
Fig 60 CHS microsphere size distribution before and after p-SCN-Bn-DOTA addition reaction. 
 
7.4.2 90Y Labeling and in vitro stability 
Maximum labeling yield for 90Y-DOTA-CHS labeling was 87.7±0.6 %, obtained at pH=7 and 37 
ºC (Fig 61) after 30 minutes. Yield was dependent on both pH and temperature (Fig 61). A rise in 
temperature might benefit the labeling, however CHS is a polysaccharide very sensitive to 
temperature and structural damages might occur. A longer labeling time did not increased the 
yield and 30 minutes was identified as the optimal labeling temperature. Labeling of resin spheres 
(SirTEX, USA) showed more than 98% yield in all conditions within 10 minutes of reaction. The 
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labeling was performed at pH=7 only since resin spheres are labeled and injected in water. Yield 
was not dependent on temperature for the studied range.   
 
Fig 61 Labeling yields for 90Y-CHS, 90Y-DOTA-CHS and 90Y-Resin at different pH values and 
temperatures.  
Another interesting observation is that direct CHS labeling did not result in high yields. This 
result is in contradiction with a previously reported 99% yield (79). CHS used in these 
experiments (also 15 kDa molecular mass) was obtained from a different manufacturer 
(Polysciences, USA). Differences in results obtained with various chitosan batches and vendors 
have been reported in the past (83). This problem is solved by the addition of p-SCN-Bn-DOTA, 
rendering the labeling independent of the chitosan nature. However, differences in degradation 
and drug entrapment and release for other applications might be found and this problem needs to 
be investigated further. 
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The performed in vitro stability study showed over 90% radiochemical purity for 90Y-DOTA-
CHS after 72 hours compared to the 80% obtained for the resin spheres (Fig 62). Considering 
these positive result for 90Y-DOTA-CHS, animal experiments were performed. 
 
Fig 62 in vitro stability study for 90Y-DOTA-CHS and 90Y-SirSpheres. 
The extended in vitro degradation of the particles showed that integrity was maintained, although 
with some surface degradation after 21 days (Fig 63). This timeframe was chosen since more than 
95% of the 90Y is physically decayed by 21 days. The obtained biodegradable microspheres 
demonstrated a long enough half-life to adequately perform RMT while allowing for ultimate 
clearance and blood flow restoration. 
 
Fig 63 Degradation of CHS microspheres after A: 1 day, B: 7 days, C: 14 days and D: 21 days 
91 
 
Finally, the maximum labeling capacity for the CHS-p-SCN-Bn-DOTA microspheres was 12.1 ± 
4.4 µCi/particle and for SirSpheres 111.7 ± 0.1 µCi /particle. Hence, in a regular treatment course 
using 3·106 to 30·106 particles, maximum possible activity load is 36-360 Ci and 335.1-3351 Ci 
for CHS-p-SCN-Bn-DOTA and SirSpheres respectively. These values are 3 orders of magnitude 
over the regular administered dose. 
7.4.3 Lung Perfusion Experiments 
Detector linearity response to activity and spectra distribution were performed as described. A 
high correlation coefficient was obtained in the studied range. Spectra comparison between the 
lowest and highest activity points revealed no difference. 
 
Fig 64 Cobra 5000 well counter (Packard, USA) efficiency and linearity calibration for 90Y 
The high specific gravity of the SirSpheres makes particles injection difficult since they deposit 
fast. An injection yield of only 15 % was reached (injected in water). The injection yield for the 
90Y-DOTA-CHS microspheres was over 50 % (injected in saline solution), very repeatable for all 
the other CHS and CHSg microspheres studied (Fig 65). The initial assessment of biodistribution 
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with a survey meter (Victoreen ASM-990, Fluke, USA) revealed a strong allocation in the lungs 
for the 90Y-DOTA-CHS microspheres while the SirSpheres distribution did not differ from the 
free 90Y. 
 
Fig 65 Injection efficiency for all the studied microparticles 
Already in the 10 minutes strong 90Y bone marrow allocation and similar distribution was 
observed in the autoradiography images for 90Y-Resin and free 90Y (Fig 67). However, collected 
organ quantification (Cobra 5000 well counter, Packard, USA) at 24 hours showed some lung 
allocation for 90Y-Resin (Fig 66). 
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Fig 66 Decay Corrected Biodistribution of 90Y-DOTA-CHS, 90Y-Resin and free 90Y  
Lung allocation of more than 95 % (decay corrected) of the injected activity was detected for 90Y-
DOTA-CHS after 24 hours, showing a significant difference with the 23 % (decay corrected) 
found for the 90Y-Resin. Free 90Y was initially allocated in the bone marrow but only 9 % 
remained after 24 hours, the rest of the activity was eliminated via urine. Over 4% of the injected 
90Y-Resin activity was found in bone marrow after 24 hours and more than 70% was eliminated. 
In contrast to this result the activity released from the lungs in the 90Y-DOTA-CHS experiments 
resulted in only a fraction of a percent being allocated to the bone marrow, and the remaining 
either in the urine or eliminated. 
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allocation of 23% of the decay corrected injected activity at 24 hours). For the 90Y-DOTA-CHS 
microspheres the radiation damage distribution was completely different. The lung were 
significantly discolored and fragile after 24 hours (due to the allocation of more than 95% of the 
decay corrected injected activity at 24 hours) while no visible damage was seen in the kidneys 
and normal urine output was observed. Note that venous injection of 90Y microspheres so that 
they locate in the lungs would never be therapeutically indicated. This model was used only to 
investigate in vivo radiochemical stability and animals were not allowed to survive longer than 24 
hours because of the organ damage that was expected to occur.  
7.5 Conclusion 
CHS microspheres within the 30±10 µm size range were successfully obtained. Surface 
modification of CHS microspheres with p-SCN-Bn-DOTA showed an optimal reaction time of 12 
hours. The surface decoration did not affect the original size distribution or morphology. 
Maximum 90Y capacity was found to be 12.1 ± 4.4 µCi/particle, which means that when using 
3·106 to 30·106 particles (normal therapeutic range) maximum possible activity load is 36-360 Ci 
(orders of magnitude higher than real activities used). Maximum obtained labeling yield was 
87.7±0.6 % when labeling at pH=7 and 37 ºC for 30 minutes.  More than 90% in vitro stability 
was found in reconstituted 1% hemoglobin lysate after 72 hours. Particle in vitro degradation 
half-life in PBS was found to be greater than 21 days. In vivo studies with 90Y-DOTA-CHS 
labeled microspheres show remarkable stability with more than 95 % of the injected activity 
(decay corrected) still in the lungs after 24 hours.  90Y-DOTA-CHS performance was superior to 
the commercially available SirTex microspheres with only 23% (decay corrected) of the injected 
activity in the lungs after 24 hours. Autorradiography images obtained at 10 minutes showed 
strong release of 90Y for the commercial particles. The addition of p-SCN-Bn-DOTA served to 
increase labeling yield and in vivo stability, but also to act as a radioprotectant for other organs 
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since less than 1% was found in bone marrow (regular 90Y target organ). The 5 % 90Y released 
from the lungs during the first 24 hours was quickly eliminated via urine. 
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CHAPTER 8 DOSIMETRY 
8.1 Abstract 
Monte Carlo particle transport code (MCNPX 2.7) and the rat whole body phantom (ROBY) 
were used to calculate animal’s dose distribution for all the obtained experimental 
biodistributions. Maximum dose per decay to several target organs was calculated and visual dose 
distribution simulations are presented. Maximum dose to the lungs is delivered as expected when 
the successful perfusion and treatment agents are use. Other organ doses were also. The 
dosimetry study carried out complements the study of the designed microspheres allocating 
specific radiation fields to specific organs. The methods used have the potential to be extrapolated 
to humans as long as a proper phantom is used. 
8.2 Introduction 
Radiomicrosphere Therapy (RMT) as well as RMT planning are based on the utilization of the 
radiolabeled microspheres (and MAA microparticles) with the radioisotopes 68Ga and 99mTc for 
imaging as well as 90Y for therapy.  Consequently, the emissions produced by the decay of the 
radioactive nuclei induce energy depositions (dose) in the tissues reached by the radiation fields.  
Dosimetry (measurement of the deposited energy, dose) is an important factor to consider for 
both: the safety of the planning agents and the effectiveness of the planned treatment. Current 
FDA’s “Guidance for Industry” only concerns about the safety of the overall treatment process 
(including planning). This means that the planning doses have to be under “reasonable limits” and 
the therapy dose biodistribution has to treat the damaged tissue with minimal (if any) damage to 
the surrounding organs (84). Concepts like “maximum feasible dose” and “maximum tolerated 
dose” are regularly used, which clearly target safety of administration. However low (if any) 
interest is paid to the therapeutic efficacy and the optimization of the administered dose.  
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The current status quo of radiotherapy was somehow justified by the complexity of the human 
tissue, organs size and distribution, changing from patient to patient. Also because the phantoms 
used to calculate deposited doses were far from a true human surrogate, making calculations 
unreliable and imprecise. However, with the advent and readily availability of CT and PET/CT 
systems, this approach is no longer justified. There is no need for anthropomorphic phantoms in 
dose calculations, since a CT will provide the real field of densities for the patient in question. 
Molecular imaging makes dose calculations even easier, since real PET quantification and 
biodistribution determination are possible. The afore mentioned advances, together with the 
readiness of powerful computers to calculate statistical energy distributions with the help of 
numerical (MCNP) methods renders the current medical practice outdated and inefficient. 
8.3 Materials and Methods 
This dosimetry assessment consisted of a numerical dosimetry approach based on the simulations 
of photon and electron transport utilizing the Monte Carlo particle transport code MCNPX 2.7 
(85).  The simulated numerical models considered specific aspects requirements related to case of 
study that can classified as: geometry, source, and detection. 
8.3.1 Geometry 
The modeled geometry is a numerical rat phantom voxelized with 0.5 mm resolution and 75 
differentiated tissues/organs and generated by the ROBY (kindly provided by Michael G. Stabin, 
(86)) phantom (the main parameters used for building the phantom are showed in the ANNEX 1. 
Fig 68 and Fig 69 show 2D and 3D views respectively, of the visualization of the MCNPX 
ROBY model (visualization of the input). 
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Fig 68 2D representations of the MCNPX ROBY model.  The different views represent the 
following planes: A: Coronal; C: Sagittal; and B: Transverse. 
 
Fig 69 3D representations of the MCNPX ROBY model (visualization: MORITZ), back (above) 
and front (bottom) views.  (Skin and muscles are removed from the image.) 
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distributions obtained from the experiments. ANNEX 2 B shows re-casted distributions for the 
MCNPX ROBY model.  This re-casting consists of obtaining the emission probability for each 
organ considering the whole body has emission probability equal to one and the 
compartmentalization of some organs/tissues.  Scripts of three of the source files used for the 
simulations are shown in the ANNEX 1. 
The experimental data was directly associated to the ROBY model in each of the measured 
organs.  However, for other organs, ROBY has a multi-region definition and some assumptions 
were made to generate the simulation sources. 
For calculations purposes in the geometric definition by ROBY software heart was considered as 
the combination of two ventricles (left: myoLV, and right: myoRV) and two atria (left: myoLA.  
The distribution in heart was assumed uniform and consequently each of the compartments was 
given an emission probability proportional to its volume adding all of them to the emission 
probability of the total heart.  The activity of blood in the experimental data for the 68Ga and 
99mTc compounds was distributed among the blood in bone marrow, the blood in the cavities of 
the heart and their main vessels, and the blood distributed among the rest of the body (in the 
space not defined as any specific  organs/tissues, mainly composed of muscle).  It was assumed 
that blood occupies 7% of the volume of the body (87), that the whole marrow is red marrow and 
that the red marrow to blood activity concentration ratio (RMBLR) is 0.32 (88).  Then, the blood 
in the cavities of the heart and their main vessels (100% blood) is distributed within blood LV, 
blood RV, blood LA, and blood RA source compartments  (named bldplLV, bldplRV, bldplLA, and 
bldplRA in the geometric definition by ROBY software), which have volumes defined by ROBY.  
The activity concentration in marrow is 0.32 that of blood LV (or of the other 100%-blood pools).  
The volume of blood in the rest of the body was assumed to be the total blood volume minus the 
volume of marrow, blood LV, blood RV, blood LA, and blood RA.  In the case of the compounds 
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with 90Y, a similar procedure was performed for the values of rest of the body, blood LV, blood 
RV, blood LA, and blood RA but for marrow, which had an explicitly defined activity.  The 
activity of Urine in the experimental data was assigned to the emission probability in the bladder 
of the numerical model. 
8.3.3 Detection 
The detection of the particles that provided the dose distributions was performed utilizing 
MCNPX and total mesh type 3 tallies (89).  The first two types of tallies were used for assessing 
through two different methods, the average doses in each organ and in each of the detection 
regions of the detectors.  Another mesh was included to calculate a voxelized 1 mm-resolution 
dosimetry along the phantom in order to visualize potential important dose distribution 
heterogeneities. 
8.3.4 General Aspects 
The composition of the materials that fill each of the regions of the phantom where extracted 
from the International Commission of Radiation Units and Measurements Report 46 that lists the 
elemental compositions for human tissues/organ (89).  In the phantom appear tissues whose 
material composition are not explicitly described in the report and, for those cases, the values 
used were approximated to show organ/tissues composition according to its similarity.  The file 
containing the definitions of the material compositions is shown in the ANNEX 1. 
8.3.5 Other considerations of the particle transport.   
In order to produce appropriate transport conditioning EFAC (see ANNEX 1, source files) and 
ESTEP (see ANNEX 1, material file), MCNPX parameters were adjusted considering a space 
resolution equal to or greater than 0.5 mm and Integrated Tiger Series option was chosen 
according to the suggestions given in (90). 
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8.4 Results and Discussion 
The MCNPX /ROBY were simulated in collaboration with Dr. Manuel Sztejnberg in the Ezeiza 
Atomic Center, National Atomic Energy Comission, Buenos Aires, Argentina. Using 107 
particles and CPU time of 57 days (Intel Core i7 CPU 860 @ 2.80 GHz x 8 and OS Ubuntu 12.04 
(64-bits) [Linux kernel: 3.2.4-40-generic]. 
Complete dosimetry results can be found in ANNEX 3. It describes the absorbed dose per decay 
in each of the organs/tissues and the maximum dose among the detectors surrounding the 
phantom.  Considering that the amount of decays per Becquerel is 5.86·103, 3.12·104, and 
3.32x105 for 68Ga, 99mTc, and 90Y respectively, relative dose distributions are calculated and 
plotted for all 99mTc compounds in Fig 71, for all 68Ga compounds in Fig 72 and for all 90Y 
compounds in Fig 73. 
In almost all of the cases the maximum dose per decay was delivered to lungs or bladder and the 
dose to the rest of the tissues is lower than 50% of the maximum.  Maximum dose per decay is 
delivered to lungs in the following cases: 68Ga-MAA (2h and 4h); 68Ga-NOTA-CHSg (2h and 
4h); 99mTc-MAA (2h and 4h); Free 99mTc (2h and 4h); 99mTc-CHSg (2h and 4h); 99mTc-PGCD 2h; 
90Y-DOTA-CHS 24h; and 90Y-Resin 24h.  For the case of 99mTc-PGCD 2h the dose to bladder is 
67% of the maximum.  Maximum dose per decay is delivered to bladder in the following cases: 
free 68Ga (2h and 4h); 99mTc-PGCD 4h; 68Ga-CHSg (confirming the need of the NOTA chelator); 
and 68Ga-PGCD.  For the cases of 99mTc-PGCD 4h and 68Ga-CHSg the dose to lungs are 69% and 
94%, respectively, of the maximum.  Maximum dose per decay is delivered to kidneys in the case 
of free 90Y 24h.  In this case, the doses to bladder and marrow are 69% and 55% of the maximum.  
In the rest of the dose distributions marrow receives less than 10% of the maximum dose.  Liver 
receives less than 12.5% of the maximum dose in all the cases but for free 90Y 24h where it 
receives less than 33% of the maximum. 
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Fig 71 MCNP derived Dose Distribution in rats for all 99mTc labeled microparticles and free 99mTc 
at 2 and 4 hours post injection 
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Fig 72 MCNP derived dose distribution in rats for all 68Ga labeled microparticles and free 68Ga at 
2 hours post injections for 68Ga-PGCD and 68Ga-CHSg; 2 and 4 hours post injection for the rest 
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Fig 73 MCNP derived dose distribution in rats for all 90Y labeled microparticles and free 90Y at 
24 hours post injection 
The maximum doses in the surroundings of the phantom that could be determined as the 
maximum between the average skin dose and the maximum dose in the detectors was for all of 
the cases equal to or lower than 1.5% of the maximum dose to an organ/tissue. 
The radiotolerance doses to the most affected organs (according to what was described in the 
previous paragraphs) are about 6.5, 20 (approximated through BED formalism), 7, 0.5 Gy (92).  
Comparing the relation of these doses to the relation between the maximum doses and organ 
doses one can determine the organs at the largest risk for each case: lungs for 68Ga-MAA- (2h and 
4h), 68Ga-NOTA-CHSg (2h and 4h), 99mTc-MAA (2h and 4h), Free 99mTc (2h and 4h), 99mTc-
CHSg (2h and 4h), 99mTc-PGCD (2h and 4h), 90Y-DOTA-CHS 24h, and 90Y-Resin 24h; bladder 
for 99mTc-PGCD 4h and 68Ga-PGCD; and marrow for Free 68Ga (2h and 4h), 68Ga-CHSg, and free 
3
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90Y 24h.  Consequently, for each of the cases the doses to the corresponding above mentioned 
organ must be considered as maximum deliverable dose in order to avoid any type of normal 
tissue complication. 
The utilization of the above mentioned tolerance doses would be a conservative approach since 
the effect of the reduction of the dose rate in the radioisotopes produces a less effective radiation 
damage induction. 
8.5 Conclusion 
The MCNPX/ROBY models for each of the compounds and sampling times were simulated with 
107 particles and CPU time of 57 days. Maximum dose per decay is delivered to lungs in the 
following cases: 68Ga-MAA, 68Ga-NOTA-CHSg, 99mTc-MAA, free 99mTc, 99mTc-CHSg, 99mTc-
PGCD; 90Y-DOTA-CHS and 90Y-Resin.  The results are expected since most of these are the 
successful lung perfusion agents. For the case of 99mTc-PGCD the dose to bladder is 67% of the 
maximum after 2 hours.  Maximum dose per decay is delivered to bladder for: free 68Ga, 99mTc-
PGCD, 68Ga-CHSg, and 68Ga-PGCD.  Maximum dose per decay is delivered to kidneys in the 
case of free 90Y.  In this case, the doses to bladder and marrow are 69% and 55% of the maximum 
respectively.  In the rest of the dose distributions marrow receives less than 10% of the maximum 
dose.  Liver receives less than 12.5% of the maximum dose in all the cases except for free 90Y 
where it receives less than 33% of the maximum. The dosimetry study carried out complements 
the study of the designed microspheres allocating specific radiation fields to specific organs.  
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LIMITATIONS AND FUTURE WORK 
In the present study all of the microspheres were injected into the tail vein and deposited into the 
lungs, while the main intent of use is in liver tumor RMT, with the microspheres injected directly 
into the hepatic artery. The different vascular environments may result in different degradation 
rates and radiolabel stabilities. For example, intravascular injection results in the particles 
traveling through the heart with much longer exposure to flowing blood, which could impact 
stability. Different enzymes in the liver compared to the lungs could impact degradation. Even 
though large changes in stability are not to be expected, future experiments must  be conducted 
injecting the radiolabeled particles in the hepatic artery and biodistribution assessed under 
conditions closer to those intended.  
The emulsion method used to prepare the particles is time consuming, and the yield obtained for 
particles 30±10 µm vary from 20% to 95% depending on the material and method used. It is well 
known that microsphere synthesis is difficult to control with the precision required for 
commercialization. Automation and bulk manufacturing may be difficult to achieve. Therefore, 
new micro-fabrication methods should be developed to increase yield and consistency.  Labeling, 
surface modification reactions and in vivo degradation are not expected to be affected by the 
change in the particle preparation method, since those depend on the intrinsic material 
characteristics. Tween®80 is known to be toxic and therefore it must be shown that no Tween® 80 
remains at the end of the manufacturing process, or an alternative surfactant must be identified. 
The 90Y-DOTA-CHS in vivo experiments need to be extended to at least 21 days (corresponding 
to near total 90Y decay), preferably with particle injection in the liver’s hepatic artery. In the 
present study particles labeled with 90Y were evaluated for only 24 hours because of their 
deposition in the lungs. Even when half-life should not be affected significantly for fast degrading 
particles (CHSg and CHSg-NOTA) in the liver, enzymes are likely to reduce the CHS-DOTA 
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microspheres degradation half-life. The combined effect of liver enzymes and 90Y radiolysis for 
90Y-DOTA-CHS needs to be studied. In the future, tumor implantation in the liver and RMT 
planning/treatment effectiveness needs to be performed.  Nevertheless, this preliminary study 
with the particles deposited in the lungs for 24 hours provided the necessary data to move forward 
with more complicated and costly experiments. 
Finally, biodistribution of 90Y-DOTA-CHS needs to be directly compared to 90Y-Resin Spheres 
injected into the liver since the later particles are prescribed to be injected in water via the hepatic 
artery in the clinical RMT procedure. The injection of 90Y-Resin into the tail vein might have 
decreased the in vivo stability of the 90Y binding since the turbulence in the heart’s chamber must 
have certainly exposed the particles to greater blood interaction than would occur when the 
particles are injected directly into the liver tumor vasculature. Having said this, the23% stability 
found 24 hours after injection into the tail vein is highly problematic from a safety standpoint. 
The very low in vivo stability of the 90Y-Resin label in blood deserves closer scrutiny. 
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OVERALL CONCLUSIONS 
Alternate labeling kits with 30±10 µm biodegradable microspheres were created and labeled with 
68Ga and/or 99mTc at >90% yield and radiochemical purity and 12 to 48 hours degradation half-
life for its potential use in RMT planning. Appropriate emulsion and purification methods for the 
creation of 30±10 µm particles were designed and implemented to provide the necessary raw 
materials for the subsequent experiments. Radiolabeling of the particles was performed with more 
than 90% 68Ga and/or 99mTc labeling yield and in vitro radiochemical purity for the studied 
periods. Surface modification of the particles with specific chelating agents to improve in vitro 
and in vivo stability was performed an optimized. In vitro stability studies of the particles in 
saline, PBS buffer and porcine plasma was performed and degradation half-lives determined. 
Several particles particle compositions were identified as treatment planning and treatment agents 
with variable degradation half-lifes. In vivo lung perfusion studies in Sprague Dawley were 
performed for the obtained particles. Stability and bio-distribution of the particles and the 
radioactive labels was determined. Three agents were identified for potential clinical translation: 
99mTc-CHSg and 68Ga-NOTA-CHSg for RMT planning and 90Y-DOTA-CHS for treatment. 
Dosimetry calculations were also performed using the MCNPX-ROBY models and radiation dose 
distribution were found for all the studies compositions. 
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ANNEXES 
ANNEX 1 MCNPX Simulation Parameters 
ROBY parameter file, roby_140x140x550_50.par 
mode = 0  # program mode (0 = phantom, 1 = heart lesion, 2 = spherical lesion, 3 = 
plaque, 4 = vectors, 5 = save anatomical variation) SEE NOTE 0  
act_phan_each = 1 # activity_phantom_each_frame (1=save phantom to file, 0=don't save)  
atten_phan_each = 1 # attenuation_coeff_phantom_each_frame (1=save phantom to file, 
0=don't save)  
act_phan_ave = 0 # activity_phantom_average    (1=save , 0=don't save) see NOTE 1  
atten_phan_ave = 0 # attenuation_coeff_phantom_average  (1=save, 0=don't save) see NOTE 
1  
 
motion_option = 1 # motion_option  (0=beating heart only, 1=respiratory motion only, 
2=both motions) see NOTE 2  
 
out_period = 0.37  # output_period (SECS) (if <= 0, then 
output_period=time_per_frame*output_frames)  
time_per_frame = 0 # time_per_frame (SECS) (**IGNORED unless output_period<=0**)  
out_frames = 1  # output_frames (# of output time frames )  
 
hrt_period = 0.171   # hrt_period (SECS) (length of beating heart cycle; 
normal = 1s) see NOTE 3  
hrt_start_ph_index = 0.0 # hrt_start_phase_index (range=0 to 1; ED=0, ES=0.4) see 
NOTE 3  
heart_base = roby_heart.nrb  # basename for heart files  
heart_curve_file = heart_curve.txt # name for file containing time curve for heart  
 
resp_period = 0.37                 # resp_period (SECS) (length of respiratory cycle; normal breathing 
= 5s) see NOTE 3  
resp_start_ph_index = 0.4 # resp_start_phase_index (range=0 to 1, full exhale= 0.0, full 
inhale=0.4) see NOTE 3  
max_diaphragm_motion = 1.0 # max_diaphragm_motion  (extent in mm's of diaphragm 
motion; normal breathing = 1 mm) see NOTE 4  
max_AP_exp = 0.7  # max_AP_expansion  (extent in mm's of the AP expansion of 
the chest; normal breathing = 0.7 mm) see NOTE 4  
 
dia_filename = diaphragm_curve.dat # name of curve defining diaphragm motion during 
respiration  
ap_filename = ap_curve.dat       # name of curve defining chest anterior-posterior motion 
during respiration  
 
organ_file = roby.nrb   # name of organ file that defines all organs  
 
diaph_scale = 1.0   # scales the diaphragm up or down  
 
phantom_long_axis_scale = 1.0  # phantom_long_axis_scale (scales phantom laterally - 
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scales everything) SEE NOTE 5  
phantom_short_axis_scale = 1.0  # phantom_short_axis_scale (scales phantom AP - scales 
everything) SEE NOTE 5  
phantom_height_scale = 1.0  # phantom_height_scale (scales phantom height - scales 
everything) SEE NOTE 5  
 
skin_long_axis_scale = 1.0  # skin_long_axis_scale (sets body transverse axis - 
scales only body outline) SEE NOTE 5  
skin_short_axis_scale = 1.0  # skin_short_axis_scale (sets body AP axis - scales only 
body outline) SEE NOTE 5  
 
bones_scale = 1.0   # scales the bones about their center axes SEE NOTE 5  
 
hrt_scale = 1.0   # hrt_scale  (scales heart in 3D)  
 
vol_liver = 0.0   # sets liver volume (0 - do not change)  
vol_pancreas = 0.0  # sets pancreas volume (0 - do not change)  
vol_stomach = 0.0  # sets stomach volume (0 - do not change)  
vol_spleen = 0.0  # sets spleen volume (0 - do not change)  
vol_rkidney = 0.0   # sets right kidney volume (0 - do not change)  
vol_lkidney = 0.0  # sets left kidney volume (0 - do not change)  
vol_bladder = 0.0  # sets bladder volume (0 - do not change)  
vol_testes = 0.0  # sets testes volume (0 - do not change)  
vol_small_intest = 0.0  # sets small intestine volume (0 - do not change)  
vol_large_intest = 0.0  # sets large intestine volume (0 - do not change)  
vol_trachea = 0.0  # sets trachea volume (0 - do not change)  
vol_thyroid = 0.0  # sets thyroid volume (0 - do not change)  
 
vessel_flag = 1   # vessel_flag (1 = include arteries and veins, 0 = do not include)  
papillary_flag = 1  # papillary_flag (1 = include papillary muscles in heart, 0 = do 
not include)  
 
frac_H2O = 0.5  # fraction (by weight) of water in wet bone and wet spine (used to calc. 
atten coeff)  
 
marrow_flag = 1   # render marrow (0 = no, 1 = yes)  
 
thickness_skin = 0.5            # thickness skin (mm)  
 
thickness_sternum = 0.4 # thickness sternum  (mm)  
thickness_scapula = 0.4  # thickness scapulas (mm)  
thickness_humerus = 0.45 # thickness humerus (mm)  
thickness_radius = 0.45  # thickness radius (mm)  
thickness_ulna = 0.45  # thickness ulna (mm)  
thickness_hand = 0.2  # thickness hand bones (mm)  
thickness_femur = 0.5  # thickness femur (mm)  
thickness_tibia = 0.75  # thickness tibia (mm)  
thickness_fibula = 0.45  # thickness fibula (mm)  
thickness_patella = 0.3  # thickness patella (mm)  
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thickness_foot = 0.2  # thickness foot bones (mm)  
thickness_ribs = 0.3  # thickness ribs     (mm)  
thickness_backbone = 0.4 # thickness backbone (mm)  
thickness_pelvis = 0.4  # thickness pelvis (mm)  
thickness_skull = 0.4  # thickness skull (mm)  
thickness_collar = 0.35  # thickness collarbones (mm)  
thickness_si = 0.6 # thickness of small intestine wall (mm)  
thickness_li = 0.6 # thickness of large intestine wall (mm)  
 
pixel_width = 0.05 # pixel width (cm);  see NOTE 7  
slice_width = 0.05 # slice width (cm);  
array_size = 140 # array size  
subvoxel_index = 1 # subvoxel_index (=1,2,3,4 -> 1,8,27,64 subvoxels/voxel, respectively)  
startslice = 1  # start_slice;   
endslice = 550  # end_slice;  
 
d_ZY_rotation = 0 # change in zy_rotation (beta) in deg. (0); see NOTE 8  
d_XZ_rotation = 0 # change in xz_rotation ( phi) in deg. (0);  
d_YX_rotation = 0 # change in yx_rotation ( psi) in deg. (0);  
 
X_tr = 0.0 # x translation in mm ;  
Y_tr = 0.0 # y translation in mm ;  
Z_tr = 0.0 # z translation in mm ;  
 
activity_unit = 0 # activity units (1= scale by voxel volume; 0= don't scale)  
 
skin_activity = 10  # skin_activity  
 
hrt_myoLV_act = 12  # hrt_myoLV_act - activity in left ventricle myocardium  
hrt_myoRV_act = 14  # hrt_myoRV_act - activity in right ventricle myocardium  
hrt_myoLA_act = 16  # hrt_myoLA_act - activity in left atrium myocardium  
hrt_myoRA_act = 18  # hrt_myoRA_act - activity in right atrium myocardium  
hrt_bldplLV_act = 20  # hrt_bldplLV_act - activity in left ventricle chamber (blood 
pool)  
hrt_bldplRV_act = 22  # hrt_bldplRV_act - activity in right ventricle chamber (blood 
pool)  
hrt_bldplLA_act = 24  # hrt_bldplLA_act - activity in left atria chamber (blood pool)  
hrt_bldplRA_act = 26  # hrt_bldplRA_act - activity in right atria chamber (blood pool)  
body_activity = 28  # body_activity (background activity) ;  
liver_activity = 30  # liver_activity;  
gall_bladder_activity = 32 # gall_bladder_activity;  
lung_activity = 34  # lung_activity;  
airway_activity = 36  # airway activity;  
st_wall_activity = 38  # st_wall_activity;  (stomach wall)  
st_cnts_activity = 40  # st_cnts_activity;   (stomach contents)  
pancreas_activity = 42  # pancreas_activity;  
kidney_activity = 44  # kidney_activity;  
spleen_activity = 46  # spleen_activity;  
sm_intest_activity = 48  # small_intest_activity;  
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large_intest_activity = 50 # large_intest_activity;  
bladder_activity = 52  # bladder_activity;  
vas_def_activity = 54  # vas_def_activity;  
testicular_activity = 56  # testicular_activity;  
rib_activity = 58  # rib_activity;  
spine_activity = 60  # spine_activity;  
skull_activity = 62  # skull_activity;  
 
humerus_activity = 64  # humerus_activity  
radius_activity = 66  # radius_activity  
ulna_activity = 68  # ulna_activity  
femur_activity = 70  # femur_activity  
fibula_activity = 72  # fibula_activity  
tibia_activity = 74  # tibia_activity  
patella_activity = 76  # patella_activity  
bone_activity = 78  # bone_activity (remaining bones)  
 
brain_activity = 80  # brain_activity;  
cerebral_cortex_activity = 82 # cerebral_cortex_activity;  
cerebellum_activity = 84  # cerebellum_activity;  
corpus_callosum_activity = 86  # corpus_callosum_activity;  
brainstem_activity = 88  # brainstem_activity;  
striatum_activity = 90  # striatum_activity;  
thal_activity = 92  # thal_activity;  
hippo_activity = 94  # hippo_activity;  
hypothalamus_activity = 96 # hypothalamus_activity;  
amygdala_activity = 98  # amygdala_activity;  
lateral_septal_nuclei_activity = 100  # lateral_septal_nuclei_activity;  
anterior_commissure_activity = 102 # anterior_commissure_activity;  
anterior_pretectal_nucleus_activity = 104 # anterior_pretectal_nucleus_activity;  
periaqueductal_gray_activity = 106 # periaqueductal_gray_activity;  
aqueduct_activity = 108   # aqueduct_activity;  
cerebral_peduncle_activity = 110  # cerebral_peduncle_activity;  
cochlear_nuclei_activity = 112  # cochlear_nuclei_activity;  
deep_mesencephalic_nuclei_activity = 114 # deep_mesencephalic_nuclei_activity;  
fimbria_activity = 116   # fimbria_activity;  
fornix_activity = 118   # fornix_activity;  
globus_pallidus_activity = 120  # globus_pallidus_activity;  
inferior_colliculus_activity = 122 # inferior_colliculus_activity;  
internal_capsule_activity = 124  # internal_capsule_activity;  
interpeduncular_nucleus_activity = 126 # interpeduncular_nucleus_activity;  
lateral_dorsal_nucleus_of_thalamus_activity = 128 # 
lateral_dorsal_nucleus_of_thalamus_activity;  
lateral_geniculate_activity = 130  # lateral_geniculate_activity;  
lateral_lemniscus_activity = 132 # lateral_lemniscus_activity;  
medial_geniculate_activity = 134  # medial_geniculate_activity;  
nucleus_accumbens_activity = 136  # nucleus_accumbens_activity;  
olfactory_areas_activity = 138  # olfactory_areas_activity;  
optic_tract_activity = 140  # optic_tract_activity;  
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pontine_gray_activity = 142  # pontine_gray_activity;  
spinal_trigeminal_tract_activity = 144 # spinal_trigeminal_tract_activity;  
substantia_nigra_activity = 146  # substantia_nigra_activity;  
superior_colliculus_activity = 148 # superior_colliculus_activity;  
pineal_gland_activity = 150  # pineal_gland_activity;  
ventral_thalamic_nuclei_activity = 152 # ventral_thalamic_nuclei_activity;  
ventricular_system_activity = 154  # ventricular_system_activity;  
 
 
thyroid_activity = 156  # thyroid activity;  
 
li_air_activity = 158 # large intestine air activity;  
si_air_activity = 160 # small intestine air activity;  
 
marrow_activity = 162 # bone marrow activity;  
 
lesn_activity = 164  # activity for heart lesion or plaque  
 
energy  = 140 # radionuclide energy in keV (range 1-40MeV, increments of 0.5 keV) ; for attn. 
map only  
 
#---------------------Heart lesion parameters------------------------------SEE NOTE 9  
ThetaCenter = 90.0  # theta center in deg. (between 0 and 360)  
ThetaWidth = 100.0  # theta width in deg., total width (between 0 and 360 deg.)  
XCenterIndex = .5  # x center (0.0=base, 1.0=apex, other fractions=distances in 
between)  
XWidthIndex = 60  # x width, total in mm's  
Wall_fract = 1.0 # wall_fract, fraction of the outer wall transgressed by the lesion  
#--------------------------------------------------------------------------  
 
#---------------------Spherical lesion parameters--------------------------SEE NOTE 10  
x_location = 80   # x coordinate (pixels) to place lesion  
y_location = 67   # y coordinate (pixels) to place lesion  
z_location = 85   # z coordinate (pixels) to place lesion  
lesn_diameter = 1.0  # Diameter of lesion (mm)  
#--------------------------------------------------------------------------  
 
#---------------------Heart plaque parameters------------------------------SEE NOTE 11  
p_center_v = 0.35  # plaque center along the length of the artery (between 0 and 1)  
p_center_u = 0.5  # plaque center along the circumference of the artery (between 0 
and 1)  
p_height = 1.0   # plaque thickness in mm.  
p_width = 2.0   # plaque width in mm.  
p_length = 2.0   # plaque length in mm.  
p_id = 1462   # vessel ID to place the plaque in  
#--------------------------------------------------------------------------  
 
#---------------------Vector parameters------------------------------------SEE NOTE 12  
vec_factor = 2          # higher number will increase the precision of the vector output  
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#--------------------------------------------------------------------------  
 
#--------------------------------------------------------------------------  
#--------------------------------------------------------------------------  
#This is a general parameter file for the DYNAMIC MOBY phatom, version 1.0  
#--------------------------------------------------------------------------  
#THE PARAMETERS CAN BE IN ANY ORDER. THE PROGRAM WILL SORT THEM.  
#--------------------------------------------------------------------------  
#                             NOTES:  
#--------------------------------------------------------------------------  
#NOTE 0: The phantom program can be run in different modes as follows.   
#  Mode 0: standard phantom generation mode that will generate phantoms of the  
#          body.  
#  Mode 1: heart lesion generator that will create phantoms of only the user  
#          defined heart lesion. Subtract these phantoms from those of mode 0  
#          to place the defect in the body.  
#  Mode 2: spherical lesion generator that will create phantoms of only the  
#          user defined lesion. Add these phantoms to those of mode 0 to place  
#          the lesions in the body.  
#  Mode 3: cardiac plaque generator that will create phantoms of only the  
#          user defined plaque. Add these phantoms to those of mode 0 to place  
#          the plaques in the body.  
#  Mode 4: vector generator that will output motion vectors as determined from  
#          the phantom surfaces. The vectors will be output as text files.  
#  Mode 5: anatomy generator will save the phantom produced from the user-defined anatomy  
#          parameters. The phantom is saved as two files, the organ file and the heart_base  
#          file. The names of these files can then be specified in the parfile for later runs  
#          with the program not having to take the time to generate the anatomy again. In using  
#          a saved anatomy, be sure to set all scalings back to 1; otherwise, the anatomy will be  
#          scaled again.  
#  
#NOTE 1: The average phantom is the average ONLY OF THOSE FRAMES GENERATED. 
That is,  
#  if you specify that only 2 frames be generated, then the average phantom is  
#  just the average of those 2 frames.  
#  ***************************************************************************  
#  ** FOR A GOOD AVERAGE, generate at least 8-16 frames per 1 complete heart  
#  ** cycle and/or per 1 complete respiratory cycle.  
#  ***************************************************************************  
#  
#NOTE 2: Heart motion refers to heart BEATING or contraction, while resp.  
#  motion refers to organ motion due to breathing. Note that the entire heart is  
#  translated or rotated due to resp. motion, even if it is not contracting.  
#  ** IF motion_option=1 , THE HEART WILL MOVE (TRANSLATE) BUT NOT BEAT.****  
#  
#NOTE 3:   Users sets the length and starting phase of both the heart  
#          and respiratory cycles. NORMAL values for length of heart beat and  
#          respiratory are cycles are 1 sec. and 5 secs., respectively,  
#          BUT THESE CAN VARY AMONG PATIENTS and will increase if the patient  
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#          is under stress.  
#  
#          An index value between 0 and 1 is used the specify the starting phase  
#          of the heart or resp cycles. IF NO MOTION IS SPECIFIED THEN THE STARTING  
#          PHASE IS USED AS THE SINGLE PHASE AT WHICH THE PHANTOM IS 
GENERATED.  
#          (see documentation for more details).  
#  
#NOTE 3A:  These parameters control the LV volume curve of the heart. The user can specify the 
LV  
#    volume at 5 points in the cardiac cycle. Check the logfile to see what the default 
volumes  
#          are.  The end-diastolic volume can only be reduced. The way to increase it would be to 
change  
#          the overall heart scale.  The end-systolic volume can be increased or reduced. The other 
volumes  
#          need to have values between the end-diastolic and end-systolic volumes.  The time 
durations for the  
#          different portions of the cardiac cycle must add up to a total of 1.  
#  
#          Changing these parameters will alter the heart_curve.  The altered curve and heart files 
can be output using  
#          mode = 5.  
#  
#NOTE 4:  These NORMAL values are for normal tidal breathing.  
#  ** Modeling a deep inhale may require higher values. **  
#  
#  The AP_expansion parameter controls the anteroposterior diameter of the ribcage, body,  
#  and lungs. The ribs rotate upward to expand the chest cavity by the amount indicated by the  
#  AP_expansion parameter. The lungs and body move with the expanding ribs. There is 
maximum amount  
#  by which the AP diameter can expand, due to the size of the ribs (some expansions are 
impossible  
#  geometrically.) If the user specifies too great an expansion, the program will terminate with an  
#  error message.  
#  
#  The diaphragm motion controls the motion of the heart, liver, the left diaphragm, stomach, 
spleen and  
#  all organs downstream from them.  
#  
#  
#NOTE 5: The phantom program outputs statistics on these anatomical parameters in the logfile it 
generates.  The logfile is  
#         named with the extension _log.  These statistics can be used to determine the amount of 
scaling desired. Be aware  
#   the phantom scaling parameters scale the entire phantom; therefore, any body, heart or 
breast scalings  will  
#         be additional to this base scaling.  
#  
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#  
#NOTE 7:  
#        - The phantom dimensions do not necessarily have to be cubic. The array_size parameter  
#          determines the x and y dimensions of the images.  The number of slices in the z dimension  
#          is determined by the start_slice and end_slice parameters.  The total number of slices is  
#          end_slice - start_slice + 1.  
#  
#NOTE 8:  
#        - rotation parameters determine  
#          initial orientation of beating (dynamic) heart LV long axis  
#        - d_zy_rotation : +y-axis rotates toward +z-axis (about x-axis) by beta  
#          d_xz_rotation : +z-axis rotates toward +x-axis (about y-axis) by phi  
#          d_yx_rotation : +x-axis rotates toward +y-axis (about z-axis) by psi  
#  
#        - Based on patient data, the mean and SD heart orientations are:  
#                zy_rot = -110 degrees (no patient data for this rotation)  
#                xz_rot = 23 +- 10 deg.  
#                yx_rot = -52 +- 11 deg.  
#  
#  Phantom will output total angles for the heart in the logfile  
#  
#NOTE 9: Creates lesion (defect) for the LEFT VENTRICLE ONLY.  
#  
#--------------------------------  
#  theta_center: location of lesion center in circumferential dimension  
#  
#  theta center =    0.0  => anterior wall  
#  theta center =  +90.0  => lateral   "  
#  theta center = +180.0  => inferior  "  
#  theta center = +270.0  => septal    "  
#--------------------------------  
#  theta_width : lesion width in circumferential dimension  
#  
#  TOTAL width of defect in degrees. So for example a width of 90 deg.  
#  means that the width is 45 deg. on either side of theta center.  
#--------------------------------  
#  x center :   lesion center in long-axis dimension  
#  
#  x center = 0    -> base of LV  
#  x center = 1.0  -> apex of LV  
#--------------------------------  
#  x width:  lesion width in long-axis dimension  
#  
#  total width. Defect extend half the total width on either side of the  
#  x_center.  
#  
#  NOTE: if the specified width extends beyond the boundaries of the LV  
#        then the defect is cut off and the effective width is less than the  
#        specified width. So for example...  
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#  
#--------------------------------  
#  Wall_fract : fraction of the LV wall that the lesion transgresses  
#  Wall_fract = 0.0 => transgresses none of the wall  
#  Wall_fract = 0.5 => transgresses the inner half of the wall  
#  Wall_fract = 1.0 => trangresses the entire wall  
#--------------------------------  
#  
#  
#NOTE 10: Creates a spherical lesion in the MOBY phantom. Depending on where the lesion is 
placed, it will move with  
#         the respiratory motion. Location of the lesion is specified in pixel values.  
#  
#  
#NOTE 11: Creates a plaque in the coronary vessel tree that will move with the 
cardiac/respiratory motion  
#  
#---------------------------------------------------------------------------  
#  plaque_center: location of plaque along the length of the specified artery  
#    center = 0    -> base of artery  
#    center = 1.0  -> apex of artery  
#  
#-------------------------------------------  
#  plaque_thickness : plaque thickness in mm.  
#  
#-------------------------------------------  
#  plaque_width :   plaque width in mm.  
#  
#-------------------------------------------  
#  plaque_length :  plaque length in mm.  
#  
#------------------------------------------------------  
#  plaque_id  :  vessel to place the plaque in  
#  
#        AORTA = 423  
#------------------------------------------------------  
#  
#NOTE12:  Using mode = 4, vectors are output for each voxel of frame 1 to the current frame. 
The vectors show the motion  
#         from the 1st frame to frame N. The vectors are output as text files with the format of  
#         output_name_vec_frame1_frameN.txt.  
#         The output vectors are a combination of known sampled points from the phantom objects 
and vectors interpolated  
#         from these sampled points.  The known vectors are designated as such in the vector output.  
You can increase  
#         the number of known points (and accuracy of the vector output) by increasing the 
parameter vec_factor.  
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ANNEX 2 
ANNEX 2 A: Table 7 Experimental organ-by-organ emission distributions 
Organ 68Ga-
MAA 
2h 
68Ga-
MAA 
2h E 
68Ga-
MAA 
4h 
68Ga-
MAA 
4h E 
68Ga-
CHSg-
NOTA 
68Ga-
CHSg-
NOTA 
E 
68Ga-
CHSg-
NOTA 4h 
68Ga-
CHSg-
NOTA 4 
h E 
Free 
68Ga 
2h 
Free 68Ga 
2h E 
Free 
68Ga 
4h 
Free 
68Ga 
4h E 
Spleen 0.1 0.0 0.1 0.0 0.1 0.0 0.1 0.0 0.6 0.5 1.6 0.1 
Blood 0.8 0.8 0.8 0.0 0.1 0.1 0.5 0.1 84.9 4.5 63.1 3.9 
Rib 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.5 0.4 1.3 0.4 
Urine 0.1 0.0 0.1 0.0 0.5 0.4 3.5 0.6 6.8 2.9 14.0 1.7 
Right 
Kidney 
0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.5 1.6 0.4 
Left 
Kidney 
0.0 0.0 0.0 0.0 0.1 0.0 0.1 0.0 0.5 0.5 1.4 0.2 
Heart 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.7 0.7 1.5 0.2 
Total 
Lungs 
98.6 0.7 98.6 0.1 98.9 0.2 95.6 0.9 3.1 2.9 8.4 0.3 
Total 
Liver 
0.4 0.2 0.4 0.1 0.2 0.1 0.2 0.1 2.3 1.9 7.2 1.2 
Organ 99mTc-
MAA 
2h 
99mTc-
MAA 
2h E 
99mTc-
MAA 
4h 
99mTc-
MAA 
4h E 
Free 
99mTc 2h 
Free 
99mTc 2h 
E 
Free 
99mTc 
4h 
Free 
99mTc 4h 
E 
99mTc-
CHSg  
2h 
99mTc-
CHSg 
2h E 
99mTc-
CHSg 
4h 
99mTc-
CHSg 
4h E 
Spleen 0.1 0.0 0.1 0.0 7.2 1.1 11.8 0.7 0.0 0.0 0.1 0.0 
Blood 0.9 0.2 0.9 0.0 1.3 1.2 0.4 0.0 0.7 0.5 0.8 0.1 
Rib 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.1 0.0 0.0 0.0 0.0 
Urine 7.6 1.3 12.3 1.2 6.1 4.0 0.6 0.2 4.9 2.5 10.0 2.1 
Right 
Kidney 
2.1 0.1 3.3 0.1 0.6 0.1 0.4 0.0 1.1 1.5 2.6 0.8 
Left 
Kidney 
2.2 0.2 3.4 0.2 0.6 0.1 0.4 0.0 1.2 1.6 2.6 0.8 
Heart 0.0 0.0 0.1 0.0 0.2 0.0 0.2 0.0 0.0 0.0 0.0 0.0 
Total 
Lungs 
86.6 0.7 79.2 1.5 39.5 1.5 45.2 10.9 91.6 6.5 83.2 4.1 
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Total 
Liver 
0.5 0.0 0.9 0.0 44.6 2.8 40.9 11.7 0.3 0.3 0.7 0.3 
           
 
  
Organ 99mTc-
PGCD 
4h 
99mTc-
PGCD 
4h E 
68Ga-
CHSg 
2h 
68Ga-
CHSg 
2h E 
CHS-
DOTA-
90Y 24h 
CHS-
DOTA-
90Y 24h E 
RMTEX-90Y 
24h 
RMTEX-90Y 
24h E 
Free-90Y 
24h 
Free-
90Y 24h 
E 
Spleen 1.2 0.3 0.9 0.2 0.0 0.0 0.1 0.0 0.1 0.0 
Blood 7.6 1.2 46.7 1.2 0.1 0.1 0.1 0.1 0.1 0.1 
Rib 0.1 0.0 0.4 0.0 0.3 0.0 4.5 1.2 9.0 0.4 
Urine 31.4 5.3 10.9 0.1 0.9 0.1 0.3 0.0 0.4 0.3 
Right Kidney 3.8 0.3 0.9 0.2 0.1 0.0 0.6 0.1 1.3 1.0 
Left Kidney 3.7 0.5 0.8 0.3 0.1 0.0 0.6 0.1 0.7 0.1 
Heart 0.2 0.1 1.2 0.2 0.2 0.1 0.1 0.0 0.1 0.0 
Total Lungs 29.9 1.1 31.9 1.3 95.4 1.6 23.0 4.3 0.2 0.0 
Total Liver 19.8 1.9 6.3 0.7 0.3 0.0 1.1 0.3 1.8 0.1 
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ANNEX 2 B: Table 8 Re-casted distributions for the MCNPX ROBY model 
 68Ga-
MAA 2h 
68Ga-
MAA 4h 
68Ga-
CHSg-
NOTA 2h 
68Ga-
CHSg-
NOTA 
4h 
Free 
68Ga 2h 
Free 68Ga 
4h 
99mTc-
MAA 2h 
99mTc-
MAA 4h 
Free 
99mTc 2h 
Free 
99mTc 4h 
heart 
LV 
1.4165E-4 1.7792E-4 2.5432E-4 3.5193E-
4 
5.5384E-
3 
1.2309E-2 3.0012E-4 4.5547E-4 1.4241E-
3 
1.6416E-
3 
heart 
RV 
2.0553E-5 2.5816E-5 3.6900E-5 5.1063E-
5 
8.0360E-
4 
1.7860E-3 4.3545E-5 6.6086E-5 2.0663E-
4 
2.3819E-
4 
heart 
LA 
3.7593E-6 4.7219E-6 6.7493E-6 9.3399E-
6 
1.4699E-
4 
3.2668E-4 7.9648E-6 1.2088E-5 3.7794E-
5 
4.3567E-
5 
heart 
RA 
5.3000E-6 6.6571E-6 9.5154E-6 1.3168E-
5 
2.0722E-
4 
4.6056E-4 1.1229E-5 1.7042E-5 5.3284E-
5 
6.1423E-
5 
blood 
LV 
2.8575E-4 2.9484E-4 3.1289E-5 1.8083E-
4 
3.1177E-
2 
2.3159E-2 3.4317E-4 3.1757E-4 4.5952E-
4 
1.5187E-
4 
blood 
RV 
2.5285E-4 2.6088E-4 2.7686E-5 1.6001E-
4 
2.7587E-
2 
2.0492E-2 3.0365E-4 2.8100E-4 4.0660E-
4 
1.3438E-
4 
blood 
LA 
8.3777E-5 8.6440E-5 9.1733E-6 5.3016E-
5 
9.1405E-
3 
6.7897E-3 1.0061E-4 9.3106E-5 1.3472E-
4 
4.4525E-
5 
blood 
RA 
3.3027E-4 3.4077E-4 3.6163E-5 2.0900E-
4 
3.6034E-
2 
2.6766E-2 3.9663E-4 3.6705E-4 5.3111E-
4 
1.7553E-
4 
body 
rest 
5.3385E-3 5.5082E-3 5.8455E-4 3.3783E-
3 
5.8246E-
1 
4.3266E-1 6.4112E-3 5.9330E-3 8.5849E-
3 
2.8373E-
3 
liver 4.1615E-3 4.1616E-3 2.4738E-3 1.5811E-
3 
2.3226E-
2 
7.2295E-2 4.5540E-3 8.8954E-3 4.4648E-
1 
4.0948E-
1 
lung 9.8559E-1 9.8519E-1 9.8847E-1 9.5574E-
1 
3.1361E-
2 
8.3633E-2 8.6566E-1 7.9180E-1 3.9480E-
1 
4.5185E-
1 
kidney 3.4462E-4 6.4526E-4 1.7168E-3 1.5842E-
3 
1.0718E-
2 
2.9883E-2 4.3414E-2 6.6444E-2 1.1586E-
2 
7.4213E-
3 
spleen 9.1440E-4 9.7711E-4 7.2734E-4 5.1691E-
4 
5.7897E-
3 
1.6148E-2 5.7300E-4 7.6736E-4 7.1775E-
2 
1.1838E-
1 
bladder 1.0375E-3 7.8540E-4 5.4485E-3 3.5174E-
2 
6.8173E-
2 
1.3975E-1 7.5964E-2 1.2274E-1 6.0699E-
2 
6.4290E-
3 
rib 0.0000E+0 0.0000E+0 0.0000E+0 5.0076E- 4.9928E- 1.2731E-2 1.2810E-4 1.5578E-4 4.2682E- 3.1113E-
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5 3 4 4 
marrow 1.4907E-3 1.5381E-3 1.6323E-4 9.4337E-
4 
1.6265E-
1 
1.2082E-1 1.7903E-3 1.6567E-3 2.3973E-
3 
7.9229E-
4 
           
 99mTc-
CHSg 2h 
99mTc-
CHSg 4h 
99mTc-
PGCD 2h 
99mTc-
PGCD 4h 
68Ga-
CHSg 
68GaPGCD 
2h 
90Y-CHS-
DOTA 24h 
90Y-
RMTEX 
24h 
Free 90Y 24h 
heart LV 3.0155E-4 3.0609E-4 9.3994E-
4 
1.6211E-
3 
9.6185E-
3 
9.5181E-3 1.6175E-3 1.8834E-3 5.0518E-3 
heart RV 4.3753E-5 4.4412E-5 1.3638E-
4 
2.3522E-
4 
1.3956E-
3 
1.3810E-3 2.3469E-4 2.7326E-4 7.3299E-4 
heart LA 8.0027E-6 8.1234E-6 2.4945E-
5 
4.3024E-
5 
2.5526E-
4 
2.5260E-4 4.2927E-5 4.9982E-5 1.3407E-4 
heart RA 1.1283E-5 1.1453E-5 3.5168E-
5 
6.0656E-
5 
3.5988E-
4 
3.5613E-4 6.0519E-5 7.0467E-5 1.8902E-4 
blood LV 2.7229E-4 3.0800E-4 2.6679E-
3 
2.8651E-
3 
1.7147E-
2 
1.7980E-2 3.9397E-5 1.0943E-4 2.6426E-4 
blood RV 2.4094E-4 2.7253E-4 2.3607E-
3 
2.5352E-
3 
1.5172E-
2 
1.5910E-2 3.4861E-5 9.6833E-5 2.3383E-4 
blood LA 7.9832E-5 9.0299E-5 7.8219E-
4 
8.4001E-
4 
5.0271E-
3 
5.2715E-3 1.1551E-5 3.2084E-5 7.7476E-5 
blood RA 3.1472E-4 3.5598E-4 3.0836E-
3 
3.3115E-
3 
1.9818E-
2 
2.0782E-2 4.5535E-5 1.2648E-4 3.0543E-4 
body rest 5.0871E-3 5.7541E-3 4.9843E-
2 
5.3528E-
2 
3.2034E-
1 
3.3592E-1 7.3604E-4 2.0445E-3 4.9370E-3 
liver 2.9627E-3 6.6119E-3 2.7583E-
2 
2.0292E-
1 
6.3462E-
2 
4.9253E-2 2.8789E-3 3.7748E-2 1.3556E-1 
lung 9.1620E-1 8.3159E-1 5.6353E-
1 
3.0638E-
1 
3.1913E-
1 
5.6386E-2 9.7954E-1 7.5793E-1 1.1508E-2 
kidney 2.3517E-2 5.2606E-2 5.5335E-
2 
7.6429E-
2 
1.7184E-
2 
2.7100E-2 1.9219E-3 3.9834E-2 1.4701E-1 
spleen 4.5143E-4 7.5350E-4 8.0913E-
3 
1.1966E-
2 
9.0263E-
3 
7.6440E-3 2.5681E-4 1.8523E-3 5.4100E-3 
bladder 4.9037E-2 9.9534E-2 2.7106E-
1 
3.2175E-
1 
1.0856E-
1 
3.5116E-1 9.3067E-3 8.3853E-3 2.5702E-2 
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rib 5.6434E-5 1.4234E-4 6.1325E-
4 
5.2629E-
4 
4.0457E-
3 
7.2820E-3 0.0000E+0 0.0000E+0 0.0000E+0 
marrow 1.4205E-3 1.6068E-3 1.3918E-
2 
1.4947E-
2 
8.9454E-
2 
9.3803E-2 3.2743E-3 1.4956E-1 6.6289E-1 
 
ANNEX 3: Table 9 Tabulated Dosimetry Calculations Results 
   68Ga-MAA 2h 68Ga-MAA 4h CHSg-NOTA-
68Ga 
CHSg-NOTA-
68Ga 4h 
   MEAN error MEAN error MEAN error MEAN error 
Dose at @ 1 cm (mGy/decay)   3.39E-
11 
6E-
13 
3.39E-
11 
6E-
13 
3.35E-
11 
6E-
13 
3.29E-
11 
6E-13 
Energy Dep (MeV)   8.228E-
1 
2E-4 8.228E-
1 
2E-4 8.231E-
1 
2E-4 8.230E-
1 
2E-4 
Avg (mGy/decay)   4.134E-
10 
1E-
13 
4.133E-
10 
1E-
13 
4.135E-
10 
1E-
13 
4.135E-
10 
1E-13 
Max D (mGy/decay)   3.87E-8  3.87E-8  3.89E-8  3.76E-8  
Min D (mGy/decay)   3.41E-
12 
 3.41E-
12 
 2.21E-
12 
 4.56E-
12 
 
           
 Vol 
(cm³) 
Mass 
(g) 
Dose per tissue 
(mGy/decay) 
     
   MEAN error MEAN error MEAN error MEAN error 
skin 1.79E+1 1.95E+1 2.07E-
11 
6E-
14 
2.08E-
11 
6E-
14 
1.98E-
11 
6E-
14 
2.03E-
11 
6E-14 
myoLV 5.75E-1 6.03E-1 5.66E-9 1E-
11 
5.66E-9 1E-
11 
5.68E-9 1E-
11 
5.51E-9 1E-11 
myoRV 8.34E-2 8.75E-2 1.36E-9 8E-
12 
1.37E-9 8E-
12 
1.36E-9 8E-
12 
1.32E-9 8E-12 
myoLA 1.53E-2 1.60E-2 4.74E-9 3E-
11 
4.74E-9 3E-
11 
4.74E-9 3E-
11 
4.59E-9 3E-11 
myoRA 2.15E-2 2.26E-2 1.13E-8 4E-
11 
1.13E-8 4E-
11 
1.14E-8 4E-
11 
1.10E-8 4E-11 
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bldplLV 8.49E-1 9.00E-1 2.22E-9 5E-
12 
2.22E-9 5E-
12 
2.21E-9 5E-
12 
2.15E-9 5E-12 
bldplRV 7.51E-1 7.96E-1 1.26E-9 4E-
12 
1.26E-9 4E-
12 
1.24E-9 4E-
12 
1.21E-9 4E-12 
bldplLA 2.49E-1 2.64E-1 9.81E-9 2E-
11 
9.81E-9 2E-
11 
9.83E-9 2E-
11 
9.51E-9 2E-11 
bldplRA 9.81E-1 1.04E+0 4.69E-9 7E-
12 
4.69E-9 7E-
12 
4.68E-9 7E-
12 
4.54E-9 7E-12 
Rest of the body 2.27E+2 2.33E+2 1.94E-
10 
1E-
13 
1.94E-
10 
1E-
13 
1.93E-
10 
1E-
13 
1.94E-
10 
1E-13 
Liver 1.04E+1 1.10E+1 1.07E-9 1E-
12 
1.07E-9 1E-
12 
1.06E-9 1E-
12 
1.02E-9 1E-12 
Lung 2.88E+0 7.48E-1 3.87E-8 2E-
11 
3.87E-8 2E-
11 
3.89E-8 2E-
11 
3.76E-8 2E-11 
Trachea 7.24E-1 7.46E-1 1.85E-8 1E-
11 
1.84E-8 1E-
11 
1.85E-8 1E-
11 
1.79E-8 1E-11 
Stomach_Contents 4.65E+0 4.79E+0 9.08E-
11 
4E-
13 
9.09E-
11 
4E-
13 
8.93E-
11 
4E-
13 
8.62E-
11 
4E-13 
Pancreas 5.08E-1 5.28E-1 3.70E-
11 
6E-
13 
3.81E-
11 
6E-
13 
3.94E-
11 
6E-
13 
3.90E-
11 
6E-13 
Kidney 2.09E+0 2.19E+0 3.73E-
11 
4E-
13 
4.70E-
11 
4E-
13 
7.89E-
11 
6E-
13 
7.54E-
11 
6E-13 
Spleen 8.13E-1 8.62E-1 1.09E-
10 
1E-
12 
1.16E-
10 
1E-
12 
9.17E-
11 
1E-
12 
7.34E-
11 
1E-12 
Small_Intestine 4.23E+0 4.35E+0 2.04E-
11 
1E-
13 
2.07E-
11 
2E-
13 
1.99E-
11 
1E-
13 
2.12E-
11 
2E-13 
Large_Intestine 1.95E+0 2.01E+0 1.72E-
11 
2E-
13 
1.71E-
11 
2E-
13 
2.36E-
11 
3E-
13 
7.25E-
11 
5E-13 
Bladder 6.30E-1 6.49E-1 1.38E-
10 
2E-
12 
1.05E-
10 
2E-
12 
6.93E-
10 
4E-
12 
4.48E-9 1E-11 
Vas_deferens 5.46E-2 5.63E-2 3.41E-
12 
5E-
13 
3.41E-
12 
5E-
13 
2.63E-
12 
4E-
13 
5.67E-
12 
7E-13 
Testes 1.64E-1 1.70E-1 3.82E-
12 
3E-
13 
3.91E-
12 
3E-
13 
2.67E-
12 
2E-
13 
6.06E-
12 
4E-13 
Wet_Rib_Bone 9.38E-1 1.32E+0 3.66E-9 4E- 3.66E-9 4E- 3.67E-9 4E- 3.55E-9 4E-12 
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12 12 12 
Wet_Spine_Bone 4.14E+0 5.88E+0 5.00E-
10 
8E-
13 
5.00E-
10 
8E-
13 
4.98E-
10 
8E-
13 
4.84E-
10 
8E-13 
Skull 1.24E+0 1.99E+0 1.00E-
11 
2E-
13 
1.01E-
11 
2E-
13 
6.52E-
12 
1E-
13 
8.52E-
12 
1E-13 
humerus 2.42E-1 3.53E-1 5.60E-
11 
8E-
13 
5.61E-
11 
8E-
13 
5.26E-
11 
7E-
13 
5.28E-
11 
7E-13 
radius 1.87E-1 2.73E-1 1.01E-
10 
1E-
12 
1.01E-
10 
1E-
12 
9.79E-
11 
1E-
12 
9.58E-
11 
1E-12 
ulna 2.09E-1 3.06E-1 7.42E-
11 
9E-
13 
7.43E-
11 
9E-
13 
7.10E-
11 
9E-
13 
7.11E-
11 
9E-13 
femur 4.44E-1 5.91E-1 7.26E-
12 
2E-
13 
7.44E-
12 
3E-
13 
3.74E-
12 
1E-
13 
7.68E-
12 
2E-13 
fibula 1.41E-1 1.87E-1 5.34E-
12 
4E-
13 
5.52E-
12 
4E-
13 
2.36E-
12 
2E-
13 
4.94E-
12 
3E-13 
tibia 5.17E-1 6.87E-1 4.82E-
12 
2E-
13 
4.87E-
12 
2E-
13 
2.21E-
12 
1E-
13 
4.56E-
12 
2E-13 
patella 3.75E-2 4.99E-2 7.50E-
12 
8E-
13 
7.78E-
12 
8E-
13 
3.88E-
12 
5E-
13 
6.55E-
12 
7E-13 
bone 1.96E+0 2.75E+0 2.95E-
11 
2E-
13 
2.97E-
11 
2E-
13 
2.69E-
11 
2E-
13 
2.95E-
11 
2E-13 
brain_(backgrnd) 6.00E-2 6.24E-2 1.23E-
11 
8E-
13 
1.27E-
11 
8E-
13 
8.67E-
12 
6E-
13 
1.06E-
11 
7E-13 
cerebral_cortex 1.58E+0 1.64E+0 9.49E-
12 
2E-
13 
9.54E-
12 
2E-
13 
7.84E-
12 
1E-
13 
8.58E-
12 
2E-13 
cerebellum 5.41E-1 5.62E-1 1.44E-
11 
4E-
13 
1.44E-
11 
4E-
13 
1.32E-
11 
3E-
13 
1.36E-
11 
3E-13 
corpus_callosum 1.20E-1 1.24E-1 8.62E-
12 
5E-
13 
8.62E-
12 
5E-
13 
8.17E-
12 
5E-
13 
8.25E-
12 
5E-13 
brainstem 6.33E-1 6.59E-1 1.41E-
11 
3E-
13 
1.41E-
11 
3E-
13 
1.30E-
11 
3E-
13 
1.34E-
11 
3E-13 
striatum 2.46E-1 2.56E-1 7.63E-
12 
4E-
13 
7.61E-
12 
4E-
13 
7.11E-
12 
3E-
13 
7.21E-
12 
3E-13 
thal 1.09E-1 1.13E-1 8.00E-
12 
5E-
13 
8.04E-
12 
5E-
13 
7.79E-
12 
5E-
13 
7.83E-
12 
5E-13 
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hippo 3.01E-1 3.13E-1 9.88E-
12 
4E-
13 
9.87E-
12 
4E-
13 
9.43E-
12 
4E-
13 
9.41E-
12 
4E-13 
hypothalamus 9.40E-2 9.78E-2 9.94E-
12 
7E-
13 
1.01E-
11 
7E-
13 
9.11E-
12 
6E-
13 
9.16E-
12 
6E-13 
amygdala 1.48E-1 1.54E-1 1.00E-
11 
6E-
13 
1.00E-
11 
6E-
13 
8.66E-
12 
5E-
13 
9.32E-
12 
5E-13 
lateral_septal_nuclei 4.69E-2 4.88E-2 6.73E-
12 
7E-
13 
6.73E-
12 
7E-
13 
6.69E-
12 
7E-
13 
6.54E-
12 
7E-13 
anterior_commissure 1.19E-2 1.24E-2 1.23E-
11 
2E-
12 
1.23E-
11 
2E-
12 
1.19E-
11 
2E-
12 
1.17E-
11 
2E-12 
anterior_pretectal_nucleus 1.36E-2 1.42E-2 9.08E-
12 
1E-
12 
9.08E-
12 
1E-
12 
9.14E-
12 
1E-
12 
8.89E-
12 
1E-12 
periaqueductal_gray 3.66E-2 3.81E-2 9.73E-
12 
1E-
12 
9.73E-
12 
1E-
12 
9.75E-
12 
1E-
12 
9.43E-
12 
9E-13 
aqueduct 4.38E-3 4.55E-3 1.14E-
11 
3E-
12 
1.14E-
11 
3E-
12 
1.04E-
11 
3E-
12 
1.14E-
11 
3E-12 
cerebral_peduncle 1.86E-2 1.94E-2 8.87E-
12 
1E-
12 
8.87E-
12 
1E-
12 
8.80E-
12 
1E-
12 
8.59E-
12 
1E-12 
cochlear_nuclei 2.23E-2 2.31E-2 1.56E-
11 
2E-
12 
1.56E-
11 
2E-
12 
1.44E-
11 
2E-
12 
1.51E-
11 
2E-12 
deep_mesencephalic_nuclei 4.38E-2 4.55E-2 1.11E-
11 
1E-
12 
1.11E-
11 
1E-
12 
1.11E-
11 
1E-
12 
1.08E-
11 
1E-12 
fimbria 2.21E-2 2.30E-2 7.36E-
12 
1E-
12 
7.36E-
12 
1E-
12 
7.22E-
12 
1E-
12 
7.10E-
12 
1E-12 
fornix 1.56E-2 1.63E-2 8.34E-
12 
1E-
12 
8.61E-
12 
1E-
12 
8.08E-
12 
1E-
12 
8.08E-
12 
1E-12 
globus_pallidus 2.70E-2 2.81E-2 8.56E-
12 
1E-
12 
8.56E-
12 
1E-
12 
7.63E-
12 
9E-
13 
7.89E-
12 
9E-13 
inferior_colliculus 6.51E-2 6.77E-2 1.27E-
11 
9E-
13 
1.27E-
11 
9E-
13 
1.21E-
11 
8E-
13 
1.19E-
11 
8E-13 
internal_capsule 4.13E-2 4.29E-2 7.70E-
12 
8E-
13 
7.72E-
12 
8E-
13 
7.63E-
12 
8E-
13 
7.47E-
12 
8E-13 
interpeduncular_nucleus 4.75E-3 4.94E-3 1.31E-
11 
3E-
12 
1.31E-
11 
3E-
12 
1.24E-
11 
3E-
12 
1.23E-
11 
3E-12 
lateral_dorsal_nucleus_of_thalamus 1.18E-2 1.22E-2 7.66E- 1E- 7.66E- 1E- 7.56E- 1E- 7.67E- 1E-12 
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12 12 12 12 12 12 12 
lateral_geniculate 1.86E-2 1.94E-2 9.55E-
12 
1E-
12 
9.55E-
12 
1E-
12 
9.29E-
12 
1E-
12 
9.52E-
12 
1E-12 
lateral_lemniscus 1.68E-2 1.74E-2 1.13E-
11 
1E-
12 
1.13E-
11 
1E-
12 
1.11E-
11 
1E-
12 
1.14E-
11 
1E-12 
medial_geniculate 1.80E-2 1.87E-2 7.74E-
12 
1E-
12 
7.74E-
12 
1E-
12 
7.76E-
12 
1E-
12 
7.72E-
12 
1E-12 
nucleus_accumbens 5.94E-2 6.18E-2 7.66E-
12 
7E-
13 
7.66E-
12 
7E-
13 
7.13E-
12 
7E-
13 
7.21E-
12 
7E-13 
olfactory_areas 3.33E-1 3.46E-1 7.73E-
12 
4E-
13 
7.86E-
12 
4E-
13 
5.12E-
12 
3E-
13 
6.34E-
12 
3E-13 
optic_tract 2.00E-2 2.08E-2 8.22E-
12 
1E-
12 
8.22E-
12 
1E-
12 
7.14E-
12 
1E-
12 
7.77E-
12 
1E-12 
pontine_gray 2.44E-2 2.54E-2 1.17E-
11 
1E-
12 
1.20E-
11 
1E-
12 
9.51E-
12 
1E-
12 
1.06E-
11 
1E-12 
spinal_trigeminal_tract 2.78E-2 2.89E-2 1.65E-
11 
1E-
12 
1.68E-
11 
1E-
12 
1.51E-
11 
1E-
12 
1.56E-
11 
1E-12 
substantia_nigra 3.54E-2 3.68E-2 9.84E-
12 
1E-
12 
9.84E-
12 
1E-
12 
9.57E-
12 
1E-
12 
9.06E-
12 
1E-12 
superior_colliculus 1.27E-1 1.32E-1 1.01E-
11 
5E-
13 
1.01E-
11 
5E-
13 
9.73E-
12 
5E-
13 
9.47E-
12 
5E-13 
pineal_gland 3.00E-3 3.12E-3 1.26E-
11 
4E-
12 
1.21E-
11 
4E-
12 
1.20E-
11 
4E-
12 
1.20E-
11 
4E-12 
ventral_thalamic_nuclei 5.75E-2 5.98E-2 8.85E-
12 
8E-
13 
8.85E-
12 
8E-
13 
8.76E-
12 
7E-
13 
8.35E-
12 
7E-13 
ventricular_system 9.65E-2 1.00E-1 1.00E-
11 
6E-
13 
1.00E-
11 
6E-
13 
9.48E-
12 
6E-
13 
9.38E-
12 
6E-13 
thyroid 2.62E-1 2.69E-1 2.12E-
11 
6E-
13 
2.12E-
11 
6E-
13 
2.05E-
11 
6E-
13 
1.99E-
11 
6E-13 
Large_Int 8.76E+0 1.06E-2 1.52E-
11 
5E-
13 
1.51E-
11 
5E-
13 
1.80E-
11 
5E-
13 
4.49E-
11 
7E-13 
Small_Int 1.00E+1 1.21E-2 1.92E-
11 
4E-
13 
1.95E-
11 
4E-
13 
1.85E-
11 
4E-
13 
2.01E-
11 
4E-13 
marrow 1.38E+1 1.43E+1 5.83E-
10 
5E-
13 
5.83E-
10 
5E-
13 
5.78E-
10 
5E-
13 
5.63E-
10 
5E-13 
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   Free 68Ga 2h Free 68Ga 4h 99mTc-MAA 2h 99mTc-MAA 4h 
   MEAN error MEAN error MEAN error MEAN error 
Dose at @ 1 cm (mGy/decay)   7.1E-11 1E-
12 
6.2E-11 1E-
12 
3.7E-12 1E-
13 
3.5E-12 1E-13 
Energy Dep (MeV)   7.848E-
1 
2E-4 7.949E-
1 
2E-4 2.673E-
2 
2E-5 2.676E-
2 
2E-5 
Avg (mGy/decay)   3.943E-
10 
1E-
13 
3.993E-
10 
1E-
13 
1.343E-
11 
1E-
14 
1.344E-
11 
1E-14 
Max D (mGy/decay)   8.79E-9  1.79E-8  2.62E-9  2.39E-9  
Min D (mGy/decay)   2.40E-
11 
 1.84E-
11 
 4.55E-
13 
 5.06E-
13 
 
           
 Vol 
(cm³) 
Mass 
(g) 
Dose per tissue 
(mGy/decay) 
     
   MEAN error MEAN error MEAN error MEAN error 
skin 1.79E+1 1.95E+1 1.30E-
10 
2E-
13 
1.02E-
10 
2E-
13 
2.33E-
12 
1E-
14 
2.32E-
12 
1E-14 
myoLV 5.75E-1 6.03E-1 1.99E-9 6E-
12 
2.69E-9 7E-
12 
5.16E-
11 
4E-
13 
4.84E-
11 
4E-13 
myoRV 8.34E-2 8.75E-2 1.91E-9 9E-
12 
1.85E-9 9E-
12 
2.30E-
11 
6E-
13 
2.19E-
11 
6E-13 
myoLA 1.53E-2 1.60E-2 2.34E-9 2E-
11 
2.27E-9 2E-
11 
4.50E-
11 
2E-
12 
4.16E-
11 
2E-12 
myoRA 2.15E-2 2.26E-2 2.39E-9 2E-
11 
2.71E-9 2E-
11 
1.31E-
10 
4E-
12 
1.22E-
10 
4E-12 
bldplLV 8.49E-1 9.00E-1 2.60E-9 6E-
12 
2.27E-9 5E-
12 
3.04E-
11 
2E-
13 
2.81E-
11 
2E-13 
bldplRV 7.51E-1 7.96E-1 3.17E-9 7E-
12 
2.63E-9 7E-
12 
2.78E-
11 
2E-
13 
2.55E-
11 
2E-13 
bldplLA 2.49E-1 2.64E-1 2.94E-9 1E-
11 
2.89E-9 1E-
11 
8.63E-
11 
8E-
13 
7.90E-
11 
8E-13 
bldplRA 9.81E-1 1.04E+0 2.73E-9 6E-
12 
2.42E-9 5E-
12 
4.20E-
11 
3E-
13 
3.89E-
11 
3E-13 
Rest of the body 2.27E+2 2.33E+2 3.39E-
10 
1E-
13 
2.95E-
10 
1E-
13 
4.92E-
12 
6E-
15 
4.97E-
12 
6E-15 
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Liver 1.04E+1 1.10E+1 3.89E-
10 
7E-
13 
8.87E-
10 
1E-
12 
1.84E-
11 
5E-
14 
1.85E-
11 
6E-14 
Lung 2.88E+0 7.48E-1 1.89E-9 4E-
12 
3.92E-9 6E-
12 
2.62E-9 3E-
12 
2.39E-9 3E-12 
Trachea 7.24E-1 7.46E-1 1.17E-9 3E-
12 
2.06E-9 5E-
12 
1.93E-
10 
8E-
13 
1.77E-
10 
8E-13 
Stomach_Contents 4.65E+0 4.79E+0 9.65E-
11 
5E-
13 
1.42E-
10 
6E-
13 
6.97E-
12 
4E-
14 
6.77E-
12 
4E-14 
Pancreas 5.08E-1 5.28E-1 2.18E-
10 
2E-
12 
2.42E-
10 
2E-
12 
5.55E-
12 
1E-
13 
6.12E-
12 
1E-13 
Kidney 2.09E+0 2.19E+0 4.97E-
10 
2E-
12 
1.11E-9 3E-
12 
5.58E-
11 
3E-
13 
8.47E-
11 
4E-13 
Spleen 8.13E-1 8.62E-1 6.36E-
10 
3E-
12 
1.58E-9 5E-
12 
5.18E-
12 
1E-
13 
6.10E-
12 
1E-13 
Small_Intestine 4.23E+0 4.35E+0 1.85E-
10 
6E-
13 
1.84E-
10 
6E-
13 
2.95E-
12 
3E-
14 
3.45E-
12 
3E-14 
Large_Intestine 1.95E+0 2.01E+0 3.22E-
10 
1E-
12 
4.16E-
10 
1E-
12 
3.48E-
12 
5E-
14 
4.67E-
12 
6E-14 
Bladder 6.30E-1 6.49E-1 8.79E-9 1E-
11 
1.79E-8 2E-
11 
3.21E-
10 
1E-
12 
5.16E-
10 
2E-12 
Vas_deferens 5.46E-2 5.63E-2 1.43E-
10 
4E-
12 
1.14E-
10 
4E-
12 
8.77E-
13 
1E-
13 
1.18E-
12 
1E-13 
Testes 1.64E-1 1.70E-1 1.51E-
10 
3E-
12 
1.21E-
10 
2E-
12 
8.59E-
13 
8E-
14 
1.31E-
12 
1E-13 
Wet_Rib_Bone 9.38E-1 1.32E+0 5.96E-
10 
1E-
12 
8.67E-
10 
2E-
12 
3.89E-
11 
2E-
13 
3.60E-
11 
2E-13 
Wet_Spine_Bone 4.14E+0 5.88E+0 3.66E-
10 
7E-
13 
3.09E-
10 
6E-
13 
1.02E-
11 
5E-
14 
9.75E-
12 
5E-14 
Skull 1.24E+0 1.99E+0 4.43E-
10 
1E-
12 
3.30E-
10 
1E-
12 
8.55E-
13 
3E-
14 
7.88E-
13 
3E-14 
humerus 2.42E-1 3.53E-1 4.42E-
10 
3E-
12 
3.34E-
10 
2E-
12 
8.16E-
12 
2E-
13 
7.50E-
12 
2E-13 
radius 1.87E-1 2.73E-1 4.05E-
10 
3E-
12 
3.12E-
10 
3E-
12 
1.47E-
11 
3E-
13 
1.36E-
11 
3E-13 
ulna 2.09E-1 3.06E-1 3.96E- 3E- 3.02E- 3E- 1.04E- 2E- 9.57E- 2E-13 
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10 12 10 12 11 13 12 
femur 4.44E-1 5.91E-1 4.87E-
10 
2E-
12 
3.66E-
10 
2E-
12 
1.36E-
12 
6E-
14 
1.83E-
12 
7E-14 
fibula 1.41E-1 1.87E-1 3.57E-
10 
3E-
12 
2.67E-
10 
3E-
12 
4.55E-
13 
6E-
14 
6.28E-
13 
7E-14 
tibia 5.17E-1 6.87E-1 3.26E-
10 
2E-
12 
2.45E-
10 
2E-
12 
4.92E-
13 
4E-
14 
6.13E-
13 
4E-14 
patella 3.75E-2 4.99E-2 4.00E-
10 
6E-
12 
2.98E-
10 
5E-
12 
5.26E-
13 
1E-
13 
8.18E-
13 
1E-13 
bone 1.96E+0 2.75E+0 3.43E-
10 
9E-
13 
2.66E-
10 
8E-
13 
3.43E-
12 
4E-
14 
3.70E-
12 
5E-14 
brain_(backgrnd) 6.00E-2 6.24E-2 4.46E-
10 
5E-
12 
3.31E-
10 
4E-
12 
8.16E-
13 
1E-
13 
8.27E-
13 
1E-13 
cerebral_cortex 1.58E+0 1.64E+0 2.18E-
10 
1E-
12 
1.64E-
10 
1E-
12 
6.95E-
13 
2E-
14 
6.60E-
13 
2E-14 
cerebellum 5.41E-1 5.62E-1 1.74E-
10 
2E-
12 
1.31E-
10 
2E-
12 
1.43E-
12 
6E-
14 
1.34E-
12 
6E-14 
corpus_callosum 1.20E-1 1.24E-1 7.69E-
11 
2E-
12 
5.86E-
11 
1E-
12 
8.14E-
13 
8E-
14 
7.57E-
13 
8E-14 
brainstem 6.33E-1 6.59E-1 1.59E-
10 
2E-
12 
1.21E-
10 
1E-
12 
1.31E-
12 
5E-
14 
1.24E-
12 
5E-14 
striatum 2.46E-1 2.56E-1 5.80E-
11 
1E-
12 
4.43E-
11 
1E-
12 
6.61E-
13 
6E-
14 
6.13E-
13 
5E-14 
thal 1.09E-1 1.13E-1 3.47E-
11 
1E-
12 
2.59E-
11 
1E-
12 
7.86E-
13 
1E-
13 
7.57E-
13 
9E-14 
hippo 3.01E-1 3.13E-1 7.29E-
11 
1E-
12 
5.52E-
11 
1E-
12 
8.37E-
13 
6E-
14 
8.02E-
13 
6E-14 
hypothalamus 9.40E-2 9.78E-2 2.09E-
10 
5E-
12 
1.60E-
10 
4E-
12 
8.10E-
13 
1E-
13 
7.85E-
13 
1E-13 
amygdala 1.48E-1 1.54E-1 2.08E-
10 
4E-
12 
1.54E-
10 
3E-
12 
8.56E-
13 
9E-
14 
8.27E-
13 
9E-14 
lateral_septal_nuclei 4.69E-2 4.88E-2 4.14E-
11 
2E-
12 
3.17E-
11 
2E-
12 
5.95E-
13 
1E-
13 
6.11E-
13 
1E-13 
anterior_commissure 1.19E-2 1.24E-2 5.93E-
11 
4E-
12 
4.91E-
11 
4E-
12 
5.41E-
13 
2E-
13 
5.20E-
13 
2E-13 
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anterior_pretectal_nucleus 1.36E-2 1.42E-2 2.70E-
11 
3E-
12 
2.03E-
11 
2E-
12 
5.88E-
13 
2E-
13 
5.06E-
13 
2E-13 
periaqueductal_gray 3.66E-2 3.81E-2 2.95E-
11 
2E-
12 
2.33E-
11 
2E-
12 
9.20E-
13 
2E-
13 
7.88E-
13 
1E-13 
aqueduct 4.38E-3 4.55E-3 3.78E-
11 
6E-
12 
2.96E-
11 
6E-
12 
6.40E-
13 
4E-
13 
6.04E-
13 
4E-13 
cerebral_peduncle 1.86E-2 1.94E-2 1.35E-
10 
6E-
12 
1.04E-
10 
5E-
12 
6.95E-
13 
2E-
13 
6.84E-
13 
2E-13 
cochlear_nuclei 2.23E-2 2.31E-2 2.34E-
10 
8E-
12 
1.74E-
10 
7E-
12 
1.41E-
12 
3E-
13 
1.36E-
12 
3E-13 
deep_mesencephalic_nuclei 4.38E-2 4.55E-2 2.82E-
11 
2E-
12 
2.19E-
11 
1E-
12 
1.32E-
12 
2E-
13 
1.25E-
12 
2E-13 
fimbria 2.21E-2 2.30E-2 2.40E-
11 
2E-
12 
1.84E-
11 
2E-
12 
9.36E-
13 
2E-
13 
8.43E-
13 
2E-13 
fornix 1.56E-2 1.63E-2 8.93E-
11 
5E-
12 
6.91E-
11 
4E-
12 
8.77E-
13 
2E-
13 
7.99E-
13 
2E-13 
globus_pallidus 2.70E-2 2.81E-2 4.93E-
11 
3E-
12 
3.78E-
11 
3E-
12 
8.94E-
13 
2E-
13 
8.44E-
13 
2E-13 
inferior_colliculus 6.51E-2 6.77E-2 1.16E-
10 
4E-
12 
8.58E-
11 
3E-
12 
1.18E-
12 
2E-
13 
1.15E-
12 
2E-13 
internal_capsule 4.13E-2 4.29E-2 3.55E-
11 
2E-
12 
2.80E-
11 
2E-
12 
8.78E-
13 
2E-
13 
8.70E-
13 
2E-13 
interpeduncular_nucleus 4.75E-3 4.94E-3 8.29E-
11 
1E-
11 
6.41E-
11 
8E-
12 
1.45E-
12 
6E-
13 
1.29E-
12 
5E-13 
lateral_dorsal_nucleus_of_thalamus 1.18E-2 1.22E-2 2.40E-
11 
3E-
12 
1.93E-
11 
2E-
12 
8.17E-
13 
3E-
13 
6.91E-
13 
2E-13 
lateral_geniculate 1.86E-2 1.94E-2 2.81E-
11 
2E-
12 
2.15E-
11 
2E-
12 
9.50E-
13 
3E-
13 
8.19E-
13 
2E-13 
lateral_lemniscus 1.68E-2 1.74E-2 4.44E-
11 
3E-
12 
3.55E-
11 
3E-
12 
1.51E-
12 
3E-
13 
1.29E-
12 
3E-13 
medial_geniculate 1.80E-2 1.87E-2 3.08E-
11 
3E-
12 
2.24E-
11 
2E-
12 
1.31E-
12 
3E-
13 
1.31E-
12 
3E-13 
nucleus_accumbens 5.94E-2 6.18E-2 1.29E-
10 
4E-
12 
9.76E-
11 
4E-
12 
7.53E-
13 
1E-
13 
7.40E-
13 
1E-13 
olfactory_areas 3.33E-1 3.46E-1 3.06E- 3E- 2.29E- 3E- 5.91E- 5E- 5.68E- 5E-14 
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10 12 10 12 13 14 13 
optic_tract 2.00E-2 2.08E-2 1.75E-
10 
7E-
12 
1.35E-
10 
6E-
12 
1.01E-
12 
4E-
13 
1.01E-
12 
4E-13 
pontine_gray 2.44E-2 2.54E-2 2.80E-
10 
1E-
11 
2.12E-
10 
8E-
12 
1.14E-
12 
2E-
13 
8.27E-
13 
2E-13 
spinal_trigeminal_tract 2.78E-2 2.89E-2 2.64E-
10 
7E-
12 
2.01E-
10 
6E-
12 
1.49E-
12 
2E-
13 
1.32E-
12 
2E-13 
substantia_nigra 3.54E-2 3.68E-2 8.98E-
11 
4E-
12 
6.85E-
11 
4E-
12 
7.70E-
13 
1E-
13 
7.56E-
13 
1E-13 
superior_colliculus 1.27E-1 1.32E-1 6.58E-
11 
2E-
12 
5.02E-
11 
2E-
12 
1.09E-
12 
1E-
13 
1.04E-
12 
1E-13 
pineal_gland 3.00E-3 3.12E-3 2.34E-
10 
2E-
11 
1.70E-
10 
2E-
11 
    
ventral_thalamic_nuclei 5.75E-2 5.98E-2 2.44E-
11 
1E-
12 
1.94E-
11 
1E-
12 
8.34E-
13 
1E-
13 
7.75E-
13 
1E-13 
ventricular_system 9.65E-2 1.00E-1 6.09E-
11 
2E-
12 
4.64E-
11 
2E-
12 
1.05E-
12 
1E-
13 
9.23E-
13 
1E-13 
thyroid 2.62E-1 2.69E-1 1.26E-
10 
2E-
12 
9.45E-
11 
2E-
12 
2.24E-
12 
1E-
13 
1.99E-
12 
1E-13 
Large_Int 8.76E+0 1.06E-2 2.63E-
10 
2E-
12 
2.98E-
10 
2E-
12 
3.11E-
12 
4E-
13 
3.73E-
12 
4E-13 
Small_Int 1.00E+1 1.21E-2 1.79E-
10 
1E-
12 
1.78E-
10 
1E-
12 
2.73E-
12 
3E-
13 
2.95E-
12 
3E-13 
marrow 1.38E+1 1.43E+1 8.03E-
10 
8E-
13 
6.49E-
10 
7E-
13 
7.13E-
12 
3E-
14 
6.75E-
12 
3E-14 
   Free 99mTc 2h Free 99mTc 4h 99mTc-CHSg 2h 99mTc-CHSg 4h 
   MEAN error MEAN error MEAN error MEAN error 
Dose at @ 1 cm (mGy/decay)   4.8E-12 1E-
13 
4.8E-12 1E-
13 
3.9E-12 1E-
13 
3.6E-12 1E-13 
Energy Dep (MeV)   2.689E-
2 
2E-5 2.685E-
2 
2E-5 2.672E-
2 
2E-5 2.675E-
2 
2E-5 
Avg (mGy/decay)   1.351E-
11 
1E-
14 
1.349E-
11 
1E-
14 
1.342E-
11 
1E-
14 
1.344E-
11 
1E-14 
Max D (mGy/decay)   1.20E-9  1.38E-9  2.77E-9  2.51E-9  
Min D (mGy/decay)   3.21E-  2.91E-  3.55E-  4.67E-  
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13 13 13 13 
           
 Vol 
(cm³) 
Mass 
(g) 
Dose per tissue 
(mGy/decay) 
     
   MEAN error MEAN error MEAN error MEAN error 
skin 1.79E+1 1.95E+1 2.43E-
12 
1E-
14 
2.42E-
12 
1E-
14 
2.33E-
12 
1E-
14 
2.32E-
12 
1E-14 
myoLV 5.75E-1 6.03E-1 3.61E-
11 
3E-
13 
3.96E-
11 
4E-
13 
5.44E-
11 
4E-
13 
4.99E-
11 
4E-13 
myoRV 8.34E-2 8.75E-2 2.41E-
11 
7E-
13 
2.61E-
11 
7E-
13 
2.41E-
11 
6E-
13 
2.23E-
11 
6E-13 
myoLA 1.53E-2 1.60E-2 2.96E-
11 
2E-
12 
3.36E-
11 
2E-
12 
4.90E-
11 
2E-
12 
4.44E-
11 
2E-12 
myoRA 2.15E-2 2.26E-2 6.63E-
11 
3E-
12 
7.50E-
11 
3E-
12 
1.38E-
10 
4E-
12 
1.27E-
10 
4E-12 
bldplLV 8.49E-1 9.00E-1 2.17E-
11 
2E-
13 
2.23E-
11 
2E-
13 
3.17E-
11 
2E-
13 
2.93E-
11 
2E-13 
bldplRV 7.51E-1 7.96E-1 2.16E-
11 
2E-
13 
2.16E-
11 
2E-
13 
2.89E-
11 
2E-
13 
2.67E-
11 
2E-13 
bldplLA 2.49E-1 2.64E-1 4.55E-
11 
6E-
13 
4.97E-
11 
6E-
13 
9.06E-
11 
8E-
13 
8.29E-
11 
8E-13 
bldplRA 9.81E-1 1.04E+0 3.04E-
11 
2E-
13 
3.14E-
11 
2E-
13 
4.37E-
11 
3E-
13 
4.04E-
11 
3E-13 
Rest of the body 2.27E+2 2.33E+2 4.34E-
12 
5E-
15 
4.24E-
12 
6E-
15 
4.87E-
12 
6E-
15 
4.94E-
12 
6E-15 
Liver 1.04E+1 1.10E+1 1.34E-
10 
2E-
13 
1.25E-
10 
2E-
13 
1.87E-
11 
5E-
14 
1.84E-
11 
5E-14 
Lung 2.88E+0 7.48E-1 1.20E-9 2E-
12 
1.38E-9 2E-
12 
2.77E-9 3E-
12 
2.51E-9 3E-12 
Trachea 7.24E-1 7.46E-1 9.10E-
11 
6E-
13 
1.04E-
10 
6E-
13 
2.04E-
10 
8E-
13 
1.85E-
10 
8E-13 
Stomach_Contents 4.65E+0 4.79E+0 1.38E-
11 
6E-
14 
1.55E-
11 
7E-
14 
7.09E-
12 
4E-
14 
6.89E-
12 
4E-14 
Pancreas 5.08E-1 5.28E-1 1.01E-
11 
2E-
13 
1.07E-
11 
2E-
13 
4.82E-
12 
1E-
13 
5.65E-
12 
1E-13 
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Kidney 2.09E+0 2.19E+0 2.16E-
11 
2E-
13 
1.69E-
11 
1E-
13 
3.21E-
11 
2E-
13 
6.71E-
11 
3E-13 
Spleen 8.13E-1 8.62E-1 2.29E-
10 
9E-
13 
3.78E-
10 
1E-
12 
4.62E-
12 
1E-
13 
5.82E-
12 
1E-13 
Small_Intestine 4.23E+0 4.35E+0 5.58E-
12 
4E-
14 
5.60E-
12 
4E-
14 
2.55E-
12 
3E-
14 
3.16E-
12 
3E-14 
Large_Intestine 1.95E+0 2.01E+0 4.57E-
12 
5E-
14 
3.47E-
12 
5E-
14 
2.73E-
12 
4E-
14 
4.04E-
12 
5E-14 
Bladder 6.30E-1 6.49E-1 2.57E-
10 
1E-
12 
2.76E-
11 
4E-
13 
2.08E-
10 
1E-
12 
4.21E-
10 
1E-12 
Vas_deferens 5.46E-2 5.63E-2 9.06E-
13 
1E-
13 
5.07E-
13 
9E-
14 
7.15E-
13 
1E-
13 
1.07E-
12 
1E-13 
Testes 1.64E-1 1.70E-1 9.09E-
13 
8E-
14 
4.16E-
13 
6E-
14 
7.10E-
13 
7E-
14 
1.06E-
12 
9E-14 
Wet_Rib_Bone 9.38E-1 1.32E+0 2.90E-
11 
2E-
13 
3.06E-
11 
2E-
13 
4.07E-
11 
2E-
13 
3.75E-
11 
2E-13 
Wet_Spine_Bone 4.14E+0 5.88E+0 7.04E-
12 
5E-
14 
7.32E-
12 
5E-
14 
1.05E-
11 
5E-
14 
1.00E-
11 
5E-14 
Skull 1.24E+0 1.99E+0 6.56E-
13 
3E-
14 
6.26E-
13 
2E-
14 
8.87E-
13 
3E-
14 
8.19E-
13 
3E-14 
humerus 2.42E-1 3.53E-1 5.27E-
12 
2E-
13 
5.63E-
12 
2E-
13 
8.49E-
12 
2E-
13 
7.90E-
12 
2E-13 
radius 1.87E-1 2.73E-1 1.04E-
11 
3E-
13 
1.11E-
11 
3E-
13 
1.53E-
11 
3E-
13 
1.41E-
11 
3E-13 
ulna 2.09E-1 3.06E-1 8.10E-
12 
2E-
13 
8.54E-
12 
2E-
13 
1.10E-
11 
2E-
13 
9.96E-
12 
2E-13 
femur 4.44E-1 5.91E-1 1.23E-
12 
6E-
14 
5.98E-
13 
4E-
14 
9.29E-
13 
5E-
14 
1.57E-
12 
7E-14 
fibula 1.41E-1 1.87E-1 3.88E-
13 
6E-
14 
3.00E-
13 
5E-
14 
3.55E-
13 
5E-
14 
4.67E-
13 
6E-14 
tibia 5.17E-1 6.87E-1 5.10E-
13 
4E-
14 
3.68E-
13 
3E-
14 
3.97E-
13 
3E-
14 
5.16E-
13 
4E-14 
patella 3.75E-2 4.99E-2 6.01E-
13 
1E-
13 
3.44E-
13 
9E-
14 
3.64E-
13 
9E-
14 
7.05E-
13 
1E-13 
bone 1.96E+0 2.75E+0 3.07E- 4E- 2.66E- 4E- 3.29E- 4E- 3.56E- 5E-14 
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12 14 12 14 12 14 12 
brain_(backgrnd) 6.00E-2 6.24E-2 6.04E-
13 
1E-
13 
6.12E-
13 
1E-
13 
7.79E-
13 
1E-
13 
7.87E-
13 
1E-13 
cerebral_cortex 1.58E+0 1.64E+0 5.17E-
13 
2E-
14 
5.16E-
13 
2E-
14 
7.21E-
13 
2E-
14 
6.72E-
13 
2E-14 
cerebellum 5.41E-1 5.62E-1 1.03E-
12 
5E-
14 
1.04E-
12 
5E-
14 
1.46E-
12 
6E-
14 
1.40E-
12 
6E-14 
corpus_callosum 1.20E-1 1.24E-1 6.25E-
13 
8E-
14 
6.68E-
13 
8E-
14 
8.39E-
13 
9E-
14 
7.75E-
13 
8E-14 
brainstem 6.33E-1 6.59E-1 9.46E-
13 
4E-
14 
9.52E-
13 
4E-
14 
1.37E-
12 
5E-
14 
1.28E-
12 
5E-14 
striatum 2.46E-1 2.56E-1 5.54E-
13 
5E-
14 
5.85E-
13 
5E-
14 
7.17E-
13 
6E-
14 
6.24E-
13 
5E-14 
thal 1.09E-1 1.13E-1 6.42E-
13 
8E-
14 
6.28E-
13 
8E-
14 
8.87E-
13 
1E-
13 
7.88E-
13 
1E-13 
hippo 3.01E-1 3.13E-1 6.02E-
13 
5E-
14 
5.97E-
13 
5E-
14 
8.77E-
13 
6E-
14 
8.39E-
13 
6E-14 
hypothalamus 9.40E-2 9.78E-2 6.75E-
13 
9E-
14 
7.17E-
13 
9E-
14 
8.16E-
13 
1E-
13 
8.28E-
13 
1E-13 
amygdala 1.48E-1 1.54E-1 5.59E-
13 
6E-
14 
6.09E-
13 
7E-
14 
9.05E-
13 
9E-
14 
8.43E-
13 
9E-14 
lateral_septal_nuclei 4.69E-2 4.88E-2 5.20E-
13 
1E-
13 
4.88E-
13 
1E-
13 
6.15E-
13 
1E-
13 
5.99E-
13 
1E-13 
anterior_commissure 1.19E-2 1.24E-2 4.72E-
13 
2E-
13 
5.29E-
13 
2E-
13 
5.82E-
13 
2E-
13 
5.41E-
13 
2E-13 
anterior_pretectal_nucleus 1.36E-2 1.42E-2 3.21E-
13 
2E-
13 
4.02E-
13 
2E-
13 
6.88E-
13 
2E-
13 
5.06E-
13 
2E-13 
periaqueductal_gray 3.66E-2 3.81E-2 8.21E-
13 
2E-
13 
8.85E-
13 
2E-
13 
8.87E-
13 
2E-
13 
8.09E-
13 
2E-13 
aqueduct 4.38E-3 4.55E-3 5.60E-
13 
3E-
13 
6.33E-
13 
3E-
13 
6.40E-
13 
4E-
13 
6.40E-
13 
4E-13 
cerebral_peduncle 1.86E-2 1.94E-2 4.40E-
13 
1E-
13 
4.85E-
13 
1E-
13 
6.95E-
13 
2E-
13 
6.95E-
13 
2E-13 
cochlear_nuclei 2.23E-2 2.31E-2 1.29E-
12 
3E-
13 
1.14E-
12 
3E-
13 
1.43E-
12 
3E-
13 
1.36E-
12 
3E-13 
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deep_mesencephalic_nuclei 4.38E-2 4.55E-2 8.15E-
13 
1E-
13 
8.55E-
13 
2E-
13 
1.35E-
12 
2E-
13 
1.32E-
12 
2E-13 
fimbria 2.21E-2 2.30E-2 7.38E-
13 
2E-
13 
8.62E-
13 
2E-
13 
1.05E-
12 
2E-
13 
9.20E-
13 
2E-13 
fornix 1.56E-2 1.63E-2 3.95E-
13 
1E-
13 
4.18E-
13 
2E-
13 
8.37E-
13 
2E-
13 
8.37E-
13 
2E-13 
globus_pallidus 2.70E-2 2.81E-2 6.57E-
13 
1E-
13 
6.89E-
13 
2E-
13 
8.32E-
13 
2E-
13 
8.31E-
13 
2E-13 
inferior_colliculus 6.51E-2 6.77E-2 8.76E-
13 
1E-
13 
9.21E-
13 
1E-
13 
1.29E-
12 
2E-
13 
1.15E-
12 
2E-13 
internal_capsule 4.13E-2 4.29E-2 7.69E-
13 
1E-
13 
6.81E-
13 
1E-
13 
8.78E-
13 
2E-
13 
9.08E-
13 
2E-13 
interpeduncular_nucleus 4.75E-3 4.94E-3 7.42E-
13 
4E-
13 
8.25E-
13 
4E-
13 
1.37E-
12 
5E-
13 
1.29E-
12 
5E-13 
lateral_dorsal_nucleus_of_thalamus 1.18E-2 1.22E-2 3.25E-
13 
1E-
13 
2.91E-
13 
1E-
13 
8.33E-
13 
3E-
13 
6.91E-
13 
2E-13 
lateral_geniculate 1.86E-2 1.94E-2 9.39E-
13 
3E-
13 
1.06E-
12 
3E-
13 
8.97E-
13 
2E-
13 
8.65E-
13 
2E-13 
lateral_lemniscus 1.68E-2 1.74E-2 8.07E-
13 
2E-
13 
9.01E-
13 
2E-
13 
1.50E-
12 
3E-
13 
1.50E-
12 
3E-13 
medial_geniculate 1.80E-2 1.87E-2 1.05E-
12 
3E-
13 
1.04E-
12 
3E-
13 
1.23E-
12 
3E-
13 
1.34E-
12 
3E-13 
nucleus_accumbens 5.94E-2 6.18E-2 5.62E-
13 
1E-
13 
5.90E-
13 
1E-
13 
7.49E-
13 
1E-
13 
7.56E-
13 
1E-13 
olfactory_areas 3.33E-1 3.46E-1 4.56E-
13 
4E-
14 
4.28E-
13 
4E-
14 
5.90E-
13 
5E-
14 
5.81E-
13 
5E-14 
optic_tract 2.00E-2 2.08E-2 8.02E-
13 
3E-
13 
8.73E-
13 
3E-
13 
1.07E-
12 
4E-
13 
1.01E-
12 
4E-13 
pontine_gray 2.44E-2 2.54E-2 8.21E-
13 
2E-
13 
8.54E-
13 
2E-
13 
1.28E-
12 
2E-
13 
1.05E-
12 
2E-13 
spinal_trigeminal_tract 2.78E-2 2.89E-2 1.09E-
12 
2E-
13 
1.04E-
12 
2E-
13 
1.53E-
12 
2E-
13 
1.40E-
12 
2E-13 
substantia_nigra 3.54E-2 3.68E-2 5.79E-
13 
1E-
13 
5.22E-
13 
1E-
13 
8.14E-
13 
2E-
13 
7.25E-
13 
1E-13 
superior_colliculus 1.27E-1 1.32E-1 7.56E- 9E- 7.96E- 9E- 1.14E- 1E- 1.08E- 1E-13 
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13 14 13 14 12 13 12 
pineal_gland 3.00E-3 3.12E-3     5.48E-
13 
5E-
13 
  
ventral_thalamic_nuclei 5.75E-2 5.98E-2 7.15E-
13 
1E-
13 
7.35E-
13 
1E-
13 
8.86E-
13 
1E-
13 
7.86E-
13 
1E-13 
ventricular_system 9.65E-2 1.00E-1 5.76E-
13 
9E-
14 
6.60E-
13 
1E-
13 
1.08E-
12 
1E-
13 
9.84E-
13 
1E-13 
thyroid 2.62E-1 2.69E-1 1.49E-
12 
8E-
14 
1.58E-
12 
8E-
14 
2.31E-
12 
1E-
13 
2.15E-
12 
1E-13 
Large_Int 8.76E+0 1.06E-2 3.61E-
12 
4E-
13 
2.49E-
12 
3E-
13 
2.54E-
12 
4E-
13 
3.60E-
12 
4E-13 
Small_Int 1.00E+1 1.21E-2 5.08E-
12 
4E-
13 
5.32E-
12 
4E-
13 
2.63E-
12 
3E-
13 
3.02E-
12 
3E-13 
marrow 1.38E+1 1.43E+1 5.43E-
12 
2E-
14 
5.34E-
12 
2E-
14 
7.30E-
12 
3E-
14 
6.93E-
12 
3E-14 
   99mTc-PGCD 2h 99mTc-PGCD 4h 68Ga-CHSg 2h 68Ga-PGCD 2h 
   MEAN error MEAN error MEAN error MEAN error 
Dose at @ 1 cm (mGy/decay)   2.8E-12 1E-
13 
3.0E-12 1E-
13 
5.4E-11 1E-
12 
4.9E-11 1E-12 
Energy Dep (MeV)   2.672E-
2 
2E-5 2.684E-
2 
2E-5 8.022E-
1 
2E-4 8.018E-
1 
2E-4 
Avg (mGy/decay)   1.342E-
11 
1E-
14 
1.349E-
11 
1E-
14 
4.030E-
10 
1E-
13 
4.028E-
10 
1E-13 
Max D (mGy/decay)   1.70E-9  1.35E-9  1.39E-8  4.48E-8  
Min D (mGy/decay)   3.76E-
13 
 4.53E-
13 
 1.41E-
11 
 1.23E-
11 
 
           
 Vol 
(cm³) 
Mass 
(g) 
Dose per tissue 
(mGy/decay) 
     
   MEAN error MEAN error MEAN error MEAN error 
skin 1.79E+1 1.95E+1 2.39E-
12 
1E-
14 
2.41E-
12 
1E-
14 
8.08E-
11 
1E-
13 
8.35E-
11 
2E-13 
myoLV 5.75E-1 6.03E-1 3.89E-
11 
4E-
13 
2.94E-
11 
3E-
13 
3.51E-9 8E-
12 
2.03E-9 6E-12 
myoRV 8.34E-2 8.75E-2 2.11E- 6E- 2.02E- 7E- 1.74E-9 9E- 1.42E-9 8E-12 
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11 13 11 13 12 
myoLA 1.53E-2 1.60E-2 3.50E-
11 
2E-
12 
2.53E-
11 
2E-
12 
2.92E-9 2E-
11 
1.72E-9 2E-11 
myoRA 2.15E-2 2.26E-2 9.04E-
11 
3E-
12 
5.74E-
11 
2E-
12 
4.93E-9 3E-
11 
1.99E-9 2E-11 
bldplLV 8.49E-1 9.00E-1 2.84E-
11 
3E-
13 
2.35E-
11 
2E-
13 
2.26E-9 5E-
12 
1.74E-9 5E-12 
bldplRV 7.51E-1 7.96E-1 2.67E-
11 
3E-
13 
2.25E-
11 
2E-
13 
2.27E-9 6E-
12 
2.02E-9 6E-12 
bldplLA 2.49E-1 2.64E-1 6.40E-
11 
7E-
13 
4.18E-
11 
6E-
13 
4.72E-9 1E-
11 
2.17E-9 9E-12 
bldplRA 9.81E-1 1.04E+0 3.62E-
11 
3E-
13 
2.89E-
11 
2E-
13 
3.02E-9 6E-
12 
1.83E-9 5E-12 
Rest of the body 2.27E+2 2.33E+2 5.58E-
12 
7E-
15 
5.47E-
12 
7E-
15 
2.67E-
10 
1E-
13 
2.73E-
10 
1E-13 
Liver 1.04E+1 1.10E+1 1.98E-
11 
6E-
14 
6.48E-
11 
1E-
13 
1.01E-9 1E-
12 
6.16E-
10 
9E-13 
Lung 2.88E+0 7.48E-1 1.70E-9 3E-
12 
9.30E-
10 
2E-
12 
1.30E-8 1E-
11 
2.70E-9 5E-12 
Trachea 7.24E-1 7.46E-1 1.26E-
10 
7E-
13 
7.10E-
11 
5E-
13 
6.33E-9 8E-
12 
1.43E-9 4E-12 
Stomach_Contents 4.65E+0 4.79E+0 6.08E-
12 
4E-
14 
7.63E-
12 
5E-
14 
1.23E-
10 
5E-
13 
9.56E-
11 
5E-13 
Pancreas 5.08E-1 5.28E-1 6.27E-
12 
1E-
13 
8.31E-
12 
1E-
13 
1.79E-
10 
2E-
12 
1.99E-
10 
2E-12 
Kidney 2.09E+0 2.19E+0 7.10E-
11 
3E-
13 
9.89E-
11 
4E-
13 
6.69E-
10 
2E-
12 
9.89E-
10 
2E-12 
Spleen 8.13E-1 8.62E-1 2.87E-
11 
3E-
13 
4.15E-
11 
4E-
13 
9.04E-
10 
4E-
12 
7.79E-
10 
4E-12 
Small_Intestine 4.23E+0 4.35E+0 4.14E-
12 
4E-
14 
5.68E-
12 
4E-
14 
1.38E-
10 
5E-
13 
1.53E-
10 
6E-13 
Large_Intestine 1.95E+0 2.01E+0 7.58E-
12 
7E-
14 
9.61E-
12 
8E-
14 
3.16E-
10 
1E-
12 
7.20E-
10 
2E-12 
Bladder 6.30E-1 6.49E-1 1.14E-9 2E-
12 
1.35E-9 3E-
12 
1.39E-8 2E-
11 
4.48E-8 3E-11 
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Vas_deferens 5.46E-2 5.63E-2 2.77E-
12 
2E-
13 
3.25E-
12 
3E-
13 
8.48E-
11 
3E-
12 
1.07E-
10 
3E-12 
Testes 1.64E-1 1.70E-1 3.02E-
12 
2E-
13 
3.54E-
12 
2E-
13 
9.00E-
11 
2E-
12 
1.13E-
10 
2E-12 
Wet_Rib_Bone 9.38E-1 1.32E+0 2.79E-
11 
2E-
13 
2.07E-
11 
2E-
13 
1.51E-9 2E-
12 
5.96E-
10 
2E-12 
Wet_Spine_Bone 4.14E+0 5.88E+0 8.39E-
12 
5E-
14 
6.72E-
12 
4E-
14 
3.57E-
10 
7E-
13 
2.41E-
10 
6E-13 
Skull 1.24E+0 1.99E+0 1.20E-
12 
3E-
14 
1.14E-
12 
3E-
14 
2.46E-
10 
9E-
13 
2.56E-
10 
9E-13 
humerus 2.42E-1 3.53E-1 6.12E-
12 
2E-
13 
4.28E-
12 
1E-
13 
2.60E-
10 
2E-
12 
2.58E-
10 
2E-12 
radius 1.87E-1 2.73E-1 1.07E-
11 
3E-
13 
8.10E-
12 
2E-
13 
2.57E-
10 
2E-
12 
2.43E-
10 
2E-12 
ulna 2.09E-1 3.06E-1 7.83E-
12 
2E-
13 
6.37E-
12 
2E-
13 
2.45E-
10 
2E-
12 
2.36E-
10 
2E-12 
femur 4.44E-1 5.91E-1 4.11E-
12 
1E-
13 
4.76E-
12 
1E-
13 
2.72E-
10 
2E-
12 
3.01E-
10 
2E-12 
fibula 1.41E-1 1.87E-1 1.41E-
12 
1E-
13 
1.57E-
12 
1E-
13 
1.98E-
10 
3E-
12 
2.14E-
10 
3E-12 
tibia 5.17E-1 6.87E-1 1.38E-
12 
6E-
14 
1.58E-
12 
7E-
14 
1.82E-
10 
1E-
12 
1.95E-
10 
2E-12 
patella 3.75E-2 4.99E-2 2.23E-
12 
3E-
13 
2.51E-
12 
3E-
13 
2.24E-
10 
5E-
12 
2.42E-
10 
5E-12 
bone 1.96E+0 2.75E+0 4.91E-
12 
5E-
14 
5.14E-
12 
5E-
14 
2.03E-
10 
7E-
13 
2.19E-
10 
7E-13 
brain_(backgrnd) 6.00E-2 6.24E-2 1.15E-
12 
2E-
13 
1.05E-
12 
2E-
13 
2.47E-
10 
4E-
12 
2.57E-
10 
4E-12 
cerebral_cortex 1.58E+0 1.64E+0 7.97E-
13 
3E-
14 
7.09E-
13 
2E-
14 
1.23E-
10 
9E-
13 
1.27E-
10 
1E-12 
cerebellum 5.41E-1 5.62E-1 1.24E-
12 
6E-
14 
1.02E-
12 
5E-
14 
1.02E-
10 
1E-
12 
1.03E-
10 
1E-12 
corpus_callosum 1.20E-1 1.24E-1 8.33E-
13 
9E-
14 
7.62E-
13 
9E-
14 
4.52E-
11 
1E-
12 
4.51E-
11 
1E-12 
brainstem 6.33E-1 6.59E-1 1.23E- 5E- 1.03E- 5E- 9.22E- 1E- 9.30E- 1E-12 
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12 14 12 14 11 12 11 
striatum 2.46E-1 2.56E-1 6.95E-
13 
6E-
14 
5.39E-
13 
5E-
14 
3.41E-
11 
1E-
12 
3.41E-
11 
1E-12 
thal 1.09E-1 1.13E-1 8.59E-
13 
1E-
13 
7.85E-
13 
1E-
13 
2.12E-
11 
1E-
12 
2.04E-
11 
1E-12 
hippo 3.01E-1 3.13E-1 8.74E-
13 
6E-
14 
7.04E-
13 
5E-
14 
4.28E-
11 
1E-
12 
4.22E-
11 
1E-12 
hypothalamus 9.40E-2 9.78E-2 8.65E-
13 
1E-
13 
8.02E-
13 
1E-
13 
1.19E-
10 
4E-
12 
1.23E-
10 
4E-12 
amygdala 1.48E-1 1.54E-1 8.87E-
13 
1E-
13 
8.72E-
13 
1E-
13 
1.19E-
10 
3E-
12 
1.22E-
10 
3E-12 
lateral_septal_nuclei 4.69E-2 4.88E-2 5.52E-
13 
1E-
13 
4.53E-
13 
1E-
13 
2.45E-
11 
2E-
12 
2.37E-
11 
2E-12 
anterior_commissure 1.19E-2 1.24E-2 4.89E-
13 
2E-
13 
5.86E-
13 
2E-
13 
3.55E-
11 
3E-
12 
3.44E-
11 
3E-12 
anterior_pretectal_nucleus 1.36E-2 1.42E-2 8.20E-
13 
2E-
13 
5.71E-
13 
2E-
13 
1.59E-
11 
2E-
12 
1.41E-
11 
2E-12 
periaqueductal_gray 3.66E-2 3.81E-2 1.01E-
12 
2E-
13 
9.09E-
13 
2E-
13 
1.94E-
11 
1E-
12 
1.65E-
11 
1E-12 
aqueduct 4.38E-3 4.55E-3 3.76E-
13 
3E-
13 
5.16E-
13 
3E-
13 
2.81E-
11 
5E-
12 
2.63E-
11 
5E-12 
cerebral_peduncle 1.86E-2 1.94E-2 8.45E-
13 
2E-
13 
6.50E-
13 
2E-
13 
7.62E-
11 
4E-
12 
7.60E-
11 
4E-12 
cochlear_nuclei 2.23E-2 2.31E-2 1.53E-
12 
3E-
13 
1.28E-
12 
2E-
13 
1.31E-
10 
6E-
12 
1.35E-
10 
6E-12 
deep_mesencephalic_nuclei 4.38E-2 4.55E-2 1.20E-
12 
2E-
13 
8.23E-
13 
1E-
13 
2.00E-
11 
1E-
12 
1.74E-
11 
1E-12 
fimbria 2.21E-2 2.30E-2 6.58E-
13 
2E-
13 
4.78E-
13 
2E-
13 
1.50E-
11 
1E-
12 
1.43E-
11 
1E-12 
fornix 1.56E-2 1.63E-2 8.34E-
13 
2E-
13 
6.62E-
13 
2E-
13 
5.24E-
11 
4E-
12 
5.19E-
11 
4E-12 
globus_pallidus 2.70E-2 2.81E-2 8.82E-
13 
2E-
13 
7.86E-
13 
2E-
13 
3.00E-
11 
2E-
12 
2.85E-
11 
2E-12 
inferior_colliculus 6.51E-2 6.77E-2 1.09E-
12 
1E-
13 
9.08E-
13 
1E-
13 
6.48E-
11 
3E-
12 
6.59E-
11 
3E-12 
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internal_capsule 4.13E-2 4.29E-2 8.29E-
13 
1E-
13 
6.86E-
13 
1E-
13 
2.21E-
11 
1E-
12 
2.18E-
11 
2E-12 
interpeduncular_nucleus 4.75E-3 4.94E-3 7.32E-
13 
4E-
13 
9.52E-
13 
5E-
13 
5.82E-
11 
8E-
12 
5.82E-
11 
8E-12 
lateral_dorsal_nucleus_of_thalamus 1.18E-2 1.22E-2 5.44E-
13 
2E-
13 
4.73E-
13 
2E-
13 
1.41E-
11 
2E-
12 
1.23E-
11 
2E-12 
lateral_geniculate 1.86E-2 1.94E-2 9.29E-
13 
2E-
13 
9.37E-
13 
2E-
13 
1.78E-
11 
2E-
12 
1.62E-
11 
2E-12 
lateral_lemniscus 1.68E-2 1.74E-2 1.26E-
12 
3E-
13 
9.79E-
13 
3E-
13 
2.81E-
11 
3E-
12 
2.86E-
11 
3E-12 
medial_geniculate 1.80E-2 1.87E-2 9.90E-
13 
3E-
13 
6.40E-
13 
2E-
13 
1.67E-
11 
2E-
12 
1.59E-
11 
2E-12 
nucleus_accumbens 5.94E-2 6.18E-2 7.59E-
13 
1E-
13 
6.40E-
13 
1E-
13 
7.49E-
11 
3E-
12 
7.60E-
11 
3E-12 
olfactory_areas 3.33E-1 3.46E-1 8.09E-
13 
6E-
14 
7.02E-
13 
6E-
14 
1.72E-
10 
2E-
12 
1.79E-
10 
3E-12 
optic_tract 2.00E-2 2.08E-2 8.10E-
13 
3E-
13 
5.59E-
13 
3E-
13 
9.99E-
11 
5E-
12 
1.03E-
10 
5E-12 
pontine_gray 2.44E-2 2.54E-2 9.69E-
13 
2E-
13 
6.67E-
13 
2E-
13 
1.63E-
10 
7E-
12 
1.66E-
10 
7E-12 
spinal_trigeminal_tract 2.78E-2 2.89E-2 1.51E-
12 
3E-
13 
1.07E-
12 
2E-
13 
1.50E-
10 
6E-
12 
1.55E-
10 
6E-12 
substantia_nigra 3.54E-2 3.68E-2 7.80E-
13 
2E-
13 
6.11E-
13 
1E-
13 
5.36E-
11 
3E-
12 
5.30E-
11 
3E-12 
superior_colliculus 1.27E-1 1.32E-1 1.05E-
12 
1E-
13 
9.06E-
13 
1E-
13 
4.01E-
11 
2E-
12 
3.95E-
11 
2E-12 
pineal_gland 3.00E-3 3.12E-3   4.54E-
13 
5E-
13 
1.27E-
10 
2E-
11 
1.29E-
10 
2E-11 
ventral_thalamic_nuclei 5.75E-2 5.98E-2 5.68E-
13 
1E-
13 
5.00E-
13 
9E-
14 
1.65E-
11 
1E-
12 
1.52E-
11 
1E-12 
ventricular_system 9.65E-2 1.00E-1 8.14E-
13 
1E-
13 
6.65E-
13 
8E-
14 
3.71E-
11 
1E-
12 
3.61E-
11 
1E-12 
thyroid 2.62E-1 2.69E-1 1.74E-
12 
9E-
14 
1.36E-
12 
8E-
14 
7.42E-
11 
2E-
12 
7.36E-
11 
2E-12 
Large_Int 8.76E+0 1.06E-2 6.86E- 5E- 8.30E- 6E- 2.27E- 2E- 4.45E- 2E-12 
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12 13 12 13 10 12 10 
Small_Int 1.00E+1 1.21E-2 3.62E-
12 
3E-
13 
4.64E-
12 
4E-
13 
1.35E-
10 
1E-
12 
1.47E-
10 
1E-12 
marrow 1.38E+1 1.43E+1 7.90E-
12 
3E-
14 
7.06E-
12 
3E-
14 
6.26E-
10 
6E-
13 
5.00E-
10 
6E-13 
   CHS-DOTA-90Y 
24h 
RMTEX-90Y 24h Free 90Y 24h 
   MEAN error MEAN error MEAN error 
Dose at @ 1 cm (mGy/decay)   2.70E-
12 
2E-13 1.62E-
11 
6E-13 6.1E-11 1E-12 
Energy Dep (MeV)   9.315E-
1 
2E-4 9.275E-
1 
2E-4 9.139E-
1 
2E-4 
Avg (mGy/decay)   4.680E-
10 
1E-13 4.660E-
10 
1E-13 4.591E-
10 
1E-13 
Max D (mGy/decay)   4.22E-8  3.28E-8  5.44E-9  
Min D (mGy/decay)   1.26E-
14 
 9.49E-
13 
 2.47E-
12 
 
         
 Vol 
(cm³) 
Mass (g)     
   MEAN error MEAN error MEAN error 
skin 1.79E+1 1.95E+1 1.09E-
12 
2E-14 1.62E-
11 
6E-14 6.87E-
11 
1E-13 
myoLV 5.75E-1 6.03E-1 7.03E-9 1E-11 5.55E-9 1E-11 8.20E-
10 
4E-12 
myoRV 8.34E-2 8.75E-2 1.57E-9 8E-12 1.34E-9 8E-12 6.49E-
10 
5E-12 
myoLA 1.53E-2 1.60E-2 5.84E-9 3E-11 4.56E-9 3E-11 3.39E-
10 
8E-12 
myoRA 2.15E-2 2.26E-2 1.32E-8 4E-11 1.02E-8 4E-11 4.44E-
10 
7E-12 
bldplLV 8.49E-1 9.00E-1 2.84E-9 6E-12 2.29E-9 5E-12 5.09E-
10 
2E-12 
bldplRV 7.51E-1 7.96E-1 1.47E-9 4E-12 1.21E-9 4E-12 3.48E-
10 
2E-12 
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bldplLA 2.49E-1 2.64E-1 1.16E-8 2E-11 9.03E-9 2E-11 4.23E-
10 
4E-12 
bldplRA 9.81E-1 1.04E+0 5.75E-9 8E-12 4.55E-9 7E-12 4.72E-
10 
2E-12 
Rest of the body 2.27E+2 2.33E+2 2.18E-
10 
9E-14 2.12E-
10 
8E-14 1.94E-
10 
1E-13 
Liver 1.04E+1 1.10E+1 1.24E-9 1E-12 1.38E-9 1E-12 1.63E-9 1E-12 
Lung 2.88E+0 7.48E-1 4.22E-8 1E-11 3.28E-8 1E-11 1.16E-9 3E-12 
Trachea 7.24E-1 7.46E-1 2.03E-8 1E-11 1.58E-8 1E-11 7.46E-
10 
3E-12 
Stomach_Contents 4.65E+0 4.79E+0 6.07E-
11 
4E-13 8.02E-
11 
5E-13 1.26E-
10 
6E-13 
Pancreas 5.08E-1 5.28E-1 8.41E-
12 
4E-13 1.46E-
10 
2E-12 5.39E-
10 
3E-12 
Kidney 2.09E+0 2.19E+0 7.25E-
11 
6E-13 1.47E-9 3E-12 5.44E-9 5E-12 
Spleen 8.13E-1 8.62E-1 2.83E-
11 
7E-13 2.06E-
10 
2E-12 6.19E-
10 
3E-12 
Small_Intestine 4.23E+0 4.35E+0 3.47E-
12 
8E-14 5.72E-
11 
3E-13 2.10E-
10 
7E-13 
Large_Intestine 1.95E+0 2.01E+0 2.28E-
11 
3E-13 7.11E-
11 
5E-13 2.53E-
10 
9E-13 
Bladder 6.30E-1 6.49E-1 1.36E-9 5E-12 1.22E-9 5E-12 3.74E-9 9E-12 
Vas_deferens 5.46E-2 5.63E-2 3.15E-
13 
2E-13 9.49E-
13 
3E-13 2.47E-
12 
6E-13 
Testes 1.64E-1 1.70E-1 2.91E-
13 
1E-13 1.35E-
12 
3E-13 4.60E-
12 
5E-13 
Wet_Rib_Bone 9.38E-1 1.32E+0 4.26E-9 3E-12 3.47E-9 3E-12 8.13E-
10 
2E-12 
Wet_Spine_Bone 4.14E+0 5.88E+0 6.19E-
10 
9E-13 6.83E-
10 
1E-12 9.28E-
10 
9E-13 
Skull 1.24E+0 1.99E+0 7.95E-
12 
2E-13 3.51E-
10 
1E-12 1.55E-9 2E-12 
humerus 2.42E-1 3.53E-1 1.37E-
11 
5E-13 2.94E-
10 
2E-12 1.28E-9 4E-12 
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radius 1.87E-1 2.73E-1 4.62E-
11 
9E-13 2.89E-
10 
2E-12 1.16E-9 5E-12 
ulna 2.09E-1 3.06E-1 1.72E-
11 
5E-13 2.80E-
10 
2E-12 1.21E-9 5E-12 
femur 4.44E-1 5.91E-1 7.56E-
12 
3E-13 3.43E-
10 
2E-12 1.52E-9 4E-12 
fibula 1.41E-1 1.87E-1 3.82E-
12 
3E-13 1.74E-
10 
2E-12 7.62E-
10 
5E-12 
tibia 5.17E-1 6.87E-1 4.74E-
12 
2E-13 2.11E-
10 
1E-12 9.31E-
10 
3E-12 
patella 3.75E-2 4.99E-2 5.29E-
12 
6E-13 3.23E-
10 
5E-12 1.41E-9 1E-11 
bone 1.96E+0 2.75E+0 1.63E-
11 
2E-13 2.00E-
10 
6E-13 8.44E-
10 
1E-12 
brain_(backgrnd) 6.00E-2 6.24E-2 8.73E-
12 
6E-13 4.22E-
10 
5E-12 1.86E-9 1E-11 
cerebral_cortex 1.58E+0 1.64E+0 4.25E-
12 
2E-13 2.06E-
10 
1E-12 9.03E-
10 
3E-12 
cerebellum 5.41E-1 5.62E-1 3.23E-
12 
3E-13 1.43E-
10 
2E-12 6.30E-
10 
4E-12 
corpus_callosum 1.20E-1 1.24E-1 1.46E-
12 
2E-13 7.09E-
11 
2E-12 3.16E-
10 
3E-12 
brainstem 6.33E-1 6.59E-1 3.20E-
12 
2E-13 1.45E-
10 
2E-12 6.37E-
10 
4E-12 
striatum 2.46E-1 2.56E-1 1.05E-
12 
2E-13 5.71E-
11 
1E-12 2.55E-
10 
3E-12 
thal 1.09E-1 1.13E-1 6.78E-
13 
2E-13 1.85E-
11 
1E-12 8.61E-
11 
2E-12 
hippo 3.01E-1 3.13E-1 1.69E-
12 
2E-13 7.11E-
11 
2E-12 3.17E-
10 
3E-12 
hypothalamus 9.40E-2 9.78E-2 4.57E-
12 
7E-13 2.04E-
10 
5E-12 9.25E-
10 
1E-11 
amygdala 1.48E-1 1.54E-1 4.75E-
12 
6E-13 2.06E-
10 
4E-12 9.30E-
10 
8E-12 
lateral_septal_nuclei 4.69E-2 4.88E-2 5.30E- 3E-13 2.69E- 2E-12 1.35E- 5E-12 
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13 11 10 
anterior_commissure 1.19E-2 1.24E-2 9.33E-
13 
5E-13 5.49E-
11 
4E-12 2.65E-
10 
1E-11 
anterior_pretectal_nucleus 1.36E-2 1.42E-2 3.18E-
13 
3E-13 7.24E-
12 
2E-12 4.42E-
11 
4E-12 
periaqueductal_gray 3.66E-2 3.81E-2 1.26E-
14 
7E-15 1.57E-
11 
2E-12 6.20E-
11 
3E-12 
aqueduct 4.38E-3 4.55E-3   2.23E-
11 
5E-12 1.09E-
10 
1E-11 
cerebral_peduncle 1.86E-2 1.94E-2 2.73E-
12 
8E-13 1.18E-
10 
5E-12 5.54E-
10 
1E-11 
cochlear_nuclei 2.23E-2 2.31E-2 5.61E-
12 
1E-12 2.10E-
10 
7E-12 9.78E-
10 
2E-11 
deep_mesencephalic_nuclei 4.38E-2 4.55E-2 2.55E-
14 
2E-14 1.59E-
11 
2E-12 7.80E-
11 
4E-12 
fimbria 2.21E-2 2.30E-2 3.50E-
13 
2E-13 1.15E-
11 
1E-12 5.65E-
11 
3E-12 
fornix 1.56E-2 1.63E-2 1.29E-
12 
5E-13 8.08E-
11 
4E-12 3.76E-
10 
1E-11 
globus_pallidus 2.70E-2 2.81E-2 4.69E-
13 
2E-13 4.95E-
11 
3E-12 2.11E-
10 
7E-12 
inferior_colliculus 6.51E-2 6.77E-2 1.64E-
12 
5E-13 1.15E-
10 
4E-12 4.91E-
10 
8E-12 
internal_capsule 4.13E-2 4.29E-2 9.05E-
13 
4E-13 2.48E-
11 
2E-12 1.12E-
10 
4E-12 
interpeduncular_nucleus 4.75E-3 4.94E-3 6.22E-
13 
6E-13 9.82E-
11 
1E-11 4.47E-
10 
2E-11 
lateral_dorsal_nucleus_of_thalamus 1.18E-2 1.22E-2   5.21E-
12 
2E-12 2.73E-
11 
4E-12 
lateral_geniculate 1.86E-2 1.94E-2 1.92E-
12 
8E-13 1.92E-
11 
2E-12 8.62E-
11 
5E-12 
lateral_lemniscus 1.68E-2 1.74E-2 1.38E-
12 
6E-13 5.24E-
11 
4E-12 2.30E-
10 
9E-12 
medial_geniculate 1.80E-2 1.87E-2 3.22E-
13 
2E-13 1.88E-
11 
3E-12 7.83E-
11 
5E-12 
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nucleus_accumbens 5.94E-2 6.18E-2 1.93E-
12 
5E-13 1.45E-
10 
4E-12 6.43E-
10 
9E-12 
olfactory_areas 3.33E-1 3.46E-1 7.78E-
12 
5E-13 3.51E-
10 
4E-12 1.56E-9 8E-12 
optic_tract 2.00E-2 2.08E-2 6.34E-
12 
1E-12 1.72E-
10 
7E-12 7.62E-
10 
1E-11 
pontine_gray 2.44E-2 2.54E-2 4.40E-
12 
1E-12 2.77E-
10 
9E-12 1.24E-9 2E-11 
spinal_trigeminal_tract 2.78E-2 2.89E-2 5.87E-
12 
1E-12 2.43E-
10 
7E-12 1.07E-9 1E-11 
substantia_nigra 3.54E-2 3.68E-2 1.69E-
12 
6E-13 8.54E-
11 
4E-12 3.85E-
10 
9E-12 
superior_colliculus 1.27E-1 1.32E-1 8.51E-
13 
2E-13 6.13E-
11 
2E-12 2.71E-
10 
5E-12 
pineal_gland 3.00E-3 3.12E-3 6.19E-
12 
3E-12 2.31E-
10 
2E-11 9.58E-
10 
4E-11 
ventral_thalamic_nuclei 5.75E-2 5.98E-2 8.26E-
13 
4E-13 1.22E-
11 
1E-12 5.38E-
11 
3E-12 
ventricular_system 9.65E-2 1.00E-1 1.25E-
12 
2E-13 4.85E-
11 
2E-12 2.13E-
10 
3E-12 
thyroid 2.62E-1 2.69E-1 3.41E-
13 
1E-13 1.17E-
11 
7E-13 4.99E-
11 
1E-12 
Large_Int 8.76E+0 1.06E-2 1.32E-
11 
3E-13 4.85E-
11 
6E-13 1.77E-
10 
1E-12 
Small_Int 1.00E+1 1.21E-2 3.63E-
12 
2E-13 5.56E-
11 
6E-13 2.05E-
10 
1E-12 
marrow 1.38E+1 1.43E+1 6.83E-
10 
5E-13 1.19E-9 8E-13 3.01E-9 1E-12 
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